233137	174	Aden DP	Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.	Nature	1979	202
8594428	174	Mazzaferro V	Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.	The New England journal of medicine	1996	790
11394657	174	Trevisani F	Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.	Journal of hepatology	2001	104
12029639	174	Hsu YS	Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.	Hepatology	2002	100
15042359	174	Zhang BH	Randomized controlled trial of screening for hepatocellular carcinoma.	Journal of cancer research and clinical oncology	2004	201
18350595	174	But DY	Natural history of hepatitis-related hepatocellular carcinoma.	World journal of gastroenterology	2008	66
19223512	174	Goldman R	Detection of hepatocellular carcinoma using glycomic analysis.	Clinical cancer research 	2009	48
19302335	174	Nguyen VT	Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden.	Journal of viral hepatitis	2009	67
19880964	174	Spee B	Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling.	Gut	2010	61
20683951	174	Asahina Y	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.	Hepatology	2010	40
25804634	174	Xu X	Liver transplantation for hepatocellular carcinoma beyond the Milan criteria.	Gut	2016	17
10893372	213	Ibrahim EH	The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.	Chest	2000	232
21601335	213	Mehrotra R	Serum albumin as a predictor of mortality in peritoneal dialysis: comparisons with hemodialysis.	American journal of kidney diseases 	2011	38
21608000	213	Peng L	Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes.	Hepatology	2011	64
24635772	213	Caironi P	Albumin replacement in patients with severe sepsis or septic shock.	The New England journal of medicine	2014	77
24768475	213	Roberts JA	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.	The Lancet. Infectious diseases	2014	36
25185465	213	Artinyan A	Infectious postoperative complications decrease long-term survival in patients undergoing curative surgery for colorectal cancer: a study of 12,075 patients.	Annals of surgery	2015	15
19179289	684	Kaletsky RL	Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.	Proceedings of the National Academy of Sciences of the United States of America	2009	175
19461879	684	Gupta RK	Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.	PLoS pathogens	2009	117
19740980	684	Le Tortorec A	Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein.	Journal of virology	2009	149
19864625	684	Gupta RK	Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration.	Proceedings of the National Academy of Sciences of the United States of America	2009	94
20193017	684	Swiecki M	Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance.	Immunological reviews	2010	118
20686043	684	Radoshitzky SR	Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin.	Journal of virology	2010	60
20926557	684	Vigan R	Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.	Journal of virology	2010	67
21610122	684	Schmidt S	HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction.	mBio	2011	42
21808013	684	Erikson E	In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans.	Proceedings of the National Academy of Sciences of the United States of America	2011	38
22357275	684	Sato K	Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice.	Journal of virology	2012	33
23028328	684	Cocka LJ	Identification of alternatively translated Tetherin isoforms with differing antiviral and signaling activities.	PLoS pathogens	2012	64
23159053	684	Galão RP	Innate sensing of HIV-1 assembly by Tetherin induces NFκB-dependent proinflammatory responses.	Cell host and microbe	2012	99
9182550	820	Frohm M	The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders.	The Journal of biological chemistry	1997	135
9465102	820	Shafer WM	Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family.	Proceedings of the National Academy of Sciences of the United States of America	1998	129
9689116	820	Bals R	The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface.	Proceedings of the National Academy of Sciences of the United States of America	1998	155
10417311	820	Oren Z	Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity.	The Biochemical journal	1999	128
11667978	820	Bals R	Epithelial antimicrobial peptides in host defense against infection.	Respiratory research	2000	98
12244186	820	Scott MG	The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses.	Journal of immunology	2002	122
12603850	820	Heilborn JD	The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium.	The Journal of investigative dermatology	2003	104
15569695	820	Bowdish DM	Impact of LL-37 on anti-infective immunity.	Journal of leukocyte biology	2005	89
16053249	820	Zanetti M	The role of cathelicidins in the innate host defenses of mammals.	Current issues in molecular biology	2005	78
16716248	820	Dürr UH	LL-37, the only human member of the cathelicidin family of antimicrobial peptides.	Biochimica et biophysica acta	2006	158
16909917	820	Bowdish DM	Immunomodulatory properties of defensins and cathelicidins.	Current topics in microbiology and immunology	2006	64
17805349	820	Carretero M	In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37.	The Journal of investigative dermatology	2008	57
18818205	820	Wang G	Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles.	The Journal of biological chemistry	2008	69
19068548	820	Nijnik A	The roles of cathelicidin LL-37 in immune defences and novel clinical applications.	Current opinion in hematology	2009	68
19389235	820	Jeng L	Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis.	Journal of translational medicine	2009	98
19710683	820	Cogen AL	Selective antimicrobial action is provided by phenol-soluble modulins derived from Staphylococcus epidermidis, a normal resident of the skin.	The Journal of investigative dermatology	2010	80
19748465	820	Yuk JM	Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin.	Cell host and microbe	2009	167
19808939	820	Doss M	Human defensins and LL-37 in mucosal immunity.	Journal of leukocyte biology	2010	59
20945332	820	Krasnodembskaya A	Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37.	Stem cells	2010	122
22031815	820	Barlow PG	Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37.	PloS one	2011	51
22589721	820	Campbell GR	Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy.	PLoS pathogens	2012	74
23246832	820	Vandamme D	A comprehensive summary of LL-37, the factotum human cathelicidin peptide.	Cellular immunology	2012	65
26556394	820	Xhindoli D	The human cathelicidin LL-37--A pore-forming antibacterial peptide and host-cell modulator.	Biochimica et biophysica acta	2016	16
1322294	920	Lewis P	Human immunodeficiency virus infection of cells arrested in the cell cycle.	The EMBO journal	1992	180
1361652	920	-	1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.	MMWR. Recommendations and reports 	1992	637
1433512	920	Willey RL	Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4.	Journal of virology	1992	204
2214018	920	Page KA	Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity.	Journal of virology	1990	144
2395859	920	Daar ES	High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.	Proceedings of the National Academy of Sciences of the United States of America	1990	162
2564898	920	Tersmette M	Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.	Journal of virology	1989	210
2665081	920	Schnittman SM	The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4.	Science	1989	173
2760980	920	Kim SY	Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression.	Journal of virology	1989	230
3257102	920	Willey RL	In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity.	Journal of virology	1988	319
3277274	920	Fauci AS	The human immunodeficiency virus: infectivity and mechanisms of pathogenesis.	Science	1988	292
3299089	920	Fischl MA	The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.	The New England journal of medicine	1987	269
6096719	920	Dalgleish AG	The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.	Nature	1984	854
7540117	920	Fisher GH	Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.	Cell	1995	207
7738173	920	Roederer M	CD8 naive T cell counts decrease progressively in HIV-infected adults.	The Journal of clinical investigation	1995	130
7935654	920	Connor EM	Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.	The New England journal of medicine	1994	399
8095306	920	Connor RI	Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals.	Journal of virology	1993	135
8096068	920	Embretson J	Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.	Nature	1993	306
8124721	920	Aiken C	Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain.	Cell	1994	235
8187174	920	York IA	A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes.	Cell	1994	164
8445728	920	Dimitrov DS	Quantitation of human immunodeficiency virus type 1 infection kinetics.	Journal of virology	1993	200
8614801	920	Wolinsky SM	Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.	Science	1996	176
9105756	920	Alvar J	Leishmania and human immunodeficiency virus coinfection: the first 10 years.	Clinical microbiology reviews	1997	111
9188531	920	Orenstein JM	Macrophages as a source of HIV during opportunistic infections.	Science	1997	152
9217758	920	Cohen MS	Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group.	Lancet	1997	181
9287227	920	Hammer SM	A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.	The New England journal of medicine	1997	394
9287228	920	Gulick RM	Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.	The New England journal of medicine	1997	297
9371822	920	Chun TW	Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.	Proceedings of the National Academy of Sciences of the United States of America	1997	463
9466638	920	Hogg RS	Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.	JAMA	1998	159
9516219	920	Palella FJ Jr	Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.	The New England journal of medicine	1998	1574
9525993	920	Koelle DM	Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes.	The Journal of clinical investigation	1998	103
10037100	920	Palefsky JM	Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women.	Journal of the National Cancer Institute	1999	118
10196297	920	Mascola JR	Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.	Journal of virology	1999	336
10232311	920	Anglaret X	Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group.	Lancet	1999	104
10232312	920	Wiktor SZ	Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial.	Lancet	1999	106
10341272	920	Zhang L	Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.	The New England journal of medicine	1999	195
10386555	920	Shapiro MF	Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study.	JAMA	1999	194
10419445	920	Lucas GM	Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.	Annals of internal medicine	1999	141
10498659	920	Benhamou Y	Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.	Hepatology	1999	208
10500077	920	Gerlach JT	Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C.	Gastroenterology	1999	163
10607709	920	Hazenberg MD	T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).	Blood	2000	129
10770911	920	Kaplan JE	Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.	Clinical infectious diseases 	2000	115
10837072	920	Pierson T	Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.	Annual review of immunology	2000	162
10877736	920	Paterson DL	Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.	Annals of internal medicine	2000	674
11009139	920	Whitworth J	Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study.	Lancet	2000	106
11117912	920	Greub G	Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.	Lancet	2000	151
11248160	920	Freedberg KA	The cost effectiveness of combination antiretroviral therapy for HIV disease.	The New England journal of medicine	2001	109
11309627	920	McCune JM	The dynamics of CD4+ T-cell depletion in HIV disease.	Nature	2001	151
11348697	920	Siegrist CA	Neonatal and early life vaccinology.	Vaccine	2001	132
11434728	920	Murphy EL	Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.	Annals of internal medicine	2001	121
11483742	920	Janini M	Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells.	Journal of virology	2001	88
11500352	920	Retamales I	Amplification of inflammation in emphysema and its association with latent adenoviral infection.	American journal of respiratory and critical care medicine	2001	91
11585784	920	Lawn SD	Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection.	Clinical microbiology reviews	2001	88
11672548	920	Eckstein DA	HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues.	Immunity	2001	106
11696593	920	Mohri H	Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy.	The Journal of experimental medicine	2001	105
11711588	920	Betts MR	Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection.	Journal of virology	2001	251
11748275	920	Kovacs JA	Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV.	The Journal of experimental medicine	2001	85
11752161	920	Zhu T	Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy.	Journal of virology	2002	115
11794218	920	Gortmaker SL	Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.	The New England journal of medicine	2001	99
11861835	920	Edwards TG	Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.	Journal of virology	2002	92
11873003	920	Morgan D	HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?	AIDS	2002	89
11917238	920	Giorgi JV	Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection.	Journal of acquired immune deficiency syndromes	2002	96
11953469	920	French N	Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults.	AIDS	2002	100
12086758	920	Badri M	Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.	Lancet	2002	145
12126821	920	Egger M	Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.	Lancet	2002	381
12131186	920	Ling B	SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans.	AIDS	2002	89
12218162	920	Sousa AE	CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load.	Journal of immunology	2002	154
12393849	920	Schacker TW	Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis.	The Journal of clinical investigation	2002	82
12409739	920	Howard AA	A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women.	AIDS	2002	87
12411292	920	Gamadia LE	Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease.	Blood	2003	108
12491162	920	Sacktor N	The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy.	Journal of neurovirology	2002	109
12493258	920	Thio CL	HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).	Lancet	2002	211
12524385	920	Douek DC	T cell dynamics in HIV-1 infection.	Annual review of immunology	2003	185
12552096	920	Chun TW	Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals.	Proceedings of the National Academy of Sciences of the United States of America	2003	76
12637625	920	Lalezari JP	Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.	The New England journal of medicine	2003	148
12648460	920	Silvestri G	Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia.	Immunity	2003	257
12693883	920	Palella FJ Jr	Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.	Annals of internal medicine	2003	109
12721933	920	Hunt PW	T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.	The Journal of infectious diseases	2003	296
12805437	920	Hermankova M	Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo.	Journal of virology	2003	81
12960820	920	Hazenberg MD	Persistent immune activation in HIV-1 infection is associated with progression to AIDS.	AIDS	2003	255
14557216	920	Kaufmann GR	CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.	Archives of internal medicine	2003	85
14557656	920	Guadalupe M	Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy.	Journal of virology	2003	336
14610491	920	Shearer WT	Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study.	The Journal of allergy and clinical immunology	2003	152
14722271	920	Brenchley JM	T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis.	Journal of virology	2004	161
14966528	920	Papagno L	Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection.	PLoS biology	2004	124
15023877	920	Hsue PY	Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection.	Circulation	2004	148
15034567	920	Reece WH	A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease.	Nature medicine	2004	86
15060436	920	Coetzee D	Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa.	AIDS	2004	207
15117761	920	Deeks SG	Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load.	Blood	2004	289
15163705	920	Han Y	Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes.	Journal of virology	2004	127
15210746	920	Matano T	Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.	The Journal of experimental medicine	2004	89
15229304	920	Fawzi WW	A randomized trial of multivitamin supplements and HIV disease progression and mortality.	The New England journal of medicine	2004	81
15234856	920	Ledergerber B	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.	Lancet	2004	75
15247338	920	Lallemant M	Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.	The New England journal of medicine	2004	104
15247339	920	Jourdain G	Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.	The New England journal of medicine	2004	105
15247437	920	Hazuda DJ	Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques.	Science	2004	73
15280419	920	Kinter AL	CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status.	The Journal of experimental medicine	2004	159
15327410	920	Szczech LA	The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection.	Kidney international	2004	80
15362047	920	Lauer GM	High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection.	Gastroenterology	2004	96
15365130	920	Valcour V	Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort.	Neurology	2004	131
15376257	920	Ulrichs T	Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung.	The Journal of pathology	2004	82
15464184	920	Newell ML	Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis.	Lancet	2004	324
15488218	920	Mermin J	Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda.	Lancet	2004	109
15545358	920	Messaoudi I	Age-related CD8 T cell clonal expansions constrict CD8 T cell repertoire and have the potential to impair immune defense.	The Journal of experimental medicine	2004	72
15555666	920	Chintu C	Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial.	Lancet	2004	96
15577629	920	Buchacz K	Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections.	AIDS	2004	92
15652606	920	Kublin JG	Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study.	Lancet	2005	86
15703422	920	Sanders GD	Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.	The New England journal of medicine	2005	159
15793563	920	Mattapallil JJ	Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection.	Nature	2005	557
15827153	920	Nobile C	Covert human immunodeficiency virus replication in dendritic cells and in DC-SIGN-expressing cells promotes long-term transmission to lymphocytes.	Journal of virology	2005	65
15840880	920	Strickler HD	Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women.	Journal of the National Cancer Institute	2005	162
15983918	920	Ivers LC	Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.	Clinical infectious diseases 	2005	119
15994817	920	Reynolds MR	CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little.	Journal of virology	2005	75
16093359	920	Pudney J	Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone.	Biology of reproduction	2005	105
16103772	920	Palefsky JM	Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men.	AIDS	2005	67
16116308	920	Fleishman JA	Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002.	Medical care	2005	74
16116467	920	Klenerman P	T cells and viral persistence: lessons from diverse infections.	Nature immunology	2005	132
16147978	920	Sylwester AW	Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects.	The Journal of experimental medicine	2005	363
16182404	920	Bräu N	Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.	Journal of hepatology	2006	89
16227428	920	Thompson PM	Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline.	Proceedings of the National Academy of Sciences of the United States of America	2005	117
16276421	920	Chun TW	HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.	The Journal of clinical investigation	2005	117
16284464	920	Lawn SD	Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design.	AIDS	2005	172
16319381	920	Severe P	Antiretroviral therapy in a thousand patients with AIDS in Haiti.	The New England journal of medicine	2005	99
16327318	920	Wools-Kaloustian K	Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya.	AIDS	2006	107
16339561	920	Fletcher JM	Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion.	Journal of immunology	2005	66
16364740	920	Yamashita M	Retroviral infection of non-dividing cells: old and new perspectives.	Virology	2006	75
16421366	920	Gallant JE	Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.	The New England journal of medicine	2006	193
16482171	920	Brenchley JM	HIV disease: fallout from a mucosal catastrophe?	Nature immunology	2006	197
16549832	920	Engels EA	Elevated incidence of lung cancer among HIV-infected individuals.	Journal of clinical oncology 	2006	77
16631548	920	Battegay M	Immunological recovery and antiretroviral therapy in HIV-1 infection.	The Lancet. Infectious diseases	2006	61
16631881	920	Mermin J	Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.	Lancet	2006	74
16645169	920	Titanji K	Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection.	Blood	2006	116
16670804	920	Bekker LG	Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa.	South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde	2006	66
16691070	920	Etard JF	Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.	AIDS	2006	124
16735692	920	Mattapallil JJ	Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge.	The Journal of experimental medicine	2006	80
16753288	920	Picker LJ	Immunopathogenesis of acute AIDS virus infection.	Current opinion in immunology	2006	73
16763152	920	Letvin NL	Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys.	Science	2006	178
16824132	920	Harari A	Functional signatures of protective antiviral T-cell immunity in human virus infections.	Immunological reviews	2006	104
16878047	920	Palella FJ Jr	Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.	Journal of acquired immune deficiency syndromes	2006	382
16885778	920	Manosuthi W	Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy.	Journal of acquired immune deficiency syndromes	2006	91
16905783	920	Gulick RM	Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.	JAMA	2006	75
16905788	920	Hammer SM	Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.	JAMA	2006	160
17063130	920	Schackman BR	The lifetime cost of current human immunodeficiency virus care in the United States.	Medical care	2006	144
17090675	920	Levine BL	Gene transfer in humans using a conditionally replicating lentiviral vector.	Proceedings of the National Academy of Sciences of the United States of America	2006	159
17135583	920	Strategies for Management of Antiretroviral Therapy (SMART) Study Group.	CD4+ count-guided interruption of antiretroviral treatment.	The New England journal of medicine	2006	629
17217334	920	Lackner AA	Current concepts in AIDS pathogenesis: insights from the SIV/macaque model.	Annual review of medicine	2007	59
17224919	920	Han Y	Experimental approaches to the study of HIV-1 latency.	Nature reviews. Microbiology	2007	91
17255740	920	Lawn SD	Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa.	AIDS	2007	112
17258731	920	von Hahn T	Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.	Gastroenterology	2007	144
17267500	920	Chaudhuri R	Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the AP2 clathrin adaptor.	Journal of virology	2007	83
17357054	920	Baeten JM	HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads.	The Journal of infectious diseases	2007	81
17457094	920	Szczech LA	Microalbuminuria in HIV infection.	AIDS	2007	58
17492591	920	Chun TW	Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.	The Journal of infectious diseases	2007	72
17503751	920	Orrell C	Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.	Antiviral therapy	2007	57
17554710	920	Kirk GD	HIV infection is associated with an increased risk for lung cancer, independent of smoking.	Clinical infectious diseases 	2007	120
17620755	920	Palombi L	Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV.	AIDS	2007	58
17659333	920	Mocroft A	Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.	Lancet	2007	62
17709519	920	Milush JM	Virally induced CD4+ T cell depletion is not sufficient to induce AIDS in a natural host.	Journal of immunology	2007	65
17713158	920	Boulle A	Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort.	Antiviral therapy	2007	58
17728240	920	Chen P	Predominant mode of human immunodeficiency virus transfer between T cells is mediated by sustained Env-dependent neutralization-resistant virological synapses.	Journal of virology	2007	172
17894380	920	Bhaskaran K	Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy.	Annals of neurology	2008	55
17913974	920	Venet F	Regulatory T cell populations in sepsis and trauma.	Journal of leukocyte biology	2008	56
17916442	920	Boasso A	Chronic innate immune activation as a cause of HIV-1 immunopathogenesis.	Clinical immunology	2008	78
17954540	920	Bolton-Moore C	Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia.	JAMA	2007	156
17959677	920	Sankaran S	Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration.	Journal of virology	2008	82
17986574	920	Koch S	Cytomegalovirus infection: a driving force in human T cell immunosenescence.	Annals of the New York Academy of Sciences	2007	62
18025885	920	Moh R	Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.	AIDS	2007	62
18171295	920	Hunt PW	Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.	The Journal of infectious diseases	2008	248
18190322	920	Goulet JL	Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity?	Clinical infectious diseases 	2007	99
18198941	920	Denton PW	Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.	PLoS medicine	2008	154
18199042	920	Patel K	Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.	Clinical infectious diseases 	2008	67
18240953	920	Moir S	Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease.	The Journal of infectious diseases	2008	62
18260759	920	Chun TW	Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.	The Journal of infectious diseases	2008	177
18266607	920	Kiwanuka N	Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection.	The Journal of infectious diseases	2008	101
18382686	920	Funderburg N	Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis.	PloS one	2008	60
18427202	920	Baker JV	CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.	AIDS	2008	106
18440426	920	Phillips AN	Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.	Lancet	2008	77
18476292	920	Strategies for Management of Antiretroviral Therapy (SMART) Study Group.	Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.	The Journal of infectious diseases	2008	123
18476293	920	Strategies for Management of Antiretroviral Therapy (SMART) Study Group.	Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.	The Journal of infectious diseases	2008	59
18480202	920	Riddler SA	Class-sparing regimens for initial treatment of HIV-1 infection.	The New England journal of medicine	2008	191
18494555	920	Bisson GP	Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy.	PLoS medicine	2008	68
18505169	920	Phillips AN	Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.	Antiviral therapy	2008	59
18525258	920	Archin NM	Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.	AIDS	2008	84
18579608	920	Chase AJ	Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation.	Journal of virology	2008	59
18598193	920	Estes J	Collagen deposition limits immune reconstitution in the gut.	The Journal of infectious diseases	2008	63
18664624	920	Brenchley JM	Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections.	Blood	2008	245
18677028	920	Hammer SM	Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.	JAMA	2008	294
18765698	920	SMART Study Group.	Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.	Annals of internal medicine	2008	66
18784453	920	Lawn SD	Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa.	AIDS	2008	303
18981768	920	Nash D	Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.	AIDS	2008	80
18981769	920	Bussmann H	Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program.	AIDS	2008	72
19020325	920	Violari A	Early antiretroviral therapy and mortality among HIV-infected infants.	The New England journal of medicine	2008	388
19072715	920	Mugavero MJ	Missed visits and mortality among patients establishing initial outpatient HIV treatment.	Clinical infectious diseases 	2009	134
19079157	920	Brenchley JM	HIV infection and the gastrointestinal immune system.	Mucosal immunology	2008	132
19079215	920	Macal M	Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses.	Mucosal immunology	2008	81
19114870	920	Lawn SD	Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa.	AIDS	2009	71
19123865	920	Robbins GK	Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.	Clinical infectious diseases 	2009	73
19123868	920	Gazzola L	The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.	Clinical infectious diseases 	2009	65
19144703	920	Duverger A	Determinants of the establishment of human immunodeficiency virus type 1 latency.	Journal of virology	2009	58
19223334	920	Chi BH	Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia.	International journal of epidemiology	2009	48
19265479	920	Jiang W	Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.	The Journal of infectious diseases	2009	236
19307857	920	Ettenhofer ML	Aging, neurocognition, and medication adherence in HIV infection.	The American journal of geriatric psychiatry 	2009	47
19339714	920	Kitahata MM	Effect of early versus deferred antiretroviral therapy for HIV on survival.	The New England journal of medicine	2009	383
19383966	920	Hasegawa A	The level of monocyte turnover predicts disease progression in the macaque model of AIDS.	Blood	2009	61
19390417	920	Hsue PY	Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis.	AIDS	2009	123
19444075	920	Grabar S	Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV.	AIDS	2009	50
19461502	920	Lawn SD	Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.	AIDS	2009	103
19504725	920	Bassett IV	Loss to care and death before antiretroviral therapy in Durban, South Africa.	Journal of acquired immune deficiency syndromes	2009	90
19569972	920	Kantor R	Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings.	Clinical infectious diseases 	2009	57
19571723	920	Marin B	Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.	AIDS	2009	71
19616720	920	Wawer MJ	Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial.	Lancet	2009	96
19620143	920	Walensky RP	When to start antiretroviral therapy in resource-limited settings.	Annals of internal medicine	2009	70
19640996	920	Piantadosi A	Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression.	Journal of virology	2009	80
19647202	920	Carson KR	Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.	The Lancet. Oncology	2009	110
19673615	920	Castelnuovo B	Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort.	Clinical infectious diseases 	2009	58
19728788	920	French MA	Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells.	The Journal of infectious diseases	2009	67
19770514	920	Sauce D	Evidence of premature immune aging in patients thymectomized during early childhood.	The Journal of clinical investigation	2009	65
19818686	920	Guiguet M	Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.	The Lancet. Oncology	2009	140
19911963	920	Hoffmann CJ	Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa.	Clinical infectious diseases 	2009	53
19923174	920	Doria-Rose NA	Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.	Journal of virology	2010	140
20023438	920	Bassett IV	Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should.	AIDS	2010	75
20089951	920	Celum C	Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.	The New England journal of medicine	2010	216
20108382	920	Lawn SD	Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease.	AIDS	2009	81
20113183	920	Cohen RA	Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era.	Journal of neurovirology	2010	72
20139992	920	Flatz L	Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.	Nature medicine	2010	43
20170371	920	Euler Z	Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.	The Journal of infectious diseases	2010	66
20181971	920	Abdool Karim SS	Timing of initiation of antiretroviral drugs during tuberculosis therapy.	The New England journal of medicine	2010	223
20181972	920	Cain KP	An algorithm for tuberculosis screening and diagnosis in people with HIV.	The New England journal of medicine	2010	87
20201977	920	Yi JS	T-cell exhaustion: characteristics, causes and conversion.	Immunology	2010	90
20208541	920	Carter CC	HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs.	Nature medicine	2010	112
20234368	920	Daayana S	Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia.	British journal of cancer	2010	57
20347483	920	Walker AS	Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.	Lancet	2010	48
20352098	920	Dheda K	Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples.	PloS one	2010	47
20380565	920	Antiretroviral Therapy Cohort Collaboration.	Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.	Clinical infectious diseases 	2010	132
20415574	920	Makadzange AT	Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa.	Clinical infectious diseases 	2010	55
20453631	920	Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group.	Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study.	AIDS	2010	121
20457954	920	Ellis RJ	Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.	Archives of neurology	2010	84
20505494	920	Ford ES	Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection.	AIDS	2010	73
20516524	920	Letendre SL	Neurologic complications of HIV disease and their treatment.	Topics in HIV medicine 	2010	84
20537376	920	Donnell D	Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.	Lancet	2010	343
20550452	920	Julg B	Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.	Clinical infectious diseases 	2010	49
20554983	920	Shapiro RL	Antiretroviral regimens in pregnancy and breast-feeding in Botswana.	The New England journal of medicine	2010	159
20559035	920	Wallet MA	Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy.	AIDS	2010	55
20561080	920	Antinori A	Late presentation of HIV infection: a consensus definition.	HIV medicine	2011	68
20597691	920	Lichtenstein KA	Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study.	Clinical infectious diseases 	2010	76
20597693	920	Meya DB	Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count &amp;lt; or = 100 cells/microL who start HIV therapy in resource-limited settings.	Clinical infectious diseases 	2010	78
20610331	920	Lawn SD	Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources.	The Lancet. Infectious diseases	2010	56
20617921	920	Walensky RP	Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC.	Clinical infectious diseases 	2010	55
20638120	920	May M	Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.	Lancet	2010	103
20647201	920	Severe P	Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.	The New England journal of medicine	2010	136
20683336	920	Selke HM	Task-shifting of antiretroviral delivery from health care workers to persons living with HIV/AIDS: clinical outcomes of a community-based program in Kenya.	Journal of acquired immune deficiency syndromes	2010	69
20697368	920	Cutler C	Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.	Bone marrow transplantation	2011	38
20711481	920	Gandhi RT	The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.	PLoS medicine	2010	119
20735240	920	Bassett IV	Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa.	Clinical infectious diseases 	2010	63
20827162	920	Yukl SA	Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.	AIDS	2010	104
20827216	920	Kranzer K	Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors.	Journal of acquired immune deficiency syndromes	2010	43
20844049	920	Murray SM	Reduction of immune activation with chloroquine therapy during chronic HIV infection.	Journal of virology	2010	48
20859193	920	Gebo KA	Contemporary costs of HIV healthcare in the HAART era.	AIDS	2010	41
20865049	920	Lugada E	Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya.	PloS one	2010	40
20889546	920	Gordon SN	Disruption of intestinal CD4+ T cell homeostasis is a key marker of systemic CD4+ T cell activation in HIV-infected individuals.	Journal of immunology	2010	48
20924117	920	Kennedy EM	Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages.	The Journal of biological chemistry	2010	42
20942667	920	Palumbo P	Antiretroviral treatment for children with peripartum nevirapine exposure.	The New England journal of medicine	2010	88
21034222	920	Moir S	Pathogenic mechanisms of HIV disease.	Annual review of pathology	2011	83
21072191	920	Kranzer K	Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa.	PloS one	2010	72
21098232	920	Draper SJ	Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.	Journal of immunology	2010	49
21105780	920	Soghoian DZ	Cytolytic CD4(+) T cells in viral immunity.	Expert review of vaccines	2010	48
21173675	920	Koyanagi A	Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy.	The Pediatric infectious disease journal	2011	45
21174240	920	Heaton RK	HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.	Journal of neurovirology	2011	438
21217181	920	Crump JA	Invasive bacterial and fungal infections among hospitalized HIV-infected and HIV-uninfected adults and adolescents in northern Tanzania.	Clinical infectious diseases 	2011	48
21220772	920	Kaplan RC	T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women.	The Journal of infectious diseases	2011	106
21249232	920	Mikell I	Characteristics of the earliest cross-neutralizing antibody response to HIV-1.	PLoS pathogens	2011	135
21325137	920	Ganesan A	High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial.	The Journal of infectious diseases	2011	48
21367910	920	Anderson JA	Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells.	Journal of virology	2011	38
21378536	920	Chege D	Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy.	AIDS	2011	44
21398272	920	Young B	Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006.	Clinical infectious diseases 	2011	64
21403397	920	Chen H	CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21.	The Journal of clinical investigation	2011	69
21412126	920	Appay V	Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients.	AIDS	2011	41
21492926	920	Samandari T	6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.	Lancet	2011	94
21494598	920	Merlini E	Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy.	PloS one	2011	42
21502083	920	Hunt PW	Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy.	The Journal of infectious diseases	2011	98
21502920	920	Okulicz JF	Epidemiology and clinical characteristics of elite controllers.	Current opinion in HIV and AIDS	2011	37
21543722	920	Letvin NL	Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys.	Science translational medicine	2011	109
21559280	920	Boyles TH	Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme.	PloS one	2011	38
21625591	920	Gallegos AM	A gamma interferon independent mechanism of CD4 T cell mediated control of M. tuberculosis infection in vivo.	PLoS pathogens	2011	54
21656145	920	Schwartz SR	High pregnancy intentions and missed opportunities for patient-provider communication about fertility in a South African cohort of HIV-positive women on antiretroviral therapy.	AIDS and behavior	2012	46
21666786	920	Cota GF	Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.	PLoS neglected tropical diseases	2011	40
21690402	920	Josefsson L	Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule.	Proceedings of the National Academy of Sciences of the United States of America	2011	75
21725250	920	Byrd DA	Neurocognitive impact of substance use in HIV infection.	Journal of acquired immune deficiency syndromes	2011	46
21737504	920	Grossman SA	Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.	Clinical cancer research 	2011	75
21750418	920	Nash D	Program-level and contextual-level determinants of low-median CD4+ cell count in cohorts of persons initiating ART in eight sub-Saharan African countries.	AIDS	2011	41
21836524	920	Govindasamy D	Linkage to HIV care from a mobile testing unit in South Africa by different CD4 count strata.	Journal of acquired immune deficiency syndromes	2011	39
21857654	920	Sullivan NJ	CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates.	Nature medicine	2011	61
21890751	920	Mugavero MJ	Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.	Clinical infectious diseases 	2011	41
21917895	920	Lederman MM	Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells.	The Journal of infectious diseases	2011	93
21963677	920	Kreijtz JH	Immune responses to influenza virus infection.	Virus research	2011	63
21990260	920	May M	Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study.	BMJ	2011	73
22010913	920	Blanc FX	Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.	The New England journal of medicine	2011	175
22010914	920	Havlir DV	Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.	The New England journal of medicine	2011	172
22010915	920	Abdool Karim SS	Integration of antiretroviral therapy with tuberculosis treatment.	The New England journal of medicine	2011	138
22074711	920	Mermin J	Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial.	BMJ	2011	54
22101430	920	Waggoner SN	Natural killer cells act as rheostats modulating antiviral T cells.	Nature	2011	142
22160724	920	Aubert RD	Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.	Proceedings of the National Academy of Sciences of the United States of America	2011	60
22173233	920	Anglaret X	AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire.	Clinical infectious diseases 	2012	34
22213804	920	Schulze Zur Wiesch J	Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence.	The Journal of experimental medicine	2012	51
22219223	920	Mahnke YD	Selective expansion of polyfunctional pathogen-specific CD4(+) T cells in HIV-1-infected patients with immune reconstitution inflammatory syndrome.	Blood	2012	36
22240256	920	Witwer KW	Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients.	Retrovirology	2012	49
22253579	920	Ciaranello AL	What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-to-child HIV transmission in Zimbabwe: a model-based analysis.	PLoS medicine	2012	31
22273267	920	Nglazi MD	Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa.	BMC infectious diseases	2012	34
22286307	920	Wilkinson TM	Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.	Nature medicine	2012	235
22315957	920	Shah K	A new frailty syndrome: central obesity and frailty in older adults with the human immunodeficiency virus.	Journal of the American Geriatrics Society	2012	32
22362849	920	Peter JG	Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients.	The European respiratory journal	2012	53
22394050	920	Ferguson L	Linking women who test HIV-positive in pregnancy-related services to long-term HIV care and treatment services: a systematic review.	Tropical medicine and international health 	2012	43
22406268	920	Shan L	Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.	Immunity	2012	263
22536323	920	Manabe YC	Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapy.	PloS one	2012	30
22547421	920	Babiker AG	Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.	Clinical trials	2013	55
22614889	920	Peluso MJ	Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.	AIDS	2012	41
22615543	920	Gibb DM	Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.	PLoS medicine	2012	37
22645358	920	Archin NM	Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection.	Proceedings of the National Academy of Sciences of the United States of America	2012	81
22668560	920	Brust JC	Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care.	The international journal of tuberculosis and lung disease 	2012	31
22673491	920	Damjanovic D	Immunopathology in influenza virus infection: uncoupling the friend from foe.	Clinical immunology	2012	37
22716976	920	Violari A	Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.	The New England journal of medicine	2012	71
22739389	920	Sunpath H	High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.	AIDS	2012	32
22784037	920	Baeten JM	Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.	The New England journal of medicine	2012	747
22789644	920	Kim MH	The Tingathe programme: a pilot intervention using community health workers to create a continuum of care in the prevention of mother to child transmission of HIV (PMTCT) cascade of services in Malawi.	Journal of the International AIDS Society	2012	44
22802730	920	Eaton JW	HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa.	PLoS medicine	2012	118
22820792	920	Thompson MA	Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.	JAMA	2012	262
22837004	920	Archin NM	Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.	Nature	2012	340
22911011	920	Suthar AB	Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.	PLoS medicine	2012	88
22973181	920	Cornell M	Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.	PLoS medicine	2012	61
22990012	920	Brenchley JM	Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections.	Blood	2012	56
22994151	920	Mugglin C	Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis.	Tropical medicine and international health 	2012	88
22998068	920	Weber R	Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study.	HIV medicine	2013	54
23065532	920	Kalichman SC	Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs.	Journal of general internal medicine	2013	34
23066160	920	Chen JY	Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana.	The Journal of infectious diseases	2012	71
23148285	920	Nayak JL	CD4+ T-cell expansion predicts neutralizing antibody responses to monovalent, inactivated 2009 pandemic influenza A(H1N1) virus subtype H1N1 vaccine.	The Journal of infectious diseases	2013	27
23172341	920	Stover J	Updates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children.	Sexually transmitted infections	2012	45
23206835	920	Jia Z	Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study.	Lancet	2013	46
23254153	920	Abraham AG	Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study.	Journal of acquired immune deficiency syndromes	2013	36
23292280	920	Yang M	Regulatory B cells in autoimmune diseases.	Cellular and molecular immunology	2013	38
23315315	920	Gale HB	Is frequent CD4+ T-lymphocyte count monitoring necessary for persons with counts &amp;gt;=300 cells/μL and HIV-1 suppression?	Clinical infectious diseases 	2013	25
23323897	920	SPARTAC Trial Investigators.	Short-course antiretroviral therapy in primary HIV infection.	The New England journal of medicine	2013	70
23323898	920	Le T	Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy.	The New England journal of medicine	2013	117
23397353	920	Barron P	Eliminating mother-to-child HIV transmission in South Africa.	Bulletin of the World Health Organization	2013	33
23408629	920	Dahabieh MS	A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection.	Journal of virology	2013	25
23418518	920	Luque-Fernandez MA	Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa.	PloS one	2013	37
23435170	920	van Heijst JW	Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation.	Nature medicine	2013	47
23446514	920	Centers for Disease Control and Prevention (CDC).	Impact of an innovative approach to prevent mother-to-child transmission of HIV--Malawi, July 2011-September 2012.	MMWR. Morbidity and mortality weekly report	2013	81
23459007	920	Eriksson S	Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.	PLoS pathogens	2013	157
23525034	920	Chang CC	Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome.	AIDS	2013	27
23532480	920	Witt MD	Incident hepatitis C virus infection in men who have sex with men: a prospective cohort analysis, 1984-2011.	Clinical infectious diseases 	2013	28
23585736	920	Johnson LF	Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies.	PLoS medicine	2013	82
23647555	920	Ngarina M	Reasons for poor adherence to antiretroviral therapy postnatally in HIV-1 infected women treated for their own health: experiences from the Mitra Plus study in Tanzania.	BMC public health	2013	25
23698063	920	Rodger AJ	Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population.	AIDS	2013	77
23698354	920	Moyer VA	Screening for HIV: U.S. Preventive Services Task Force Recommendation Statement.	Annals of internal medicine	2013	80
23719296	920	Younan PM	Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model.	Blood	2013	31
23732522	920	Pan X	Restrictions to HIV-1 replication in resting CD4+ T lymphocytes.	Cell research	2013	28
23737751	920	Laird GM	Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay.	PLoS pathogens	2013	58
23772614	920	Okoye AA	CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure.	Immunological reviews	2013	54
23772616	920	Paiardini M	HIV-associated chronic immune activation.	Immunological reviews	2013	47
23780395	920	Hall HI	Differences in human immunodeficiency virus care and treatment among subpopulations in the United States.	JAMA internal medicine	2013	112
23818847	920	Josefsson L	Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule.	PLoS pathogens	2013	33
23852127	920	Jain V	Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.	The Journal of infectious diseases	2013	83
23878231	920	Pace CS	Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.	Proceedings of the National Academy of Sciences of the United States of America	2013	27
23886064	920	Lederman MM	Residual immune dysregulation syndrome in treated HIV infection.	Advances in immunology	2013	68
23921881	920	Mocroft A	The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.	Clinical infectious diseases 	2013	26
23943825	920	Grant PM	Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.	Clinical infectious diseases 	2013	29
24041796	920	Naranbhai V	Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy.	The Journal of infectious diseases	2014	21
24064670	920	Turner DL	Lung niches for the generation and maintenance of tissue-resident memory T cells.	Mucosal immunology	2014	58
24121761	920	Gray KM	Jurisdiction level differences in HIV diagnosis, retention in care, and viral suppression in the United States.	Journal of acquired immune deficiency syndromes	2014	21
24180001	920	Pérez-Santiago J	Gut Lactobacillales are associated with higher CD4 and less microbial translocation during HIV infection.	AIDS	2013	28
24198226	920	Lahuerta M	Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries.	Clinical infectious diseases 	2014	38
24204277	920	Wibmer CK	Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.	PLoS pathogens	2013	65
24209829	920	Cotton MF	Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.	Lancet	2013	50
24218101	920	Rowley CF	Developments in CD4 and viral load monitoring in resource-limited settings.	Clinical infectious diseases 	2014	21
24226057	920	Luetkemeyer AF	Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs.	Journal of acquired immune deficiency syndromes	2014	21
24352352	920	Ellis RJ	Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.	Clinical infectious diseases 	2014	23
24382064	920	Bwakura-Dangarembizi M	A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.	The New England journal of medicine	2014	28
24384692	920	Ananworanich J	Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children.	AIDS	2014	23
24417396	920	Cribbs SK	Metabolomics of bronchoalveolar lavage differentiate healthy HIV-1-infected subjects from controls.	AIDS research and human retroviruses	2014	20
24442222	920	Silverberg MJ	Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care.	Journal of acquired immune deficiency syndromes	2014	29
24447595	920	Wynberg E	Impact of point-of-care CD4 testing on linkage to HIV care: a systematic review.	Journal of the International AIDS Society	2014	40
24448112	920	Wang S	Micro-a-fluidics ELISA for rapid CD4 cell count at the point-of-care.	Scientific reports	2014	22
24457342	920	Engsig FN	Long-term mortality in HIV-positive individuals virally suppressed for &amp;gt;3 years with incomplete CD4 recovery.	Clinical infectious diseases 	2014	23
24465532	920	Ngarina M	Women's preferences regarding infant or maternal antiretroviral prophylaxis for prevention of mother-to-child transmission of HIV during breastfeeding and their views on Option B+ in Dar es Salaam, Tanzania.	PloS one	2014	25
24497929	920	Serrano-Villar S	Increased risk of serious non-AIDS-related events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio.	PloS one	2014	32
24501199	920	Wertheimer AM	Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans.	Journal of immunology	2014	40
24508219	920	Pfefferbaum A	Accelerated aging of selective brain structures in human immunodeficiency virus infection: a controlled, longitudinal magnetic resonance imaging study.	Neurobiology of aging	2014	28
24556869	920	May MT	Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.	AIDS	2014	57
24602844	920	Grinsztejn B	Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.	The Lancet. Infectious diseases	2014	101
24608176	920	Sullivan PS	Understanding racial HIV/STI disparities in black and white men who have sex with men: a multilevel approach.	PloS one	2014	54
24675585	920	Nakiyingi L	Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults.	Journal of acquired immune deficiency syndromes	2014	31
24687069	920	Post WS	Associations between HIV infection and subclinical coronary atherosclerosis.	Annals of internal medicine	2014	65
24706775	920	Cillo AR	Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.	Proceedings of the National Academy of Sciences of the United States of America	2014	73
24723284	920	Kojic EM	Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.	Clinical infectious diseases 	2014	24
24759213	920	Kumar A	HIV-1 latency in monocytes/macrophages.	Viruses	2014	37
24771333	920	Ingle SM	Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients.	Clinical infectious diseases 	2014	25
24941443	920	Blair JM	Behavioral and clinical characteristics of persons receiving medical care for HIV infection - Medical Monitoring Project, United States, 2009.	MMWR supplements	2014	24
24965451	920	Buzon MJ	Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells.	Journal of virology	2014	52
24977376	920	Clouse K	"What they wanted was to give birth; nothing else": barriers to retention in option B+ HIV care among postpartum women in South Africa.	Journal of acquired immune deficiency syndromes	2014	33
25056899	920	Arenaccio C	Exosomes from human immunodeficiency virus type 1 (HIV-1)-infected cells license quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef- and ADAM17-dependent mechanism.	Journal of virology	2014	28
25071787	920	Turner DL	Mucosal resident memory CD4 T cells in protection and immunopathology.	Frontiers in immunology	2014	24
25095831	920	Govindasamy D	Interventions to improve or facilitate linkage to or retention in pre-ART (HIV) care and initiation of ART in low- and middle-income settings--a systematic review.	Journal of the International AIDS Society	2014	57
25097264	920	Hill AL	Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1.	Proceedings of the National Academy of Sciences of the United States of America	2014	67
25104632	920	Eaton JW	Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.	The Lancet. Global health	2014	44
25187662	920	Derhovanessian E	Latent infection with cytomegalovirus is associated with poor memory CD4 responses to influenza A core proteins in the elderly.	Journal of immunology	2014	23
25203931	920	Boulle A	Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies.	PLoS medicine	2014	29
25253353	920	Soriano-Sarabia N	Quantitation of replication-competent HIV-1 in populations of resting CD4+ T cells.	Journal of virology	2014	26
25254512	920	Mavigner M	Persistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplant.	PLoS pathogens	2014	24
25301494	920	Phillips T	Disengagement of HIV-positive pregnant and postpartum women from antiretroviral therapy services: a cohort study.	Journal of the International AIDS Society	2014	28
25363779	920	Farh KK	Genetic and epigenetic fine mapping of causal autoimmune disease variants.	Nature	2015	216
25382623	920	Jaafoura S	Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4⁺ memory T Cells.	Nature communications	2014	27
25426834	920	Ledgerwood JE	Chimpanzee Adenovirus Vector Ebola Vaccine.	The New England journal of medicine	2017	37
25467647	920	Ford N	The future role of CD4 cell count for monitoring antiretroviral therapy.	The Lancet. Infectious diseases	2015	19
25501345	920	Koller M	Immunodeficiency in children starting antiretroviral therapy in low-, middle-, and high-income countries.	Journal of acquired immune deficiency syndromes	2015	17
25512624	920	Crowell TA	Hospitalization Rates and Reasons Among HIV Elite Controllers and Persons With Medically Controlled HIV Infection.	The Journal of infectious diseases	2015	17
25516189	920	Siedner MJ	Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis.	Clinical infectious diseases 	2015	52
25586559	920	Klase Z	Dysbiotic bacteria translocate in progressive SIV infection.	Mucosal immunology	2015	28
25601912	920	Barnabas RV	Initiation of antiretroviral therapy and viral suppression after home HIV testing and counselling in KwaZulu-Natal, South Africa, and Mbarara district, Uganda: a prospective, observational intervention study.	The lancet. HIV	2014	34
25681373	920	Fouts TR	Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
25706092	920	Sulkowski MS	Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.	JAMA	2015	65
25706232	920	Osinusi A	Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.	JAMA	2015	41
25723975	920	Charurat ME	Uptake of treatment as prevention for HIV and continuum of care among HIV-positive men who have sex with men in Nigeria.	Journal of acquired immune deficiency syndromes	2015	16
25726088	920	Ndiaye BP	Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.	The Lancet. Respiratory medicine	2015	24
25775592	920	McElroy AK	Human Ebola virus infection results in substantial immune activation.	Proceedings of the National Academy of Sciences of the United States of America	2015	39
25882821	920	Friis-Møller N	An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study.	European journal of preventive cardiology	2016	14
25967273	920	Wang Z	Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by CD8⁺ T cells.	Nature communications	2015	19
26041300	920	Saunders KO	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.	Journal of virology	2015	19
26044074	920	Pera A	Immunosenescence: Implications for response to infection and vaccination in older people.	Maturitas	2015	25
26067822	920	Chavez L	HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells.	PLoS pathogens	2015	27
26130226	920	Lu W	CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients.	Journal of the International AIDS Society	2015	17
26192873	920	INSIGHT START Study Group.	Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.	The New England journal of medicine	2015	340
26193126	920	TEMPRANO ANRS 12136 Study Group.	A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.	The New England journal of medicine	2015	161
26349551	920	Cao W	Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.	Clinical infectious diseases 	2016	13
26405463	920	Kumar A	Epigenetic control of HIV-1 post integration latency: implications for therapy.	Clinical epigenetics	2015	17
26424550	920	Mussini C	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.	The lancet. HIV	2015	21
26452565	920	Younas M	Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy.	HIV medicine	2016	16
26459351	920	Schulz AR	Low Thymic Activity and Dendritic Cell Numbers Are Associated with the Immune Response to Primary Viral Infection in Elderly Humans.	Journal of immunology	2015	17
26633768	920	Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa.	Sustainable HIV treatment in Africa through viral-load-informed differentiated care.	Nature	2015	34
26633769	920	Sharma M	Systematic review and meta-analysis of community and facility-based HIV testing to address linkage to care gaps in sub-Saharan Africa.	Nature	2015	38
26725450	920	De Santis O	Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.	The Lancet. Infectious diseases	2016	17
26743582	920	Ondondo B	Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection.	Molecular therapy 	2016	13
26858442	920	Simonetti FR	Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2016	40
26934227	920	Ma C	NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.	Nature	2016	23
26962942	920	Monaco CL	Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome.	Cell host and microbe	2016	24
27036993	920	Haas AD	Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study.	The lancet. HIV	2016	15
27199430	920	Lu CL	Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.	Science	2016	37
27424812	920	Cohen MS	Antiretroviral Therapy for the Prevention of HIV-1 Transmission.	The New England journal of medicine	2016	40
27470028	920	GBD 2015 HIV Collaborators.	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015.	The lancet. HIV	2016	36
27738167	920	Byrareddy SN	Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy.	Science	2016	20
28199305	920	Mordmüller B	Sterile protection against human malaria by chemoattenuated PfSPZ vaccine.	Nature	2017	10
2431484	925	Walker CM	CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.	Science	1986	248
6272109	925	Gottlieb MS	Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.	The New England journal of medicine	1981	287
7808485	925	Cao Y	Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.	The New England journal of medicine	1995	230
8464405	925	Levy JA	Pathogenesis of human immunodeficiency virus infection.	Microbiological reviews	1993	205
8892876	925	Wills MR	The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.	Journal of virology	1996	155
9420212	925	Matano T	Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques.	Journal of virology	1998	185
9510252	925	Albert ML	Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs.	Nature	1998	397
10837060	925	Harty JT	CD8+ T cell effector mechanisms in resistance to infection.	Annual review of immunology	2000	179
11009080	925	Lechner F	CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained.	European journal of immunology	2000	99
11014195	925	Allen TM	Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.	Nature	2000	264
11927944	925	Appay V	Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.	Nature medicine	2002	394
12165524	925	Khan N	Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals.	Journal of immunology	2002	167
12351674	925	Zhang L	Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor.	Science	2002	83
12368910	925	Migueles SA	HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors.	Nature immunology	2002	331
12574372	925	Karrer U	Memory inflation: continuous accumulation of antiviral CD8+ T cells over time.	Journal of immunology	2003	125
12743287	925	Casimiro DR	Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.	Journal of virology	2003	140
12808447	925	Mongkolsapaya J	Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.	Nature medicine	2003	218
12904795	925	Sullivan NJ	Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.	Nature	2003	143
14633592	925	Theil D	Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response.	The American journal of pathology	2003	89
15140968	925	Webster GJ	Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy.	Journal of virology	2004	82
15194783	925	Allen TM	Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection.	Journal of virology	2004	140
15254203	925	Shrestha B	Role of CD8+ T cells in control of West Nile virus infection.	Journal of virology	2004	166
15280772	925	French MA	Immune restoration disease after antiretroviral therapy.	AIDS	2004	113
15585874	925	Khan N	Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a coresident EBV infection.	Journal of immunology	2004	87
15731261	925	Almanzar G	Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons.	Journal of virology	2005	103
15962289	925	Cox AL	Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.	Hepatology	2005	88
16227247	925	Allen TM	Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution.	Journal of virology	2005	164
16456027	925	Hadrup SR	Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly.	Journal of immunology	2006	115
16496339	925	Neumann-Haefelin C	Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution.	Hepatology	2006	67
17143259	925	Johnson JE	The histopathology of fatal untreated human respiratory syncytial virus infection.	Modern pathology 	2007	115
17325200	925	Zhu J	Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation.	The Journal of experimental medicine	2007	136
17767161	925	Belz GT	Minimal activation of memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells.	Nature immunology	2007	60
18199637	925	Rehr M	Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy.	Journal of virology	2008	54
18462013	925	Streeck H	Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells.	PLoS medicine	2008	110
18468462	925	Miller JD	Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.	Immunity	2008	203
18535580	925	Appay V	CD8+ T cell efficacy in vaccination and disease.	Nature medicine	2008	117
19381260	925	Chen CY	A critical role for CD8 T cells in a nonhuman primate model of tuberculosis.	PLoS pathogens	2009	84
19487423	925	Goonetilleke N	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection.	The Journal of experimental medicine	2009	287
19494307	925	Sáez-Cirión A	Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses.	Journal of immunology	2009	82
20061007	925	Whiteside TL	Immune responses to malignancies.	The Journal of allergy and clinical immunology	2010	45
20193009	925	Shortman K	The CD8+ dendritic cell subset.	Immunological reviews	2010	165
20536568	925	Welsh RM	Heterologous immunity between viruses.	Immunological reviews	2010	84
21398582	925	Yamamoto T	Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection.	Blood	2011	65
21683702	925	Cotton JA	Host parasite interactions and pathophysiology in Giardia infections.	International journal for parasitology	2011	37
21869816	925	Sun JC	NK cell development, homeostasis and function: parallels with CD8⁺ T cells.	Nature reviews. Immunology	2011	137
22090105	925	Kloverpris HN	HLA-B*57 Micropolymorphism shapes HLA allele-specific epitope immunogenicity, selection pressure, and HIV immune control.	Journal of virology	2012	35
22308228	925	Dock JN	Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence.	Aging and disease	2011	40
22355349	925	Weiss WR	Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites.	PloS one	2012	31
22554418	925	Nikolich-Žugich J	Age-related changes in CD8 T cell homeostasis and immunity to infection.	Seminars in immunology	2012	31
23061726	925	Chou JP	T cell replicative senescence in human aging.	Current pharmaceutical design	2013	42
23290140	925	Nishimura T	Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation.	Cell stem cell	2013	64
23516360	925	Sáez-Cirión A	Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.	PLoS pathogens	2013	232
23657257	925	Zhu J	Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection.	Nature	2013	66
23681698	925	Howland SW	Brain microvessel cross-presentation is a hallmark of experimental cerebral malaria.	EMBO molecular medicine	2013	37
23874205	925	Novais FO	Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis.	PLoS pathogens	2013	39
24166483	925	Borthwick N	Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1.	Molecular therapy 	2014	65
24284865	925	Ewer KJ	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.	Nature communications	2013	86
24490585	925	Hanke T	Conserved immunogens in prime-boost strategies for the next-generation HIV-1 vaccines.	Expert opinion on biological therapy	2014	25
24905492	925	Martin B	Restoration of HCV-specific CD8+ T cell function by interferon-free therapy.	Journal of hepatology	2014	25
25165115	925	Pereyra F	HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes.	Journal of virology	2014	20
25320311	925	Weiskopf D	The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.	Journal of virology	2015	24
25855494	925	Fuertes Marraco SA	Long-lasting stem cell-like memory CD8+ T cells with a naïve-like profile upon yellow fever vaccination.	Science translational medicine	2015	27
26362266	925	Ndhlovu ZM	Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point.	Immunity	2015	26
27158907	925	Ishizuka AS	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.	Nature medicine	2016	24
27270402	925	Pulko V	Human memory T cells with a naive phenotype accumulate with aging and respond to persistent viruses.	Nature immunology	2016	14
8764092	1029	Naviaux RK	The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses.	Journal of virology	1996	230
17680565	1029	Smeets SJ	A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen.	International journal of cancer	2007	117
18161048	1029	Nishida N	Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma.	Hepatology	2008	74
18360824	1029	Hafkamp HC	Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas.	International journal of cancer	2008	70
19289615	1029	Lassen P	Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck.	Journal of clinical oncology 	2009	102
20451455	1029	Marur S	HPV-associated head and neck cancer: a virus-related cancer epidemic.	The Lancet. Oncology	2010	283
22833868	1029	Rothenberg SM	The molecular pathogenesis of head and neck squamous cell carcinoma.	The Journal of clinical investigation	2012	72
22949073	1029	Rietbergen MM	Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm.	International journal of cancer	2013	25
23751258	1029	Pathai S	Accelerated biological ageing in HIV-infected individuals in South Africa: a case-control study.	AIDS	2013	28
24798001	1029	Ahn SM	Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.	Hepatology	2014	45
24817381	1029	Alemany L	Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide.	International journal of cancer	2015	33
24821878	1029	Serup-Hansen E	Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal.	Journal of clinical oncology 	2014	24
25267748	1029	Chung CH	p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.	Journal of clinical oncology 	2014	44
26024833	1029	Fu WM	Hotair mediates hepatocarcinogenesis through suppressing miRNA-218 expression and activating P14 and P16 signaling.	Journal of hepatology	2015	24
1370653	1080	Rosenfeld MA	In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium.	Cell	1992	160
9922383	1080	Pilewski JM	Role of CFTR in airway disease.	Physiological reviews	1999	108
14762183	1080	Freedman SD	Association of cystic fibrosis with abnormalities in fatty acid metabolism.	The New England journal of medicine	2004	75
16443646	1080	Van Goor F	Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.	American journal of physiology. Lung cellular and molecular physiology	2006	149
18083779	1080	De La Fuente R	Small-molecule screen identifies inhibitors of a human intestinal calcium-activated chloride channel.	Molecular pharmacology	2008	61
18703788	1080	Kim RD	Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome.	American journal of respiratory and critical care medicine	2008	66
20110417	1080	Meyerholz DK	Pathology of gastrointestinal organs in a porcine model of cystic fibrosis.	The American journal of pathology	2010	56
20622026	1080	Meyerholz DK	Loss of cystic fibrosis transmembrane conductance regulator function produces abnormalities in tracheal development in neonatal pigs and young children.	American journal of respiratory and critical care medicine	2010	59
22481418	1080	Cohen TS	Cystic fibrosis: a mucosal immunodeficiency syndrome.	Nature medicine	2012	95
23704228	1080	Cohen-Cymberknoh M	Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications.	Thorax	2013	29
24925916	1080	Mall MA	CFTR: cystic fibrosis and beyond.	The European respiratory journal	2014	26
24927234	1080	Rowe SM	Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.	American journal of respiratory and critical care medicine	2014	54
25814049	1080	Cantin AM	Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy.	Journal of cystic fibrosis 	2015	31
25917910	1080	Filkins LM	Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model.	Journal of bacteriology	2015	29
27140670	1080	Elborn JS	Cystic fibrosis.	Lancet	2016	20
8649512	1234	Dragic T	HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.	Nature	1996	824
8751444	1234	Samson M	Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.	Nature	1996	583
8756719	1234	Liu R	Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.	Cell	1996	636
8791590	1234	Dean M	Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.	Science	1996	538
9050881	1234	Bleul CC	The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.	Proceedings of the National Academy of Sciences of the United States of America	1997	302
9094670	1234	Chackerian B	Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection.	Journal of virology	1997	120
9525605	1234	Platt EJ	Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.	Journal of virology	1998	505
9836644	1234	Martin MP	Genetic acceleration of AIDS progression by a promoter variant of CCR5.	Science	1998	112
10068581	1234	Giorgi JV	Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.	The Journal of infectious diseases	1999	379
10221916	1234	Harouse JM	Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.	Science	1999	128
10339592	1234	Hoffman TL	Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.	Proceedings of the National Academy of Sciences of the United States of America	1999	111
11160699	1234	Harouse JM	Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3).	Journal of virology	2001	99
11238869	1234	Kolchinsky P	Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.	Journal of virology	2001	89
11317000	1234	Chakraborty H	Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model.	AIDS	2001	86
11588058	1234	Donaghy H	Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load.	Blood	2001	111
11809184	1234	Fellay J	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.	Lancet	2002	82
12036486	1234	Long EM	HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus.	AIDS research and human retroviruses	2002	84
12368468	1234	Münk C	A dominant block to HIV-1 replication at reverse transcription in simian cells.	Proceedings of the National Academy of Sciences of the United States of America	2002	130
12518064	1234	Qin XF	Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.	Proceedings of the National Academy of Sciences of the United States of America	2003	223
15078900	1234	Hu Q	Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue.	The Journal of experimental medicine	2004	85
15365096	1234	Brenchley JM	CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.	The Journal of experimental medicine	2004	650
15637236	1234	Gonzalez E	The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility.	Science	2005	400
16205738	1234	Fätkenheuer G	Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.	Nature medicine	2005	141
16251317	1234	Dorr P	Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.	Antimicrobial agents and chemotherapy	2005	301
16258536	1234	Veazey RS	Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.	Nature	2005	119
16418398	1234	Glass WG	CCR5 deficiency increases risk of symptomatic West Nile virus infection.	The Journal of experimental medicine	2006	132
16973562	1234	Sagar M	Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.	Journal of virology	2006	133
17015824	1234	Dunfee RL	The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia.	Proceedings of the National Academy of Sciences of the United States of America	2006	89
17132723	1234	Zhang L	HIV-1 infection and pathogenesis in a novel humanized mouse model.	Blood	2007	71
17147468	1234	Mehandru S	Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection.	PLoS medicine	2006	104
17243065	1234	Wilkin TJ	HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.	Clinical infectious diseases 	2007	61
17507467	1234	Huang W	Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations.	Journal of virology	2007	78
17670939	1234	An DS	Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates.	Proceedings of the National Academy of Sciences of the United States of America	2007	69
17875002	1234	Zeremski M	The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.	Journal of viral hepatitis	2007	60
18179388	1234	Lim JK	Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic.	The Journal of infectious diseases	2008	62
18549313	1234	Hirsch MS	Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.	Clinical infectious diseases 	2008	123
18587387	1234	Perez EE	Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases.	Nature biotechnology	2008	342
18832244	1234	Gulick RM	Maraviroc for previously treated patients with R5 HIV-1 infection.	The New England journal of medicine	2008	213
18832245	1234	Fätkenheuer G	Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.	The New England journal of medicine	2008	106
19012957	1234	McElrath MJ	HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.	Lancet	2008	334
19213682	1234	Hütter G	Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.	The New England journal of medicine	2009	430
19414777	1234	Cassol E	M1 and M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms.	Journal of immunology	2009	49
19470664	1234	Kim HJ	Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly.	Genome research	2009	142
19487424	1234	Salazar-Gonzalez JF	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.	The Journal of experimental medicine	2009	343
19648930	1234	Zhu J	Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition.	Nature medicine	2009	137
19692480	1234	Johnston SH	A quantitative affinity-profiling system that reveals distinct CD4/CCR5 usage patterns among human immunodeficiency virus type 1 and simian immunodeficiency virus strains.	Journal of virology	2009	47
19997090	1234	Kim SS	RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice.	Molecular therapy 	2010	67
20018916	1234	Shimizu S	A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model.	Blood	2010	73
20144043	1234	El Hed A	Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection.	The Journal of infectious diseases	2010	65
20147895	1234	Saba E	HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model.	Mucosal immunology	2010	57
20601939	1234	Holt N	Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.	Nature biotechnology	2010	236
21047964	1234	Schulze Zur Wiesch J	Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.	Journal of virology	2011	56
21133894	1234	Jones KL	Chemokine receptor CCR5: from AIDS to atherosclerosis.	British journal of pharmacology	2011	36
21148083	1234	Allers K	Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.	Blood	2011	204
21288824	1234	Swenson LC	Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.	The Journal of infectious diseases	2011	58
21533216	1234	Wilen CB	Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.	PLoS pathogens	2011	64
21587341	1234	Vandamme AM	European recommendations for the clinical use of HIV drug resistance testing: 2011 update.	AIDS reviews	2011	36
22048765	1234	McKinnon LR	Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility.	Journal of immunology	2011	59
22147802	1234	Chalmet K	Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: correlates and evidence for transmission.	The Journal of infectious diseases	2012	34
22190722	1234	Ochsenbauer C	Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages.	Journal of virology	2012	129
22273578	1234	Yuan J	Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment.	Molecular therapy 	2012	36
22297516	1234	Wilen CB	Molecular mechanisms of HIV entry.	Advances in experimental medicine and biology	2012	65
22398281	1234	Walker JE	Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.	Journal of virology	2012	30
22784116	1234	Reshef R	Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.	The New England journal of medicine	2012	58
22974526	1234	Henrich TJ	Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR.	Journal of virological methods	2012	36
23043157	1234	Shaw GM	HIV transmission.	Cold Spring Harbor perspectives in medicine	2012	57
23460751	1234	Henrich TJ	Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.	The Journal of infectious diseases	2013	84
23903844	1234	Alvarez Y	Preferential HIV infection of CCR6+ Th17 cells is associated with higher levels of virus receptor expression and lack of CCR5 ligands.	Journal of virology	2013	35
24030490	1234	Tan Q	Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex.	Science	2013	131
24129241	1234	Bedognetti D	CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.	British journal of cancer	2013	25
24162716	1234	Didigu CA	Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection.	Blood	2014	36
24218476	1234	Bachelerie F	International Union of Basic and Clinical Pharmacology. corrected. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.	Pharmacological reviews	2014	112
24597865	1234	Tebas P	Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.	The New England journal of medicine	2014	257
24652495	1234	Mitchell CM	Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells.	The Journal of infectious diseases	2014	21
24813472	1234	Wilson EM	Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.	The Journal of infectious diseases	2014	25
25541967	1234	Wang W	CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection.	PloS one	2014	35
25854553	1234	Li C	Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.	The Journal of general virology	2015	21
25964300	1234	Mock U	mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5.	Nucleic acids research	2015	19
26424571	1234	Sather BD	Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template.	Science translational medicine	2015	36
12975468	1236	Day CL	Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers.	The Journal of clinical investigation	2003	101
14676302	1236	Younes SA	HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity.	The Journal of experimental medicine	2003	160
15057302	1236	Accapezzato D	Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection.	The Journal of clinical investigation	2004	81
15067072	1236	Pichyangkul S	Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway.	Journal of immunology	2004	83
18452966	1236	Durbin AP	Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever.	Virology	2008	55
19933869	1236	Akondy RS	The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.	Journal of immunology	2009	100
23196209	1236	Derhovanessian E	Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination.	Vaccine	2013	30
24056771	1236	Sridhar S	Cellular immune correlates of protection against symptomatic pandemic influenza.	Nature medicine	2013	137
10760308	1351	Felker GM	Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.	The New England journal of medicine	2000	172
15845517	1351	Cieslewicz MJ	Structural and genetic diversity of group B streptococcus capsular polysaccharides.	Infection and immunity	2005	67
16300480	1351	Martin-Ruiz CM	Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study.	Aging cell	2005	78
16790697	1351	Winer RL	Condom use and the risk of genital human papillomavirus infection in young women.	The New England journal of medicine	2006	105
20865073	1351	Ochieng-Ooko V	Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya.	Bulletin of the World Health Organization	2010	56
21915573	1351	Ritter MA	The effect of alignment and BMI on failure of total knee replacement.	The Journal of bone and joint surgery. American volume	2011	43
22133894	1351	Cohen MJ	Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients.	Annals of surgery	2012	43
22552668	1351	Bozic KJ	Patient-related risk factors for periprosthetic joint infection and postoperative mortality following total hip arthroplasty in Medicare patients.	The Journal of bone and joint surgery. American volume	2012	39
25671255	1351	Carter BD	Smoking and mortality--beyond established causes.	The New England journal of medicine	2015	72
11504927	1380	Moir S	HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals.	Proceedings of the National Academy of Sciences of the United States of America	2001	92
12592401	1380	Tugizov SM	Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells.	Nature medicine	2003	77
18625747	1380	Moir S	Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals.	The Journal of experimental medicine	2008	235
21421840	1380	Charles ED	Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset.	Blood	2011	40
9987089	1401	Zimmermann J	Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.	Kidney international	1999	125
10360695	1401	Spangehl MJ	Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties.	The Journal of bone and joint surgery. American volume	1999	110
10368284	1401	Thompson D	The physiological structure of human C-reactive protein and its complex with phosphocholine.	Structure	1999	107
10903648	1401	Danesh J	Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses.	BMJ	2000	214
11063384	1401	Loos BG	Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients.	Journal of periodontology	2000	101
11532280	1401	Volanakis JE	Human C-reactive protein: expression, structure, and function.	Molecular immunology	2001	101
11577954	1401	Noack B	Periodontal infections contribute to elevated systemic C-reactive protein level.	Journal of periodontology	2001	91
15173056	1401	Willerson JT	Inflammation as a cardiovascular risk factor.	Circulation	2004	159
15241098	1401	Wong CH	The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections.	Critical care medicine	2004	93
15307030	1401	Simon L	Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis.	Clinical infectious diseases 	2004	183
15337754	1401	Black S	C-reactive Protein.	The Journal of biological chemistry	2004	186
15557131	1401	Confalonieri M	Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study.	American journal of respiratory and critical care medicine	2005	76
15635109	1401	Ridker PM	C-reactive protein levels and outcomes after statin therapy.	The New England journal of medicine	2005	246
16251239	1401	Fried LF	Kidney function as a predictor of noncardiovascular mortality.	Journal of the American Society of Nephrology 	2005	78
16595481	1401	Bauer TW	Diagnosis of periprosthetic infection.	The Journal of bone and joint surgery. American volume	2006	64
16715031	1401	Uzzan B	Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis.	Critical care medicine	2006	117
16980117	1401	Agranoff D	Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum.	Lancet	2006	62
17192343	1401	Samaras K	Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and corrected hypoadiponectinemia.	Diabetes care	2007	61
17335562	1401	Müller B	Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia.	BMC infectious diseases	2007	58
17426195	1401	Meduri GU	Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.	Chest	2007	93
17524614	1401	Frey DJ	The effects of 40 hours of total sleep deprivation on inflammatory markers in healthy young adults.	Brain, behavior, and immunity	2007	71
17634459	1401	Schreiber S	Maintenance therapy with certolizumab pegol for Crohn's disease.	The New England journal of medicine	2007	121
17947302	1401	Lequerré T	Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.	Annals of the rheumatic diseases	2008	64
18256376	1401	Szeto CC	Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients.	Clinical journal of the American Society of Nephrology 	2008	52
18279736	1401	Miller M	Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.	Journal of the American College of Cardiology	2008	68
18279948	1401	Besselink MG	Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.	Lancet	2008	143
18344877	1401	Reingold J	Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study.	Journal of acquired immune deficiency syndromes	2008	53
18942885	1401	Kuller LH	Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.	PLoS medicine	2008	516
19011614	1401	Lu J	Structural recognition and functional activation of FcgammaR by innate pentraxins.	Nature	2008	67
19387353	1401	Triant VA	Association of C-reactive protein and HIV infection with acute myocardial infarction.	Journal of acquired immune deficiency syndromes	2009	99
19416992	1401	Cals JW	Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial.	BMJ	2009	89
19712036	1401	Ross AC	Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy.	Clinical infectious diseases 	2009	75
20144219	1401	Pierrakos C	Sepsis biomarkers: a review.	Critical care	2010	197
20212299	1401	Cals JW	Point-of-care C-reactive protein testing and antibiotic prescribing for respiratory tract infections: a randomized controlled trial.	Annals of family medicine	2010	41
20397003	1401	Mårtensson J	Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury.	Intensive care medicine	2010	62
20610634	1401	Thurnham DI	Adjusting plasma ferritin concentrations to remove the effects of subclinical inflammation in the assessment of iron deficiency: a meta-analysis.	The American journal of clinical nutrition	2010	82
20627925	1401	Nguyen-Van-Tam JS	Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009).	Thorax	2010	57
20810860	1401	Berbari E	Inflammatory blood laboratory levels as markers of prosthetic joint infection: a systematic review and meta-analysis.	The Journal of bone and joint surgery. American volume	2010	41
20930640	1401	Baker JV	Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.	Journal of acquired immune deficiency syndromes	2011	56
21062445	1401	Hagau N	Clinical aspects and cytokine response in severe H1N1 influenza A virus infection.	Critical care	2010	57
21252259	1401	Sandler NG	Plasma levels of soluble CD14 independently predict mortality in HIV infection.	The Journal of infectious diseases	2011	346
21253011	1401	Boulware DR	Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study.	PLoS medicine	2010	85
21324198	1401	Koch A	Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.	Critical care	2011	50
21364762	1401	Erdman LK	Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: a retrospective case-control study.	PloS one	2011	48
21398306	1401	Kibe S	Diagnostic and prognostic biomarkers of sepsis in critical care.	The Journal of antimicrobial chemotherapy	2011	51
21560033	1401	Shozushima T	Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome.	Journal of infection and chemotherapy 	2011	39
21653621	1401	Van den Bruel A	Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review.	BMJ	2011	40
21952978	1401	Fleischmann R	Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.	Arthritis and rheumatism	2012	64
22228627	1401	Prentice AM	Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children.	Blood	2012	44
22492856	1401	Parrinello CM	Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women.	The Journal of infectious diseases	2012	41
22708923	1401	Bartlett DB	The age-related increase in low-grade systemic inflammation (Inflammaging) is not driven by cytomegalovirus infection.	Aging cell	2012	31
22752869	1401	Eyre DW	Predictors of first recurrence of Clostridium difficile infection: implications for initial management.	Clinical infectious diseases 	2012	34
22809118	1401	Su L	Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study.	BMC infectious diseases	2012	41
22810411	1401	Parvizi J	Management of periprosthetic joint infection: the current knowledge: AAOS exhibit selection.	The Journal of bone and joint surgery. American volume	2012	35
22983683	1401	Berend KR	Two-stage treatment of hip periprosthetic joint infection is associated with a high rate of infection control but high mortality.	Clinical orthopaedics and related research	2013	26
23252526	1401	Ruperto N	Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.	The New England journal of medicine	2012	69
23361084	1401	McInnes IB	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.	Annals of the rheumatic diseases	2014	37
23432640	1401	Voorhees PM	A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.	British journal of haematology	2013	33
23915885	1401	Little P	Effects of internet-based training on antibiotic prescribing rates for acute respiratory-tract infections: a multinational, cluster, randomised, factorial, controlled trial.	Lancet	2013	50
23945504	1401	Borges ÁH	Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers.	AIDS	2013	34
24154724	1401	Rook GA	Regulation of the immune system by biodiversity from the natural environment: an ecosystem service essential to health.	Proceedings of the National Academy of Sciences of the United States of America	2013	38
24185532	1401	Shah BA	Neonatal sepsis: an old problem with new insights.	Virulence	2014	26
24396135	1401	Simonsen KA	Early-onset neonatal sepsis.	Clinical microbiology reviews	2014	49
24443059	1401	Aleksandrova K	Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer.	Hepatology	2014	29
24592925	1401	Rogers GB	A novel microbiota stratification system predicts future exacerbations in bronchiectasis.	Annals of the American Thoracic Society	2014	28
24661739	1401	Amrein K	Vitamin D status and its association with season, hospital and sepsis mortality in critical illness.	Critical care	2014	26
24800240	1401	Henriquez-Camacho C	Biomarkers for sepsis.	BioMed research international	2014	22
24903083	1401	Garnacho-Montero J	Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis.	Critical care	2014	29
25187582	1401	Deirmengian C	Combined measurement of synovial fluid α-Defensin and C-reactive protein levels: highly accurate for diagnosing periprosthetic joint infection.	The Journal of bone and joint surgery. American volume	2014	26
25190134	1401	Behnes M	Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment.	Critical care	2014	28
25688779	1401	Torres A	Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.	JAMA	2015	45
25761863	1401	Michelena J	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis.	Hepatology	2015	26
26271406	1401	Hunt L	Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study.	The Lancet. Infectious diseases	2015	32
26947523	1401	de Jong E	Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.	The Lancet. Infectious diseases	2016	24
28615259	1401	Namaste SM	Adjusting ferritin concentrations for inflammation: Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project.	The American journal of clinical nutrition	2017	6
9069290	1432	Han J	Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation.	Nature	1997	165
10604986	1432	Kol A	Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells.	Journal of immunology	2000	102
14699082	1432	Doyle SE	Toll-like receptors induce a phagocytic gene program through p38.	The Journal of experimental medicine	2004	95
15855434	1432	Zink MC	Neuroprotective and anti-human immunodeficiency virus activity of minocycline.	JAMA	2005	65
16198162	1432	Kaminska B	MAPK signalling pathways as molecular targets for anti-inflammatory therapy--from molecular mechanisms to therapeutic benefits.	Biochimica et biophysica acta	2005	142
21047517	1432	Földes G	Modulation of human embryonic stem cell-derived cardiomyocyte growth: a testbed for studying human cardiac hypertrophy?	Journal of molecular and cellular cardiology	2011	36
25151490	1432	Lanna A	The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells.	Nature immunology	2014	37
25361077	1432	Corazzari M	Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma.	Cell death and differentiation	2015	19
7629501	1437	Sallusto F	Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.	The Journal of experimental medicine	1995	427
7814646	1437	Jung HC	A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion.	The Journal of clinical investigation	1995	297
12829592	1437	Hayashi F	Toll-like receptors stimulate human neutrophil function.	Blood	2003	187
12952922	1437	Doran KS	Group B streptococcal beta-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis.	The Journal of clinical investigation	2003	76
15322213	1437	Kao CY	IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways.	Journal of immunology	2004	133
15634923	1437	Schaefer TM	Innate immunity in the human female reproductive tract: antiviral response of uterine epithelial cells to the TLR3 agonist poly(I:C).	Journal of immunology	2005	78
16783192	1437	Finnerty CC	Cytokine expression profile over time in severely burned pediatric patients.	Shock	2006	72
17483528	1437	Sharkey DJ	Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells.	Molecular human reproduction	2007	61
18292469	1437	O'Reilly MA	Neonatal hyperoxia enhances the inflammatory response in adult mice infected with influenza A virus.	American journal of respiratory and critical care medicine	2008	53
18332343	1437	Nagel MA	The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features.	Neurology	2008	74
18495536	1437	Park BH	Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.	The Lancet. Oncology	2008	135
19590022	1437	Meisel C	Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.	American journal of respiratory and critical care medicine	2009	113
19966223	1437	Chen Q	Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice.	Proceedings of the National Academy of Sciences of the United States of America	2009	75
20017188	1437	Scriba TJ	Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells.	European journal of immunology	2010	67
20224308	1437	Roberts L	Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression.	AIDS	2010	66
20817712	1437	Tadokera R	Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome.	The European respiratory journal	2011	47
21153402	1437	Hall MW	Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome.	Intensive care medicine	2011	53
21628671	1437	Lai L	Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine.	The Journal of infectious diseases	2011	58
22822024	1437	Leentjens J	Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study.	American journal of respiratory and critical care medicine	2012	32
22913682	1437	Browne SK	Adult-onset immunodeficiency in Thailand and Taiwan.	The New England journal of medicine	2012	73
23393196	1437	Breitbach CJ	Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.	Cancer research	2013	40
23509356	1437	Rosen LB	Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis.	Journal of immunology	2013	40
24020520	1437	Bartlett DL	Oncolytic viruses as therapeutic cancer vaccines.	Molecular cancer	2013	66
24485901	1437	Hutchins NA	The new normal: immunomodulatory agents against sepsis immune suppression.	Trends in molecular medicine	2014	43
24643864	1437	Saijo T	Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients.	mBio	2014	30
26104913	1437	Arnold KB	Increased levels of inflammatory cytokines in the female reproductive tract are associated with altered expression of proteases, mucosal barrier proteins, and an influx of HIV-susceptible target cells.	Mucosal immunology	2016	23
26719429	1437	Kohlhapp FJ	Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.	Clinical cancer research 	2016	11
12974876	1440	Treutiger CJ	High mobility group 1 B-box mediates activation of human endothelium.	Journal of internal medicine	2003	82
16497969	1440	Rosenberg PS	The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy.	Blood	2006	72
16750358	1440	Aapro MS	EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.	European journal of cancer	2006	72
17448250	1440	Bozza FA	Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis.	Critical care	2007	132
17655751	1440	Cohen PR	Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.	Orphanet journal of rare diseases	2007	76
21095116	1440	Aapro MS	2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.	European journal of cancer	2011	120
22611244	1440	Tanaka S	Development of mature and functional human myeloid subsets in hematopoietic stem cell-engrafted NOD/SCID/IL2rγKO mice.	Journal of immunology	2012	40
23398819	1440	Clarke SL	Barth syndrome.	Orphanet journal of rare diseases	2013	29
23615461	1440	Cunningham D	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.	Lancet	2013	30
11722623	1493	Shevach EM	Control of T-cell activation by CD4+ CD25+ suppressor T cells.	Immunological reviews	2001	98
15749840	1493	Andersson J	The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients.	Journal of immunology	2005	139
16493086	1493	Babu S	Regulatory networks induced by live parasites impair both Th1 and Th2 pathways in patent lymphatic filariasis: implications for parasite persistence.	Journal of immunology	2006	85
17606980	1493	Okazaki T	PD-1 and PD-1 ligands: from discovery to clinical application.	International immunology	2007	172
17906628	1493	Kaufmann DE	Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction.	Nature immunology	2007	185
19247441	1493	Nakamoto N	Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade.	PLoS pathogens	2009	113
19843932	1493	Jeffery LE	1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3.	Journal of immunology	2009	96
20038811	1493	Derré L	BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.	The Journal of clinical investigation	2010	67
20660788	1493	Antonelli LR	Elevated frequencies of highly activated CD4+ T cells in HIV+ patients developing immune reconstitution inflammatory syndrome.	Blood	2010	55
21360567	1493	Schurich A	Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection.	Hepatology	2011	55
21474713	1493	Qureshi OS	Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.	Science	2011	248
23466307	1493	Sangro B	A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.	Journal of hepatology	2013	80
24860567	1493	Corthay A	Does the immune system naturally protect against cancer?	Frontiers in immunology	2014	29
25213377	1493	Kuehn HS	Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.	Science	2014	83
25993145	1493	Postow MA	Managing immune checkpoint-blocking antibody side effects.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2015	32
26206937	1493	Lo B	AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.	Science	2015	32
26837003	1493	Dubin K	Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.	Nature communications	2016	12
27192569	1493	Attanasio J	Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.	Immunity	2016	11
27951441	1493	O'Donnell JS	Resistance to PD1/PDL1 checkpoint inhibition.	Cancer treatment reviews	2017	6
11175848	1672	Islam D	Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator.	Nature medicine	2001	97
16254366	1672	Sun L	Human beta-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection.	Journal of virology	2005	75
21248850	1672	Schroeder BO	Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1.	Nature	2011	115
10586069	1673	O'Neil DA	Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium.	Journal of immunology	1999	143
12374875	1673	Ong PY	Endogenous antimicrobial peptides and skin infections in atopic dermatitis.	The New England journal of medicine	2002	302
12960356	1673	Nomura I	Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes.	Journal of immunology	2003	128
15004048	1673	Joly S	Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms.	Journal of clinical microbiology	2004	72
15322146	1673	Wang TT	Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression.	Journal of immunology	2004	302
18252915	1991	Elizur A	Airway inflammation in cystic fibrosis.	Chest	2008	58
19372250	1991	Sly PD	Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.	American journal of respiratory and critical care medicine	2009	60
23328639	1991	Hoenderdos K	The neutrophil in chronic obstructive pulmonary disease.	American journal of respiratory cell and molecular biology	2013	43
24740504	1991	Yoo DG	Release of cystic fibrosis airway inflammatory markers from Pseudomonas aeruginosa-stimulated human neutrophils involves NADPH oxidase-dependent extracellular DNA trap formation.	Journal of immunology	2014	20
25474078	1991	Zemanick ET	Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods.	Annals of the American Thoracic Society	2015	17
26673780	1991	Rochael NC	Classical ROS-dependent and early/rapid ROS-independent release of Neutrophil Extracellular Traps triggered by Leishmania parasites.	Scientific reports	2015	17
26712312	1991	Martinod K	Neutrophil elastase-deficient mice form neutrophil extracellular traps in an experimental model of deep vein thrombosis.	Journal of thrombosis and haemostasis 	2016	10
26846833	1991	Aliberti S	Clinical phenotypes in adult patients with bronchiectasis.	The European respiratory journal	2016	14
11756984	2054	Friedrich AW	Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms.	The Journal of infectious diseases	2002	202
17085726	2054	Gyles CL	Shiga toxin-producing Escherichia coli: an overview.	Journal of animal science	2007	145
22289607	2054	Beutin L	Outbreak of Shiga toxin-producing Escherichia coli (STEC) O104:H4 infection in Germany causes a paradigm shift with regard to human pathogenicity of STEC strains.	Journal of food protection	2012	46
22760050	2054	Scheutz F	Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature.	Journal of clinical microbiology	2012	142
17393520	2056	Wurmbach E	Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.	Hepatology	2007	173
20105662	2056	Walker A	Breast milk as the gold standard for protective nutrients.	The Journal of pediatrics	2010	49
21449784	2056	Bacon BR	Boceprevir for previously treated chronic HCV genotype 1 infection.	The New England journal of medicine	2011	386
23669289	2056	Hézode C	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.	Journal of hepatology	2013	96
24645943	2056	Kamar N	Ribavirin for chronic hepatitis E virus infection in transplant recipients.	The New England journal of medicine	2014	44
25076907	2056	Nairz M	Iron at the interface of immunity and infection.	Frontiers in pharmacology	2014	50
26976799	2056	Pockros PJ	Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.	Gastroenterology	2016	18
16193056	2187	Nybakken GE	Structural basis of West Nile virus neutralization by a therapeutic antibody.	Nature	2005	141
19713934	2187	Cherrier MV	Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody.	The EMBO journal	2009	65
21737702	2187	Ekiert DC	A highly conserved neutralizing epitope on group 2 influenza A viruses.	Science	2011	234
22622405	2187	François B	Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial.	Critical care medicine	2012	30
22723463	2187	Teoh EP	The structural basis for serotype-specific neutralization of dengue virus by a human antibody.	Science translational medicine	2012	69
24211234	2187	Davies AM	Structural determinants of unique properties of human IgG4-Fc.	Journal of molecular biology	2014	24
24421336	2187	Fibriansah G	A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface.	EMBO molecular medicine	2014	37
24553139	2187	Khan AG	Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2.	Nature	2014	76
25275316	2187	de Alwis R	Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.	PLoS pathogens	2014	23
25473061	2187	Meola A	Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.	Journal of virology	2015	18
25698059	2187	Fibriansah G	A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins.	Nature communications	2015	43
17318616	2209	Jacobsen M	Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis.	Journal of molecular medicine	2007	73
18041019	2209	Kou Z	Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells.	Journal of medical virology	2008	60
22538802	2209	Gibot S	Combination biomarkers to diagnose sepsis in the critically ill patient.	American journal of respiratory and critical care medicine	2012	59
24205913	2209	Sutherland JS	Differential gene expression of activating Fcγ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity.	Clinical microbiology and infection 	2014	20
27354515	2209	Priyamvada L	Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus.	Proceedings of the National Academy of Sciences of the United States of America	2016	50
9078201	2214	Pulliam L	Unique monocyte subset in patients with AIDS dementia.	Lancet	1997	110
11704885	2214	Fischer-Smith T	CNS invasion by CD14+/CD16+ peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection.	Journal of neurovirology	2001	109
14645713	2214	Mavilio D	Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates.	Proceedings of the National Academy of Sciences of the United States of America	2003	96
16203869	2214	Bryceson YT	Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells.	The Journal of experimental medicine	2005	137
17100877	2214	Bryceson YT	Activation, coactivation, and costimulation of resting human natural killer cells.	Immunological reviews	2006	129
17135573	2214	Ziegler-Heitbrock L	The CD14+ CD16+ blood monocytes: their role in infection and inflammation.	Journal of leukocyte biology	2007	255
19628705	2214	Bryceson YT	Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors.	Blood	2009	58
19965656	2214	Fauriat C	Regulation of human NK-cell cytokine and chemokine production by target cell recognition.	Blood	2010	141
21187373	2214	De Maria A	Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation.	Proceedings of the National Academy of Sciences of the United States of America	2011	78
21825173	2214	Lopez-Vergès S	Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection.	Proceedings of the National Academy of Sciences of the United States of America	2011	166
22096237	2214	Della Chiesa M	Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?	Blood	2012	60
22313961	2214	Hearps AC	HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy.	AIDS	2012	49
22363505	2214	Kamat A	A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy.	PloS one	2012	37
22669579	2214	Xu H	IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques.	Mucosal immunology	2012	42
23365694	2214	Martin GE	Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women.	PloS one	2013	37
24367364	2214	Nielsen CM	Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease.	Frontiers in immunology	2013	27
24370480	2214	Baker JV	Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort.	AIDS	2014	32
24862332	2214	Tavazzi E	Brain inflammation is a common feature of HIV-infected patients without HIV encephalitis or productive brain infection.	Current HIV research	2014	28
24981333	2214	Kwissa M	Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation.	Cell host and microbe	2014	30
27117418	2214	Liu LL	Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans.	Cell reports	2016	17
10657556	2244	Yudkin JS	Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?	Atherosclerosis	2000	214
11719299	2244	Seemungal T	Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease.	American journal of respiratory and critical care medicine	2001	174
22144540	2244	Zhang YZ	Hemorrhagic fever caused by a novel Bunyavirus in China: pathogenesis and correlates of fatal outcome.	Clinical infectious diseases 	2012	52
22385985	2244	Adinolfi LE	Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis.	Atherosclerosis	2012	35
24086778	2244	Huy NT	Factors associated with dengue shock syndrome: a systematic review and meta-analysis.	PLoS neglected tropical diseases	2013	35
24691204	2244	Longenecker CT	Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection.	AIDS	2014	44
18177778	2335	Goldenberg RL	Epidemiology and causes of preterm birth.	Lancet	2008	873
19819674	2335	Fairweather D	Alternatively activated macrophages in infection and autoimmunity.	Journal of autoimmunity	2009	70
19920174	2335	Chesnokova LS	Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8.	Proceedings of the National Academy of Sciences of the United States of America	2009	70
17041621	2475	Corradetti MN	Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?	Oncogene	2006	128
18559509	2475	Wang L	Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells.	Cancer research	2008	59
18596100	2475	Wang FZ	Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication.	Journal of virology	2008	63
18848473	2475	Weichhart T	The TSC-mTOR signaling pathway regulates the innate inflammatory response.	Immunity	2008	184
19567830	2475	Cobbold SP	Infectious tolerance via the consumption of essential amino acids and mTOR signaling.	Proceedings of the National Academy of Sciences of the United States of America	2009	98
20034776	2475	Yang Z	Mammalian autophagy: core molecular machinery and signaling regulation.	Current opinion in cell biology	2010	478
20229590	2475	Johnston PB	A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.	American journal of hematology	2010	49
20581392	2475	Walz G	Everolimus in patients with autosomal dominant polycystic kidney disease.	The New England journal of medicine	2010	125
20631133	2475	Spangle JM	The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis.	Journal of virology	2010	54
21047224	2475	Krueger DA	Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.	The New England journal of medicine	2010	206
21511946	2475	McLean JE	Flavivirus NS4A-induced autophagy protects cells against death and enhances virus replication.	The Journal of biological chemistry	2011	57
22409888	2475	Molinolo AA	mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.	Clinical cancer research 	2012	36
22674982	2475	Shrivastava S	Hepatitis C virus upregulates Beclin1 for induction of autophagy and activates mTOR signaling.	Journal of virology	2012	38
22919032	2475	McInturff AM	Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α.	Blood	2012	43
23601105	2475	Chang HH	A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity.	Cell host and microbe	2013	28
23708729	2475	Ryter SW	Autophagy: a critical regulator of cellular metabolism and homeostasis.	Molecules and cells	2013	43
23818640	2475	Meckes DG Jr	Modulation of B-cell exosome proteins by gamma herpesvirus infection.	Proceedings of the National Academy of Sciences of the United States of America	2013	44
24534190	2475	Gomez-Rodriguez J	Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells.	The Journal of experimental medicine	2014	37
24556090	2475	Maciolek JA	Metabolism of activated T lymphocytes.	Current opinion in immunology	2014	27
24973821	2475	Marçais A	The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells.	Nature immunology	2014	52
26794930	2475	Armstrong AJ	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.	The Lancet. Oncology	2016	16
26917434	2475	Davenport EE	Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study.	The Lancet. Respiratory medicine	2016	22
27279544	2475	Choueiri TK	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.	The Lancet. Oncology	2016	35
11423617	2539	Tishkoff SA	Haplotype diversity and linkage disequilibrium at human G6PD: recent origin of alleles that confer malarial resistance.	Science	2001	152
16968913	2539	Hill DR	Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.	The American journal of tropical medicine and hygiene	2006	87
17611006	2539	Mason PJ	G6PD deficiency: the genotype-phenotype association.	Blood reviews	2007	56
17978087	2539	Beutler E	Glucose-6-phosphate dehydrogenase deficiency and antimalarial drug development.	The American journal of tropical medicine and hygiene	2007	70
18215251	2539	Vafa M	Multiplicity of Plasmodium falciparum infection in asymptomatic children in Senegal: relation to transmission, age and erythrocyte variants.	Malaria journal	2008	62
18305266	2539	Calis JC	Severe anemia in Malawian children.	The New England journal of medicine	2008	88
19091042	2539	White NJ	The role of anti-malarial drugs in eliminating malaria.	Malaria journal	2008	92
19233695	2539	Nkhoma ET	The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis.	Blood cells, molecules and diseases	2009	92
20007901	2539	Louicharoen C	Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians.	Science	2009	58
20628650	2539	Padayatty SJ	Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects.	PloS one	2010	48
21311583	2539	malERA Consultative Group on Diagnoses and Diagnostics.	A research agenda for malaria eradication: diagnoses and diagnostics.	PLoS medicine	2011	111
22940027	2539	Amaratunga C	Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study.	The Lancet. Infectious diseases	2012	137
23152723	2539	Howes RE	G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map.	PLoS medicine	2012	101
24188096	2539	Domingo GJ	G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests.	Malaria journal	2013	33
24228846	2539	Howes RE	Spatial distribution of G6PD deficiency variants across malaria-endemic regions.	Malaria journal	2013	35
24239324	2539	Eziefula AC	Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial.	The Lancet. Infectious diseases	2014	35
24360369	2539	Llanos-Cuentas A	Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.	Lancet	2014	67
24376273	2539	Rolling T	Delayed hemolysis after treatment with parenteral artesunate in African children with severe malaria--a double-center prospective study.	The Journal of infectious diseases	2014	23
25261933	2539	Malaria Genomic Epidemiology Network.	Reappraisal of known malaria resistance loci in a large multicenter study.	Nature genetics	2014	36
26906747	2539	Dicko A	Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial.	The Lancet. Infectious diseases	2016	12
11698284	2736	Kulkosky J	Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.	Blood	2001	119
18070897	2736	Fontán P	Global transcriptional profile of Mycobacterium tuberculosis during THP-1 human macrophage infection.	Infection and immunity	2008	56
20881210	2736	Krejbich-Trotot P	Chikungunya virus mobilizes the apoptotic machinery to invade host cell defenses.	FASEB journal 	2011	37
21862628	2736	Beare PA	Dot/Icm type IVB secretion system requirements for Coxiella burnetii growth in human macrophages.	mBio	2011	74
24651015	2736	Kool M	Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.	Cancer cell	2014	102
25422265	2736	Larson CL	Coxiella burnetii effector proteins that localize to the parasitophorous vacuole membrane promote intracellular replication.	Infection and immunity	2015	21
12571259	2814	Muñoz N	Epidemiologic classification of human papillomavirus types associated with cervical cancer.	The New England journal of medicine	2003	1044
16507827	2814	Castellsagué X	Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.	Journal of the National Cancer Institute	2006	105
18973271	2814	Meijer CJ	Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.	International journal of cancer	2009	89
9738173	2875	-	Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.	Pediatrics	1998	307
10210705	2875	Kenny-Walsh E	Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group.	The New England journal of medicine	1999	144
10632283	2875	Sulkowski MS	Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.	JAMA	2000	119
12093239	2875	Prati D	Updated definitions of healthy ranges for serum alanine aminotransferase levels.	Annals of internal medicine	2002	219
12809815	2875	Clark JM	The prevalence and etiology of elevated aminotransferase levels in the United States.	The American journal of gastroenterology	2003	255
15361502	2875	Chan HL	Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.	Gut	2004	100
17021358	2875	Saukkonen JJ	An official ATS statement: hepatotoxicity of antituberculosis therapy.	American journal of respiratory and critical care medicine	2006	137
21139063	2875	Thomson EC	Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men.	Gut	2011	38
21688282	2875	Bhala N	The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.	Hepatology	2011	78
22941922	2875	Tseng TC	Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads.	Hepatology	2013	32
24107395	2875	Gordon SC	Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population.	Clinical gastroenterology and hepatology 	2014	25
25140957	2875	DeVincenzo JP	Oral GS-5806 activity in a respiratory syncytial virus challenge study.	The New England journal of medicine	2014	51
26667191	2875	Ballestri S	Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.	Journal of gastroenterology and hepatology	2016	25
16670345	3002	McElhaney JE	T cell responses are better correlates of vaccine protection in the elderly.	Journal of immunology	2006	154
17360672	3002	Verjans GM	Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia.	Proceedings of the National Academy of Sciences of the United States of America	2007	88
17535975	3002	Stary G	Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells.	The Journal of experimental medicine	2007	86
22105371	3002	Béziat V	CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients.	European journal of immunology	2012	79
27337592	3002	van Wilgenburg B	MAIT cells are activated during human viral infections.	Nature communications	2016	12
11796574	3075	Stevenson B	Differential binding of host complement inhibitor factor H by Borrelia burgdorferi Erp surface proteins: a possible mechanism underlying the expansive host range of Lyme disease spirochetes.	Infection and immunity	2002	87
15870199	3075	Hageman GS	A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2005	604
17399790	3075	Skerka C	Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration.	Molecular immunology	2007	55
20686663	3075	Lewis LA	The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.	PLoS pathogens	2010	68
21589640	3075	Echenique-Rivera H	Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival.	PLoS pathogens	2011	57
25859752	3075	Loirat C	An international consensus approach to the management of atypical hemolytic uremic syndrome in children.	Pediatric nephrology	2016	24
11148222	3105	Goulder PJ	Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection.	The Journal of experimental medicine	2001	87
15936272	3105	Prugnolle F	Pathogen-driven selection and worldwide HLA class I diversity.	Current biology 	2005	101
17620360	3105	Hislop AD	A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.	The Journal of experimental medicine	2007	64
20631300	3105	Van Tendeloo VF	Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.	Proceedings of the National Academy of Sciences of the United States of America	2010	85
7964509	3106	Taurog JD	The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats.	The Journal of experimental medicine	1994	202
9105754	3106	Bottone EJ	Yersinia enterocolitica: the charisma continues.	Clinical microbiology reviews	1997	148
11386265	3106	Gao X	Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.	The New England journal of medicine	2001	139
11460164	3106	Goulder PJ	Evolution and transmission of stable CTL escape mutations in HIV infection.	Nature	2001	205
11943262	3106	Hetherington S	Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.	Lancet	2002	107
12768008	3106	Migueles SA	The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.	Journal of virology	2003	77
15067030	3106	Draenert R	Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection.	The Journal of experimental medicine	2004	140
16369537	3106	Frahm N	Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes.	Nature immunology	2006	101
17496894	3106	Martin MP	Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.	Nature genetics	2007	273
17641165	3106	Fellay J	A whole-genome association study of major determinants for host control of HIV-1.	Science	2007	503
17892322	3106	Lewinsohn DA	Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B.	PLoS pathogens	2007	57
18353945	3106	Emu B	HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control.	Journal of virology	2008	117
18596105	3106	Matthews PC	Central role of reverting mutations in HLA associations with human immunodeficiency virus set point.	Journal of virology	2008	91
19109381	3106	Boutwell CL	Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein.	Journal of virology	2009	50
19242411	3106	Kawashima Y	Adaptation of HIV-1 to human leukocyte antigen class I.	Nature	2009	187
20205591	3106	Pelak K	Host determinants of HIV-1 control in African Americans.	The Journal of infectious diseases	2010	68
20523897	3106	Hersperger AR	Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control.	PLoS pathogens	2010	134
20595679	3106	Feehally J	HLA has strongest association with IgA nephropathy in genome-wide analysis.	Journal of the American Society of Nephrology 	2010	41
20616031	3106	Gras S	Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses.	Proceedings of the National Academy of Sciences of the United States of America	2010	54
22102287	3106	Wooldridge L	A single autoimmune T cell receptor recognizes more than a million different peptides.	The Journal of biological chemistry	2012	87
22683743	3106	Chen H	TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection.	Nature immunology	2012	83
22999948	3106	Goulder PJ	HIV and HLA class I: an evolving relationship.	Immunity	2012	74
12456506	3146	Fiuza C	Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells.	Blood	2003	160
15502843	3146	Wang H	Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis.	Nature medicine	2004	249
15753748	3146	Sundén-Cullberg J	Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock.	Critical care medicine	2005	111
16721263	3146	Goldstein RS	Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia.	Shock	2006	60
17334246	3146	Angus DC	Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis.	Critical care medicine	2007	58
18431461	3146	Klune JR	HMGB1: endogenous danger signaling.	Molecular medicine	2008	192
20530955	3146	de Jong HK	The systemic pro-inflammatory response in sepsis.	Journal of innate immunity	2010	44
21349088	3146	Deretic V	Autophagy in immunity and cell-autonomous defense against intracellular microbes.	Immunological reviews	2011	126
21412769	3146	Carbone M	Malignant mesothelioma: facts, myths, and hypotheses.	Journal of cellular physiology	2012	78
21473909	3146	Vezzani A	IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures.	Brain, behavior, and immunity	2011	53
21958433	3146	Romero R	Damage-associated molecular patterns (DAMPs) in preterm labor with intact membranes and preterm PROM: a study of the alarmin HMGB1.	The journal of maternal-fetal and neonatal medicine 	2011	43
22842346	3146	Chiba S	Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1.	Nature immunology	2012	117
25010388	3146	Kang R	HMGB1 in health and disease.	Molecular aspects of medicine	2014	76
25078709	3146	Romero R	Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes.	American journal of reproductive immunology	2014	36
25941621	3146	Kepp O	Consensus guidelines for the detection of immunogenic cell death.	Oncoimmunology	2014	89
2538243	3383	Greve JM	The major human rhinovirus receptor is ICAM-1.	Cell	1989	245
8476577	3383	Bevilacqua MP	Endothelial-leukocyte adhesion molecules.	Annual review of immunology	1993	186
10393703	3383	Combes V	In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.	The Journal of clinical investigation	1999	124
19560161	3383	Steppan J	Sepsis and major abdominal surgery lead to flaking of the endothelial glycocalix.	The Journal of surgical research	2011	38
20824088	3383	Joergensen L	Surface co-expression of two different PfEMP1 antigens on single plasmodium falciparum-infected erythrocytes facilitates binding to ICAM1 and PECAM1.	PLoS pathogens	2010	41
21399646	3383	Flach TL	Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity.	Nature medicine	2011	83
23295265	3383	O'Shea TM	Inflammation-initiating illnesses, inflammation-related proteins, and cognitive impairment in extremely preterm infants.	Brain, behavior, and immunity	2013	28
23524845	3383	Skibsted S	Biomarkers of endothelial cell activation in early sepsis.	Shock	2013	25
23864627	3383	Nanbo A	Exosomes derived from Epstein-Barr virus-infected cells are internalized via caveola-dependent endocytosis and promote phenotypic modulation in target cells.	Journal of virology	2013	35
24471509	3383	Kennedy JL	Comparison of viral load in individuals with and without asthma during infections with rhinovirus.	American journal of respiratory and critical care medicine	2014	22
9756471	3439	Neumann AU	Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.	Science	1998	398
10559305	3439	Didcock L	The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation.	Journal of virology	1999	174
10799569	3439	Diamond MS	Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons.	Journal of virology	2000	120
11390447	3439	Giacomini E	Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response.	Journal of immunology	2001	114
11449369	3439	Krug A	Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells.	European journal of immunology	2001	168
11507197	3439	Guo JT	Effect of alpha interferon on the hepatitis C virus replicon.	Journal of virology	2001	159
11971031	3439	Chehimi J	Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals.	Journal of immunology	2002	102
12604793	3439	Baechler EC	Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.	Proceedings of the National Academy of Sciences of the United States of America	2003	515
14530357	3439	Loré K	Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses.	Journal of immunology	2003	81
14639532	3439	Bosio CM	Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation.	The Journal of infectious diseases	2003	83
14991609	3439	Coccia EM	Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells.	European journal of immunology	2004	122
15669887	3439	Raison CL	Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.	The Journal of clinical psychiatry	2005	65
16188985	3439	Best SM	Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist.	Journal of virology	2005	102
16284360	3439	Guerrero-Plata A	Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus.	American journal of respiratory cell and molecular biology	2006	76
16418394	3439	Peng G	Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.	The Journal of experimental medicine	2006	119
16840343	3439	Chen K	Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.	Journal of virology	2006	64
17353365	3439	Dunn C	Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.	The Journal of experimental medicine	2007	102
19187331	3439	Dougherty RH	Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype.	Clinical and experimental allergy 	2009	64
19424421	3439	Brown KN	Rapid influx and death of plasmacytoid dendritic cells in lymph nodes mediate depletion in acute simian immunodeficiency virus infection.	PLoS pathogens	2009	65
19597505	3439	Meier A	Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1.	Nature medicine	2009	138
19620293	3439	Subrata LS	Interactions between innate antiviral and atopic immunoinflammatory pathways precipitate and sustain asthma exacerbations in children.	Journal of immunology	2009	52
19648060	3439	Belderbos ME	Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: low LPS-induced IL-12p70 and high IL-10 persist throughout the first month of life.	Clinical immunology	2009	56
19910029	3439	Ogbogu PU	Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.	The Journal of allergy and clinical immunology	2009	60
19917677	3439	Kollmann TR	Neonatal innate TLR-mediated responses are distinct from those of adults.	Journal of immunology	2009	136
19959873	3439	Jacquelin B	Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.	The Journal of clinical investigation	2009	184
20106931	3439	Laurent-Rolle M	The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling.	Journal of virology	2010	84
20145197	3439	Fitzgerald-Bocarsly P	Plasmacytoid dendritic cells in HIV infection: striking a delicate balance.	Journal of leukocyte biology	2010	59
20404274	3439	Her Z	Active infection of human blood monocytes by Chikungunya virus triggers an innate immune response.	Journal of immunology	2010	52
20519386	3439	Gardner J	Chikungunya virus arthritis in adult wild-type mice.	Journal of virology	2010	94
20610724	3439	Goujon C	Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells.	Journal of virology	2010	62
20660196	3439	Rodriguez-Madoz JR	Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex.	Journal of virology	2010	46
21199525	3439	Yuen MF	Treatment of chronic hepatitis B: Evolution over two decades.	Journal of gastroenterology and hepatology	2011	43
21800339	3439	Marukian S	Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures.	Hepatology	2011	85
21923413	3439	Niewold TB	Interferon alpha as a primary pathogenic factor in human lupus.	Journal of interferon and cytokine research 	2011	48
22806323	3439	Lai CL	Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.	Hepatology	2013	35
22878466	3439	Schaefer M	Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement.	Journal of hepatology	2012	34
22981791	3439	Baraldo S	Deficient antiviral immune responses in childhood: distinct roles of atopy and asthma.	The Journal of allergy and clinical immunology	2012	33
23046671	3439	Micco L	Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.	Journal of hepatology	2013	35
23302870	3439	Ioannidis I	Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells.	Journal of virology	2013	37
23400715	3439	Petri M	Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.	Arthritis and rheumatism	2013	47
23947345	3439	Durbin RK	Interferon induction and function at the mucosal surface.	Immunological reviews	2013	42
24602409	3439	Su KP	Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial.	Biological psychiatry	2014	22
24846384	3439	Menachery VD	Pathogenic influenza viruses and coronaviruses utilize similar and contrasting approaches to control interferon-stimulated gene responses.	mBio	2014	29
25733157	3439	Gane EJ	The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection.	Journal of hepatology	2015	25
25754160	3439	Serti E	Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function.	Gastroenterology	2015	19
9807989	3440	Poynard T	Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)	Lancet	1998	277
12360468	3440	McHutchison JG	Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.	Gastroenterology	2002	160
19353740	3440	Flisiak R	The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.	Hepatology	2009	57
24065148	3440	Zhou J	Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis.	The Journal of infectious diseases	2014	32
24308446	3440	Oshansky CM	Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load.	American journal of respiratory and critical care medicine	2014	24
16188991	3456	Préhaud C	Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon.	Journal of virology	2005	105
17617600	3456	Kato A	TLR3- and Th2 cytokine-dependent production of thymic stromal lymphopoietin in human airway epithelial cells.	Journal of immunology	2007	129
18162040	3456	Kirn DH	Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.	PLoS medicine	2007	81
20011590	3456	Lee SM	Systems-level comparison of host-responses elicited by avian H5N1 and seasonal H1N1 influenza viruses in primary human macrophages.	PloS one	2009	48
20090947	3456	Chan RW	Influenza H5N1 and H1N1 virus replication and innate immune responses in bronchial epithelial cells are influenced by the state of differentiation.	PloS one	2010	41
20519382	3456	Lei X	The 3C protein of enterovirus 71 inhibits retinoid acid-inducible gene I-mediated interferon regulatory factor 3 activation and type I interferon responses.	Journal of virology	2010	61
20538852	3456	Graef KM	The PB2 subunit of the influenza virus RNA polymerase affects virulence by interacting with the mitochondrial antiviral signaling protein and inhibiting expression of beta interferon.	Journal of virology	2010	66
20699220	3456	Iwai A	Influenza A virus polymerase inhibits type I interferon induction by binding to interferon beta promoter stimulator 1.	The Journal of biological chemistry	2010	49
22869572	3456	Saeed M	Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells.	Antimicrobial agents and chemotherapy	2012	32
22879820	3456	Marsh GA	Cedar virus: a novel Henipavirus isolated from Australian bats.	PLoS pathogens	2012	50
23631912	3456	Barker JR	STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection.	mBio	2013	55
23685241	3456	Wu S	miR-146a facilitates replication of dengue virus by dampening interferon induction by targeting TRAF6.	The Journal of infection	2013	25
24403588	3456	García-Arriaza J	A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.	Journal of virology	2014	24
24463573	3456	Beug ST	Smac mimetics and innate immune stimuli synergize to promote tumor death.	Nature biotechnology	2014	34
24937476	3456	Djukanović R	The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial.	American journal of respiratory and critical care medicine	2014	29
27060565	3456	Frumence E	The South Pacific epidemic strain of Zika virus replicates efficiently in human epithelial A549 cells leading to IFN-β production and apoptosis induction.	Virology	2016	15
1590992	3458	Sher A	Regulation of immunity to parasites by T cells and T cell-derived cytokines.	Annual review of immunology	1992	153
1925582	3458	Yamamura M	Defining protective responses to pathogens: cytokine profiles in leprosy lesions.	Science	1991	244
7475549	3458	Diepolder HM	Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection.	Lancet	1995	151
8757634	3458	Fuss IJ	Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.	Journal of immunology	1996	241
8993017	3458	D'Elios MM	T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease.	Journal of immunology	1997	135
9145744	3458	Berman JD	Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years.	Clinical infectious diseases 	1997	106
9176497	3458	Döcke WD	Monocyte deactivation in septic patients: restoration by IFN-gamma treatment.	Nature medicine	1997	203
9294140	3458	Lalvani A	Rapid effector function in CD8+ memory T cells.	The Journal of experimental medicine	1997	171
9603732	3458	Altare F	Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency.	Science	1998	172
10201989	3458	Fehniger TA	Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.	Journal of immunology	1999	129
10646872	3458	Jaiswal M	Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism.	Cancer research	2000	104
10790425	3458	Lechner F	Analysis of successful immune responses in persons infected with hepatitis C virus.	The Journal of experimental medicine	2000	356
10792007	3458	Boussiotis VA	IL-10-producing T cells suppress immune responses in anergic tuberculosis patients.	The Journal of clinical investigation	2000	117
10880527	3458	Appay V	HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function.	The Journal of experimental medicine	2000	201
11170064	3458	To KF	Pathology of fatal human infection associated with avian influenza A H5N1 virus.	Journal of medical virology	2001	104
11673535	3458	Pathan AA	Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment.	Journal of immunology	2001	103
11900986	3458	Ikeda H	The roles of IFN gamma in protection against tumor development and cancer immunoediting.	Cytokine and growth factor reviews	2002	152
12001037	3458	Libraty DH	Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.	The Journal of infectious diseases	2002	160
12218109	3458	Artavanis-Tsakonas K	Innate immune response to malaria: rapid induction of IFN-gamma from human NK cells by live Plasmodium falciparum-infected erythrocytes.	Journal of immunology	2002	84
12810858	3458	Alimonti JB	Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS.	The Journal of general virology	2003	96
15100412	3458	Wieland S	Genomic analysis of the host response to hepatitis B virus infection.	Proceedings of the National Academy of Sciences of the United States of America	2004	143
15494483	3458	De Rosa SC	Vaccination in humans generates broad T cell cytokine responses.	Journal of immunology	2004	73
15537905	3458	Mannon PJ	Anti-interleukin-12 antibody for active Crohn's disease.	The New England journal of medicine	2004	154
15567126	3458	Pai M	Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.	The Lancet. Infectious diseases	2004	193
15589309	3458	Dorman SE	Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies.	Lancet	2004	89
15709009	3458	Lindesmith L	Cellular and humoral immunity following Snow Mountain virus challenge.	Journal of virology	2005	79
15941805	3458	Kang YA	Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country.	JAMA	2005	81
15987480	3458	Raza K	Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin.	Arthritis research and therapy	2005	99
16299275	3458	Faria DR	Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis.	Infection and immunity	2005	79
16357824	3458	Mazurek GH	Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States.	MMWR. Recommendations and reports 	2005	150
16374252	3458	Fuss IJ	Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody.	Inflammatory bowel diseases	2006	68
16678181	3458	Hunt NH	Immunopathogenesis of cerebral malaria.	International journal for parasitology	2006	80
16785573	3458	Xu D	Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.	Journal of immunology	2006	101
16803570	3458	Feuchtinger T	Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation.	British journal of haematology	2006	65
16931093	3458	Leyten EM	Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis.	Microbes and infection	2006	87
17170386	3458	Arend SM	Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts.	American journal of respiratory and critical care medicine	2007	63
17230481	3458	Correale J	Association between parasite infection and immune responses in multiple sclerosis.	Annals of neurology	2007	88
17336692	3458	Dinarello CA	Interleukin-18 and the pathogenesis of inflammatory diseases.	Seminars in nephrology	2007	61
17438063	3458	Aspord C	Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development.	The Journal of experimental medicine	2007	79
17463418	3458	Martineau AR	A single dose of vitamin D enhances immunity to mycobacteria.	American journal of respiratory and critical care medicine	2007	113
17507983	3458	Barton ES	Herpesvirus latency confers symbiotic protection from bacterial infection.	Nature	2007	194
17553885	3458	Kannanganat S	Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells.	Journal of virology	2007	114
17565023	3458	Lalvani A	Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy.	Chest	2007	77
17689290	3458	Nylén S	Interleukin-10 and the pathogenesis of human visceral leishmaniasis.	Trends in immunology	2007	102
17916356	3458	Dolganiuc A	Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection.	Gastroenterology	2007	65
18005941	3458	Potvin S	Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.	Biological psychiatry	2008	171
18037347	3458	Martire B	Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study.	Clinical immunology	2008	52
18183290	3458	Kubica M	A potential new pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-derived macrophages.	PloS one	2008	91
18209073	3458	Roti M	Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus.	Journal of immunology	2008	57
18209095	3458	Scriba TJ	Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response.	Journal of immunology	2008	135
18256187	3458	Trumpfheller C	The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine.	Proceedings of the National Academy of Sciences of the United States of America	2008	114
18275276	3458	Pereyra F	Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.	The Journal of infectious diseases	2008	244
18292584	3458	Soares AP	Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles.	Journal of immunology	2008	81
18554755	3458	Elias D	Poor immunogenicity of BCG in helminth infected population is associated with increased in vitro TGF-beta production.	Vaccine	2008	59
18582195	3458	Hawkridge T	Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.	The Journal of infectious diseases	2008	63
18684007	3458	Cranage M	Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.	PLoS medicine	2008	72
18722511	3458	Klehmet J	Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial.	Neuroscience	2009	51
18755923	3458	Meintjes G	Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome.	American journal of respiratory and critical care medicine	2008	54
19017986	3458	Bertholet S	Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis.	Journal of immunology	2008	52
19055947	3458	Terabe M	The role of NKT cells in tumor immunity.	Advances in cancer research	2008	91
19105661	3458	Martinez FO	Alternative activation of macrophages: an immunologic functional perspective.	Annual review of immunology	2009	630
19287090	3458	Levy Y	Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.	The Journal of clinical investigation	2009	114
19342414	3458	van Zyl-Smit RN	Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing.	American journal of respiratory and critical care medicine	2009	50
19387262	3458	Dheda K	T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings.	Current opinion in pulmonary medicine	2009	64
19487422	3458	Strowig T	Priming of protective T cell responses against virus-induced tumors in mice with human immune system components.	The Journal of experimental medicine	2009	92
19613840	3458	Bicanic T	Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients.	Clinical infectious diseases 	2009	78
19636353	3458	Malhotra I	Can prenatal malaria exposure produce an immune tolerant phenotype? A prospective birth cohort study in Kenya.	PLoS medicine	2009	62
19747917	3458	Ahlenstiel G	Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner.	Gastroenterology	2010	91
19875682	3458	Mauad T	Lung pathology in fatal novel human influenza A (H1N1) infection.	American journal of respiratory and critical care medicine	2010	99
20003352	3458	Bermejo-Martin JF	Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza.	Critical care	2009	91
20019339	3458	Chen X	Reduced Th17 response in patients with tuberculosis correlates with IL-6R expression on CD4+ T Cells.	American journal of respiratory and critical care medicine	2010	48
20063313	3458	Wammes LJ	Regulatory T cells in human geohelminth infection suppress immune responses to BCG and Plasmodium falciparum.	European journal of immunology	2010	46
20200277	3458	Unsinger J	IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis.	Journal of immunology	2010	75
20226890	3458	van Dissel JT	Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.	Vaccine	2010	61
20368575	3458	Vermijlen D	Human cytomegalovirus elicits fetal gammadelta T cell responses in utero.	The Journal of experimental medicine	2010	50
20470046	3458	Wyrick PB	Chlamydia trachomatis persistence in vitro: an overview.	The Journal of infectious diseases	2010	73
20558627	3458	Kagina BM	Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns.	American journal of respiratory and critical care medicine	2010	108
20610802	3458	McCall MB	Interferon-γ--central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria.	Journal of leukocyte biology	2010	61
20677939	3458	Boulware DR	Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome.	The Journal of infectious diseases	2010	59
20725040	3458	Berry MP	An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.	Nature	2010	449
20824205	3458	Mehra S	Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas.	PloS one	2010	41
20881185	3458	Silverman JM	Leishmania exosomes modulate innate and adaptive immune responses through effects on monocytes and dendritic cells.	Journal of immunology	2010	56
21187448	3458	Rajasagi NK	Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1.	Journal of immunology	2011	44
21187913	3458	Peppa D	Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection.	PLoS pathogens	2010	64
21288814	3458	Skowronski DM	Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age.	The Journal of infectious diseases	2011	41
21628665	3458	Wauquier N	The acute phase of Chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation.	The Journal of infectious diseases	2011	39
21669030	3458	Mandalakas AM	Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis.	The international journal of tuberculosis and lung disease 	2011	42
21734244	3458	Rikihisa Y	Mechanisms of obligatory intracellular infection with Anaplasma phagocytophilum.	Clinical microbiology reviews	2011	44
21775682	3458	Day CL	Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load.	Journal of immunology	2011	84
21965332	3458	Varadarajan N	A high-throughput single-cell analysis of human CD8⁺ T cell functions reveals discordance for cytokine secretion and cytolysis.	The Journal of clinical investigation	2011	50
21998409	3458	Fabri M	Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages.	Science translational medicine	2011	135
22289511	3458	McElhaney JE	The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines.	Vaccine	2012	48
22323453	3458	Gleason MK	Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.	Blood	2012	58
22416258	3458	Jurado JO	IL-17 and IFN-γ expression in lymphocytes from patients with active tuberculosis correlates with the severity of the disease.	Journal of leukocyte biology	2012	42
22539471	3458	Singh OP	Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood.	Clinical and vaccine immunology 	2012	33
22569268	3458	Kamat A	Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection.	Journal of acquired immune deficiency syndromes	2012	61
22658928	3458	Thakur A	Immune markers and correlates of protection for vaccine induced immune responses.	Vaccine	2012	35
22700860	3458	Meintjes G	Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome.	American journal of respiratory and critical care medicine	2012	30
22761577	3458	Niedelman W	The rhoptry proteins ROP18 and ROP5 mediate Toxoplasma gondii evasion of the murine, but not the human, interferon-gamma response.	PLoS pathogens	2012	48
22772450	3458	Smith KM	miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis.	Journal of immunology	2012	45
22983442	3458	Romee R	Cytokine activation induces human memory-like NK cells.	Blood	2012	82
23144328	3458	Kartalija M	Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes.	American journal of respiratory and critical care medicine	2013	31
23169501	3458	Icheva V	Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.	Journal of clinical oncology 	2013	47
23468501	3458	Jegaskanda S	Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques.	Journal of virology	2013	47
23493728	3458	Jarvis JN	The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis.	The Journal of infectious diseases	2013	29
23999600	3458	Garg A	HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity.	The Journal of infectious diseases	2014	22
24173214	3458	Taylor HE	The innate immune factor apolipoprotein L1 restricts HIV-1 infection.	Journal of virology	2014	22
24442432	3458	Della Chiesa M	Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C-/- umbilical cord blood.	Journal of immunology	2014	31
24934179	3458	Masi A	Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis.	Molecular psychiatry	2015	34
24967632	3458	Jo J	Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver.	PLoS pathogens	2014	29
25184558	3458	Dutta NK	Latent tuberculosis infection: myths, models, and molecular mechanisms.	Microbiology and molecular biology reviews 	2014	23
25211344	3458	Sedegah M	Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes.	PloS one	2014	25
25329659	3458	Luetke-Eversloh M	Human cytomegalovirus drives epigenetic imprinting of the IFNG locus in NKG2Chi natural killer cells.	PLoS pathogens	2014	34
25469528	3458	Villar-García J	Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial.	Journal of acquired immune deficiency syndromes	2015	26
25534940	3458	Cardoso TM	Protective and pathological functions of CD8+ T cells in Leishmania braziliensis infection.	Infection and immunity	2015	16
25562578	3458	Andrews JR	The dynamics of QuantiFERON-TB gold in-tube conversion and reversion in a cohort of South African adolescents.	American journal of respiratory and critical care medicine	2015	17
25611466	3458	Gideon HP	Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization.	PLoS pathogens	2015	42
25703555	3458	Boisson-Dupuis S	Inherited and acquired immunodeficiencies underlying tuberculosis in childhood.	Immunological reviews	2015	21
26405286	3458	Getahun H	Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.	The European respiratory journal	2015	21
27068708	3458	Fletcher HA	T-cell activation is an immune correlate of risk in BCG vaccinated infants.	Nature communications	2016	16
1978068	3552	Kwiatkowski D	TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria.	Lancet	1990	205
2494664	3552	Osborn L	Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B.	Proceedings of the National Academy of Sciences of the United States of America	1989	423
2783334	3552	Waage A	The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.	The Journal of experimental medicine	1989	198
8052854	3552	Kopp E	Inhibition of NF-kappa B by sodium salicylate and aspirin.	Science	1994	266
8558837	3552	Peek RM Jr	Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains.	Laboratory investigation; a journal of technical methods and pathology	1995	146
9049801	3552	Kornman KS	The interleukin-1 genotype as a severity factor in adult periodontal disease.	Journal of clinical periodontology	1997	106
10767254	3552	Opal SM	Anti-inflammatory cytokines.	Chest	2000	187
10936147	3552	Dinarello CA	Proinflammatory cytokines.	Chest	2000	269
11581570	3552	Alexander C	Bacterial lipopolysaccharides and innate immunity.	Journal of endotoxin research	2001	149
12220547	3552	Arend WP	The balance between IL-1 and IL-1Ra in disease.	Cytokine and growth factor reviews	2002	140
12270950	3552	Watkins LR	Beyond neurons: evidence that immune and glial cells contribute to pathological pain states.	Physiological reviews	2002	132
12433676	3552	Nemeth E	Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.	Blood	2003	253
16402109	3552	Lucas SM	The role of inflammation in CNS injury and disease.	British journal of pharmacology	2006	233
17088043	3552	Dantzer R	Twenty years of research on cytokine-induced sickness behavior.	Brain, behavior, and immunity	2007	262
17724127	3552	Allantaz F	Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade.	The Journal of experimental medicine	2007	81
19428098	3552	Lopez-Souza N	In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects.	The Journal of allergy and clinical immunology	2009	61
19665429	3552	Aggarwal BB	Inflammation and cancer: how friendly is the relationship for cancer patients?	Current opinion in pharmacology	2009	77
22418018	3552	Ravelli A	Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment.	Genes and immunity	2012	44
24312098	3552	Kim B	The Interleukin-1α Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of Cytokines.	Frontiers in immunology	2013	30
24990750	3552	Mayer-Barber KD	Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk.	Nature	2014	116
25278425	3552	Cayrol C	IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy.	Current opinion in immunology	2014	77
2835680	3553	Michie HR	Detection of circulating tumor necrosis factor after endotoxin administration.	The New England journal of medicine	1988	218
8520783	3553	Bonfield TL	Inflammatory cytokines in cystic fibrosis lungs.	American journal of respiratory and critical care medicine	1995	150
9240577	3553	Yoon BH	Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy.	American journal of obstetrics and gynecology	1997	116
9925898	3553	Ostrowski K	Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans.	The Journal of physiology	1999	105
10358063	3553	Nath A	Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon.	The Journal of biological chemistry	1999	105
10608764	3553	Gogos CA	Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options.	The Journal of infectious diseases	2000	116
11058758	3553	Fournier T	Alpha-1-acid glycoprotein.	Biochimica et biophysica acta	2000	114
11982604	3553	Baize S	Inflammatory responses in Ebola virus-infected patients.	Clinical and experimental immunology	2002	95
12441323	3553	Figueiredo C	Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma.	Journal of the National Cancer Institute	2002	144
12626527	3553	Mahanty S	Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses.	Journal of immunology	2003	113
16373510	3553	Gavrilin MA	Internalization and phagosome escape required for Francisella to induce human monocyte IL-1beta processing and release.	Proceedings of the National Academy of Sciences of the United States of America	2006	103
16740164	3553	Cone RA	Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission.	BMC infectious diseases	2006	63
17044947	3553	Cavaillon JM	Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis.	Critical care	2006	123
18042719	3553	Tiemessen MM	CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages.	Proceedings of the National Academy of Sciences of the United States of America	2007	176
18240548	3553	Romero R	Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury.	Nutrition reviews	2007	92
19104081	3553	Netea MG	Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages.	Blood	2009	195
19156204	3553	Ng LF	IL-1beta, IL-6, and RANTES as biomarkers of Chikungunya severity.	PloS one	2009	65
19234215	3553	Bryan NB	Activation of inflammasomes requires intracellular redistribution of the apoptotic speck-like protein containing a caspase recruitment domain.	Journal of immunology	2009	59
19487419	3553	Minegishi Y	Molecular explanation for the contradiction between systemic Th17 defect and localized bacterial infection in hyper-IgE syndrome.	The Journal of experimental medicine	2009	71
19686799	3553	Long-Smith CM	The influence of microglia on the pathogenesis of Parkinson's disease.	Progress in neurobiology	2009	51
19710611	3553	Prasad AS	Zinc: role in immunity, oxidative stress and chronic inflammation.	Current opinion in clinical nutrition and metabolic care	2009	56
19716304	3553	Bryant C	Molecular mechanisms involved in inflammasome activation.	Trends in cell biology	2009	87
19717510	3553	Muñoz-Planillo R	A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome.	Journal of immunology	2009	99
19842207	3553	Zhang JY	Interleukin-17-producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B.	Hepatology	2010	89
20148899	3553	Mishra BB	Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome.	Cellular microbiology	2010	73
20620944	3553	Hughes T	Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue.	Immunity	2010	64
21533209	3553	Burl S	Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants.	PloS one	2011	44
21784976	3553	Novikov A	Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1β production in human macrophages.	Journal of immunology	2011	60
22521247	3553	Philbin VJ	Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways.	The Journal of allergy and clinical immunology	2012	32
22764097	3553	Denes A	Caspase-1: is IL-1 just the tip of the ICEberg?	Cell death and disease	2012	53
23143332	3553	Zhu W	Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability.	Nature	2012	36
23306544	3553	Tiringer K	A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection.	American journal of respiratory and critical care medicine	2013	26
23483986	3553	Dowling DJ	The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.	PloS one	2013	25
23954649	3553	Garcia JM	Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study.	Clinical gastroenterology and hepatology 	2014	25
24133185	3553	Allers K	Macrophages accumulate in the gut mucosa of untreated HIV-infected patients.	The Journal of infectious diseases	2014	22
24356306	3553	Doitsh G	Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection.	Nature	2014	194
24356959	3553	van der Burgh R	Defects in mitochondrial clearance predispose human monocytes to interleukin-1β hypersecretion.	The Journal of biological chemistry	2014	24
24403560	3553	Doerflinger SY	Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelia in a species-specific manner.	The Journal of infectious diseases	2014	31
24550444	3553	de Luca A	IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans.	Proceedings of the National Academy of Sciences of the United States of America	2014	55
24743880	3553	Portugal S	Exposure-dependent control of malaria-induced inflammation in children.	PLoS pathogens	2014	30
24952505	3553	Franklin BS	The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation.	Nature immunology	2014	84
25057045	3553	Dinh DM	Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection.	The Journal of infectious diseases	2015	56
25129678	3553	Ghebre MA	Biological clustering supports both "Dutch" and "British" hypotheses of asthma and chronic obstructive pulmonary disease.	The Journal of allergy and clinical immunology	2015	19
25412102	3553	Escudero-Pérez B	Shed GP of Ebola virus triggers immune activation and increased vascular permeability.	PLoS pathogens	2014	26
25762540	3553	Dudek-Perić AM	Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin.	Cancer research	2015	16
25879289	3553	Jorgensen I	Pyroptotic cell death defends against intracellular pathogens.	Immunological reviews	2015	41
26055245	3553	Szabo G	Inflammasome activation and function in liver disease.	Nature reviews. Gastroenterology and hepatology	2015	34
27383986	3553	Liu X	Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores.	Nature	2016	45
2995487	3558	McDougal JS	Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen.	Journal of immunology	1985	169
8011282	3558	Romagnani S	Lymphokine production by human T cells in disease states.	Annual review of immunology	1994	169
10358758	3558	Lenardo M	Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment.	Annual review of immunology	1999	192
10371503	3558	Chun TW	Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.	Nature medicine	1999	122
10611346	3558	Davey RT Jr	HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.	Proceedings of the National Academy of Sciences of the United States of America	1999	198
12218168	3558	Wedemeyer H	Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.	Journal of immunology	2002	173
12663797	3558	Wherry EJ	Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.	Journal of virology	2003	484
15128946	3558	Sundrud MS	Inhibition of primary human T cell proliferation by Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion.	Proceedings of the National Academy of Sciences of the United States of America	2004	80
15141157	3558	Nakamura K	Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model.	Gene therapy	2004	141
15218108	3558	Sivori S	CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells.	Proceedings of the National Academy of Sciences of the United States of America	2004	87
15972602	3558	Wikby A	An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans.	The journals of gerontology. Series A, Biological sciences and medical sciences	2005	83
15980149	3558	Klebanoff CA	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.	Proceedings of the National Academy of Sciences of the United States of America	2005	231
16051844	3558	Brooks DG	Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection.	Journal of virology	2005	82
17093248	3558	Brennan DC	Rabbit antithymocyte globulin versus basiliximab in renal transplantation.	The New England journal of medicine	2006	77
17110377	3558	Stopak KS	Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells.	The Journal of biological chemistry	2007	75
17289812	3558	Biancotto A	Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1.	Blood	2007	87
19364969	3558	Sabatino M	Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy.	Journal of clinical oncology 	2009	49
19404981	3558	Pinna D	Clonal dissection of the human memory B-cell repertoire following infection and vaccination.	European journal of immunology	2009	49
19726501	3558	Migueles SA	Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.	Journal of virology	2009	67
19828532	3558	INSIGHT-ESPRIT Study Group.	Interleukin-2 therapy in patients with HIV infection.	The New England journal of medicine	2009	135
20952687	3558	Brunstein CG	Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.	Blood	2011	272
22072753	3558	Lachmann R	Polyfunctional T cells accumulate in large human cytomegalovirus-specific T cell responses.	Journal of virology	2012	33
22129253	3558	Saadoun D	Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.	The New England journal of medicine	2011	142
22436957	3558	Tan J	Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.	JAMA	2012	99
22706088	3558	Moorman JP	Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection.	Journal of immunology	2012	32
22710188	3558	Kennedy PTF	Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.	Gastroenterology	2012	39
25503054	3558	Schuetz A	Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation.	PLoS pathogens	2014	48
26444729	3558	Kappos L	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.	The New England journal of medicine	2015	26
27500725	3558	He J	Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.	Nature medicine	2016	11
10606632	3559	Novak EJ	MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen.	The Journal of clinical investigation	1999	107
12119350	3559	Jonuleit H	Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells.	The Journal of experimental medicine	2002	126
12840064	3559	Anderson BE	Memory CD4+ T cells do not induce graft-versus-host disease.	The Journal of clinical investigation	2003	99
15032588	3559	Sakaguchi S	Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.	Annual review of immunology	2004	720
15520849	3559	Fehérvari Z	CD4+ Tregs and immune control.	The Journal of clinical investigation	2004	100
16169501	3559	Walther M	Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection.	Immunity	2005	118
16741253	3559	Amrolia PJ	Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.	Blood	2006	60
16903920	3559	Rouse BT	Regulatory T cells in virus infections.	Immunological reviews	2006	95
17277167	3559	Arruvito L	Expansion of CD4+CD25+and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction.	Journal of immunology	2007	59
17360656	3559	Kinter A	Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals.	Proceedings of the National Academy of Sciences of the United States of America	2007	70
17389235	3559	Nylén S	Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis.	The Journal of experimental medicine	2007	120
17483450	3559	Joosten SA	Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4.	Proceedings of the National Academy of Sciences of the United States of America	2007	61
18242215	3559	Harris PR	Helicobacter pylori gastritis in children is associated with a regulatory T-cell response.	Gastroenterology	2008	67
18337568	3559	Ebinuma H	Identification and in vitro expansion of functional antigen-specific CD25+ FoxP3+ regulatory T cells in hepatitis C virus infection.	Journal of virology	2008	56
19538496	3559	Robinson DS	Regulatory T cells and asthma.	Clinical and experimental allergy 	2009	45
20615947	3559	Shultz LD	Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice.	Proceedings of the National Academy of Sciences of the United States of America	2010	96
21525866	3559	Gori A	Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the "COPA" pilot randomized trial.	Mucosal immunology	2011	45
21750674	3559	Nikolova M	CD39/adenosine pathway is involved in AIDS progression.	PLoS pathogens	2011	42
23453135	3559	van de Veen W	IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses.	The Journal of allergy and clinical immunology	2013	49
7836930	3569	van der Pouw Kraan TC	Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.	The Journal of experimental medicine	1995	116
11001908	3569	Keller SA	Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells.	Blood	2000	110
11080265	3569	Steensberg A	Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6.	The Journal of physiology	2000	120
11303144	3569	Bruunsgaard H	Aging and proinflammatory cytokines.	Current opinion in hematology	2001	131
11500339	3569	Harbarth S	Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.	American journal of respiratory and critical care medicine	2001	106
11717646	3569	Yoon BH	Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes.	American journal of obstetrics and gynecology	2001	107
12480034	3569	Miller GE	Clinical depression and inflammatory risk markers for coronary heart disease.	The American journal of cardiology	2002	93
12626436	3569	Starkie R	Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans.	FASEB journal 	2003	96
15373964	3569	Dinarello CA	Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed.	Journal of endotoxin research	2004	79
15630704	3569	El-Hage N	Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat.	Glia	2005	96
15886319	3569	Kemna E	Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS.	Blood	2005	105
16849509	3569	Levy O	The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn.	Journal of immunology	2006	71
16864705	3569	Angelone DF	Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in vitro and in vivo.	Pediatric research	2006	61
17085599	3569	Sato A	Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells.	Proceedings of the National Academy of Sciences of the United States of America	2006	88
17698689	3569	Kellum JA	Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study.	Archives of internal medicine	2007	172
17849470	3569	Hong DS	Interleukin-6 and its receptor in cancer: implications for translational therapeutics.	Cancer	2007	101
18242584	3569	Brydon L	Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans.	Biological psychiatry	2008	81
18369199	3569	Yende S	Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis.	American journal of respiratory and critical care medicine	2008	70
18791359	3569	Jeschke MG	Pathophysiologic response to severe burn injury.	Annals of surgery	2008	137
18971361	3569	Han YW	Uncultivated bacteria as etiologic agents of intra-amniotic inflammation leading to preterm birth.	Journal of clinical microbiology	2009	79
19365271	3569	Bicanic T	Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study.	Journal of acquired immune deficiency syndromes	2009	56
19409533	3569	Harrison NA	Neural origins of human sickness in interoceptive responses to inflammation.	Biological psychiatry	2009	69
19585655	3569	Marra F	Adipokines in liver diseases.	Hepatology	2009	93
19678756	3569	Rodger AJ	Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.	The Journal of infectious diseases	2009	63
19738918	3569	Bilbo SD	Early-life programming of later-life brain and behavior: a critical role for the immune system.	Frontiers in behavioral neuroscience	2009	123
19794059	3569	Mehta NN	Experimental endotoxemia induces adipose inflammation and insulin resistance in humans.	Diabetes	2010	82
19828697	3569	Funderburg NT	Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation.	Blood	2010	89
19937696	3569	Hösel M	Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection.	Hepatology	2009	72
20032961	3569	Murugan R	Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival.	Kidney international	2010	66
20180702	3569	Gordon MA	Invasive non-typhoid salmonellae establish systemic intracellular infection in HIV-infected adults: an emerging disease pathogenesis.	Clinical infectious diseases 	2010	43
20230889	3569	Boksa P	Effects of prenatal infection on brain development and behavior: a review of findings from animal models.	Brain, behavior, and immunity	2010	114
20303729	3569	Laugerette F	Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation.	The Journal of nutritional biochemistry	2011	46
20583924	3569	Uldrick TS	An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease.	Clinical infectious diseases 	2010	59
20622030	3569	DeVincenzo JP	Viral load drives disease in humans experimentally infected with respiratory syncytial virus.	American journal of respiratory and critical care medicine	2010	72
20629534	3569	Cassol E	Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy.	The Journal of infectious diseases	2010	73
21209110	3569	Kang JG	Kaposi's sarcoma-associated herpesvirus ORF57 promotes escape of viral and human interleukin-6 from microRNA-mediated suppression.	Journal of virology	2011	40
21245574	3569	Hassman LM	KSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiation.	The Journal of clinical investigation	2011	36
21248066	3569	Hung IF	Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.	Clinical infectious diseases 	2011	37
21288813	3569	Chow A	Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor.	The Journal of infectious diseases	2011	62
21346738	3569	Conti HR	New mechanism of oral immunity to mucosal candidiasis in hyper-IgE syndrome.	Mucosal immunology	2011	41
21505312	3569	Marchetti G	Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count.	AIDS	2011	64
21726511	3569	Sandler NG	Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection.	Gastroenterology	2011	90
21873546	3569	Armitage AE	Hepcidin regulation by innate immune and infectious stimuli.	Blood	2011	69
22187279	3569	Boomer JS	Immunosuppression in patients who die of sepsis and multiple organ failure.	JAMA	2011	264
22197776	3569	Andaluz-Ojeda D	A combined score of pro- and anti-inflammatory interleukins improves mortality prediction in severe sepsis.	Cytokine	2012	31
22411804	3569	Villenave R	In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo.	Proceedings of the National Academy of Sciences of the United States of America	2012	46
22416101	3569	Bakker OJ	Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: a randomized trial.	JAMA	2012	50
22692596	3569	Endo S	Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study.	Journal of infection and chemotherapy 	2012	40
23065151	3569	Funderburg NT	Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome.	Blood	2012	73
23071313	3569	Rossato M	IL-10-induced microRNA-187 negatively regulates TNF-α, IL-6, and IL-12p40 production in TLR4-stimulated monocytes.	Proceedings of the National Academy of Sciences of the United States of America	2012	39
23252525	3569	De Benedetti F	Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.	The New England journal of medicine	2012	66
23348980	3569	Kruger P	A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis.	American journal of respiratory and critical care medicine	2013	32
23486877	3569	Desplats P	Molecular and pathologic insights from latent HIV-1 infection in the human brain.	Neurology	2013	53
23532539	3569	Dethlefsen C	The role of intratumoral and systemic IL-6 in breast cancer.	Breast cancer research and treatment	2013	56
23559466	3569	Erlandson KM	Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy.	The Journal of infectious diseases	2013	46
24033321	3569	Patel AR	Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease.	American journal of respiratory and critical care medicine	2013	30
24274987	3569	Combs CA	Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes.	American journal of obstetrics and gynecology	2014	51
24378753	3569	Noel N	Elevated IP10 levels are associated with immune activation and low CD4⁺ T-cell counts in HIV controller patients.	AIDS	2014	28
24417618	3569	Romero R	A novel molecular microbiologic technique for the rapid diagnosis of microbial invasion of the amniotic cavity and intra-amniotic infection in preterm labor with intact membranes.	American journal of reproductive immunology	2014	31
24618232	3569	Serra R	Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines.	International wound journal	2016	10
24622416	3569	Gitelman SE	Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.	The lancet. Diabetes and endocrinology	2013	29
24728071	3569	Miller CJ	Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.	PloS one	2014	22
24795473	3569	Tenorio AR	Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.	The Journal of infectious diseases	2014	99
24870935	3569	Nordell AD	Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.	Journal of the American Heart Association	2014	34
25042199	3569	van Rhee F	Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.	The Lancet. Oncology	2014	36
25084831	3569	Darcy CJ	Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients.	Critical care	2014	20
25190175	3569	Romero R	Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes.	The journal of maternal-fetal and neonatal medicine 	2015	30
25387317	3569	Somsouk M	Gut epithelial barrier and systemic inflammation during chronic HIV infection.	AIDS	2015	26
25388133	3569	Haake DA	Leptospirosis in humans.	Current topics in microbiology and immunology	2015	35
25583168	3569	Hileman CO	Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.	The Journal of infectious diseases	2015	16
25720095	3569	Romero R	Clinical chorioamnionitis at term I: microbiology of the amniotic cavity using cultivation and molecular techniques.	Journal of perinatal medicine	2015	22
25849830	3569	Couturier J	Human adipose tissue as a reservoir for memory CD4+ T cells and HIV.	AIDS	2015	16
25888319	3569	Ramis IB	Polymorphisms of the IL-6, IL-8 and IL-10 genes and the risk of gastric pathology in patients infected with Helicobacter pylori.	Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi	2017	5
25898198	3569	Hunter CA	IL-6 as a keystone cytokine in health and disease.	Nature immunology	2015	100
25916550	3569	Li P	Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment.	Cell research	2015	23
25921609	3569	Frasca D	Inflammaging decreases adaptive and innate immune responses in mice and humans.	Biogerontology	2016	16
26121490	3569	Scicluna BP	A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission.	American journal of respiratory and critical care medicine	2015	16
26347573	3569	Siedner MJ	Persistent Immune Activation and Carotid Atherosclerosis in HIV-Infected Ugandans Receiving Antiretroviral Therapy.	The Journal of infectious diseases	2016	12
26428501	3569	Kim CJ	Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance.	American journal of obstetrics and gynecology	2015	26
26891037	3569	Gutiérrez C	Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy.	AIDS	2016	15
15630452	3574	Wang FX	IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.	The Journal of clinical investigation	2005	94
16461915	3574	Malaspina A	Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7.	Proceedings of the National Academy of Sciences of the United States of America	2006	81
16699374	3574	Rosenberg SA	IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.	Journal of immunotherapy	2006	119
19060209	3574	Catalfamo M	HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells.	Proceedings of the National Academy of Sciences of the United States of America	2008	54
19167470	3574	Raqib R	Effects of in utero arsenic exposure on child immunity and morbidity in rural Bangladesh.	Toxicology letters	2009	56
19380868	3574	Sereti I	IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.	Blood	2009	115
21422987	3574	Lewin SR	HIV cure and eradication: how will we get from the laboratory to effective clinical trials?	AIDS	2011	40
22550117	3574	Lévy Y	Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study.	Clinical infectious diseases 	2012	65
23053510	3574	Venet F	IL-7 restores lymphocyte functions in septic patients.	Journal of immunology	2012	36
23427891	3574	Hotchkiss RS	Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.	The Lancet. Infectious diseases	2013	203
24067565	3574	Boomer JS	The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?	Virulence	2014	32
24497828	3574	Sereti I	Decreases in colonic and systemic inflammation in chronic HIV infection after IL-7 administration.	PLoS pathogens	2014	32
24585897	3574	Shive CL	Inflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease.	The Journal of infectious diseases	2014	25
3480540	3576	Yoshimura T	Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines.	Proceedings of the National Academy of Sciences of the United States of America	1987	175
7729872	3576	Sharma SA	Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro.	Infection and immunity	1995	115
8011292	3576	Murphy PM	The molecular biology of leukocyte chemoattractant receptors.	Annual review of immunology	1994	211
10449781	3576	Penfold ME	Cytomegalovirus encodes a potent alpha chemokine.	Proceedings of the National Academy of Sciences of the United States of America	1999	102
11083887	3576	Hull J	Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families.	Thorax	2000	94
11179105	3576	Aaron SD	Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease.	American journal of respiratory and critical care medicine	2001	90
18524406	3576	Candela M	Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production.	International journal of food microbiology	2008	55
19667085	3576	Nasser MW	Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer.	Journal of immunology	2009	49
20049649	3576	Bucki R	Cathelicidin LL-37: a multitask antimicrobial peptide.	Archivum immunologiae et therapiae experimentalis	2010	46
20159964	3576	Silverman JM	An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages.	Journal of cell science	2010	75
24955983	3576	Green BJ	Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma.	PloS one	2014	26
25281755	3576	Ramos EL	Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.	The Journal of infectious diseases	2015	19
11095260	3586	van den Biggelaar AH	Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10.	Lancet	2000	112
11342442	3586	Cooper MA	Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.	Blood	2001	248
11773404	3586	Spencer JV	Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10.	Journal of virology	2002	89
12359728	3586	van der Kleij D	A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization.	The Journal of biological chemistry	2002	113
12773629	3586	Asadullah K	Interleukin-10 therapy--review of a new approach.	Pharmacological reviews	2003	170
15070757	3586	Verreck FA	Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria.	Proceedings of the National Academy of Sciences of the United States of America	2004	192
15128934	3586	Granelli-Piperno A	HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation.	Proceedings of the National Academy of Sciences of the United States of America	2004	90
15529255	3586	Kanto T	Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection.	The Journal of infectious diseases	2004	71
15919939	3586	Rushbrook SM	Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection.	Journal of virology	2005	79
15919940	3586	Boettler T	T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.	Journal of virology	2005	115
16931407	3586	Mege JL	The two faces of interleukin 10 in human infectious diseases.	The Lancet. Infectious diseases	2006	65
17234458	3586	Chen X	CD4(+)CD25(+)FoxP3(+) regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease.	Clinical immunology	2007	79
17336072	3586	Blackburn SD	IL-10, T cell exhaustion and viral persistence.	Trends in microbiology	2007	69
18467372	3586	Robinson K	Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses.	Gut	2008	55
18613849	3586	Allan SE	CD4+ T-regulatory cells: toward therapy for human diseases.	Immunological reviews	2008	67
18701085	3586	Maroof A	Posttranscriptional regulation of II10 gene expression allows natural killer cells to express immunoregulatory function.	Immunity	2008	62
19136511	3586	Gonzalez-Rey E	Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis.	Gut	2009	162
20158392	3586	Ubol S	Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies.	The Journal of infectious diseases	2010	48
20213444	3586	Goyette J	Inflammation-associated S100 proteins: new mechanisms that regulate function.	Amino acids	2011	65
20661303	3586	Van Grol J	HIV-1 inhibits autophagy in bystander macrophage/monocytic cells through Src-Akt and STAT3.	PloS one	2010	42
20889800	3586	O'Leary S	IL-10 blocks phagosome maturation in mycobacterium tuberculosis-infected human macrophages.	American journal of respiratory cell and molecular biology	2011	60
21034969	3586	Sonnenberg GF	Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces.	Advances in immunology	2010	45
21254163	3586	Zhang Z	Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients.	Hepatology	2011	44
21576823	3586	Behrens EM	Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice.	The Journal of clinical investigation	2011	42
22222887	3586	Peterson RA	Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression.	Toxicologic pathology	2012	48
22586040	3586	Swaminathan S	Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expression.	Journal of immunology	2012	38
22972930	3586	Das A	IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection.	Journal of immunology	2012	57
24415936	3586	Jagannathan P	IFNγ/IL-10 co-producing cells dominate the CD4 response to malaria in highly exposed children.	PLoS pathogens	2014	35
24532064	3586	Ling Z	Altered fecal microbiota composition associated with food allergy in infants.	Applied and environmental microbiology	2014	32
24712468	3586	Finlay CM	Induction of regulatory cells by helminth parasites: exploitation for the treatment of inflammatory diseases.	Immunological reviews	2014	24
24712471	3586	Candando KM	B10 cell regulation of health and disease.	Immunological reviews	2014	38
24722226	3586	Wagener J	Fungal chitin dampens inflammation through IL-10 induction mediated by NOD2 and TLR9 activation.	PLoS pathogens	2014	47
26463422	3586	Melenotte C	B-cell non-Hodgkin lymphoma linked to Coxiella burnetii.	Blood	2016	10
12477762	3605	Fujino S	Increased expression of interleukin 17 in inflammatory bowel disease.	Gut	2003	356
17899546	3605	Zelante T	IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance.	European journal of immunology	2007	177
18613831	3605	Tesmer LA	Th17 cells in human disease.	Immunological reviews	2008	186
18615114	3605	Eyerich K	Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22.	The Journal of investigative dermatology	2008	57
18617638	3605	Koenen HJ	Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells.	Blood	2008	177
19177575	3605	Lemmers A	The interleukin-17 pathway is involved in human alcoholic liver disease.	Hepatology	2009	91
19700754	3605	Katsifis GE	Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis.	The American journal of pathology	2009	54
20200272	3605	Hueber AJ	Mast cells express IL-17A in rheumatoid arthritis synovium.	Journal of immunology	2010	94
21505189	3605	Caccamo N	Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells.	Blood	2011	57
22643849	3605	Klatt NR	Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection.	Mucosal immunology	2012	66
23054412	3605	Amedei A	Helicobacter pylori secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma.	Internal and emergency medicine	2014	28
23255555	3605	Cosgrove C	Early and nonreversible decrease of CD161++ /MAIT cells in HIV infection.	Blood	2013	59
23631916	3605	Josset L	Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus.	mBio	2013	40
24035250	3605	Baeten D	Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.	Lancet	2013	67
24585899	3605	Byakwaga H	The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy.	The Journal of infectious diseases	2014	28
25007392	3605	Langley RG	Secukinumab in plaque psoriasis--results of two phase 3 trials.	The New England journal of medicine	2014	115
25697599	3605	Siebert S	Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases.	Pharmacological reviews	2015	26
25949860	3605	Partlová S	Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma.	Oncoimmunology	2015	22
26135703	3605	McInnes IB	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.	Lancet	2015	40
26422723	3605	Mease PJ	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.	The New England journal of medicine	2015	34
26829644	3605	Ryan ES	Loss of Function of Intestinal IL-17 and IL-22 Producing Cells Contributes to Inflammation and Viral Persistence in SIV-Infected Rhesus Macaques.	PLoS pathogens	2016	13
27114460	3605	Toubiana J	Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype.	Blood	2016	21
9060447	3627	Farber JM	Mig and IP-10: CXC chemokines that target lymphocytes.	Journal of leukocyte biology	1997	164
16960776	3627	Romero AI	Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.	The Journal of infectious diseases	2006	62
17133471	3627	Lagging M	IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.	Hepatology	2006	63
17251300	3627	Hyrcza MD	Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells.	Journal of virology	2007	77
19360120	3627	Stahl-Hennig C	Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques.	PLoS pathogens	2009	70
20348884	3627	Kim CJ	The frequency, clinical significance, and pathological features of chronic chorioamnionitis: a lesion associated with spontaneous preterm birth.	Modern pathology 	2010	51
21183794	3627	Casrouge A	Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV.	The Journal of clinical investigation	2011	54
21390311	3627	Lagging M	Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.	PloS one	2011	47
22551810	3627	Valcour V	Central nervous system viral invasion and inflammation during acute HIV infection.	The Journal of infectious diseases	2012	107
23056251	3627	Liovat AS	Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection.	PloS one	2012	38
23822777	3627	Suthanthiran M	Urinary-cell mRNA profile and acute cellular rejection in kidney allografts.	The New England journal of medicine	2013	49
26400999	3627	Freeman ML	CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection.	Clinical infectious diseases 	2016	21
20557928	3645	Jewkes RK	Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study.	Lancet	2010	245
21251183	3645	Petoumenos K	Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*).	HIV medicine	2011	45
22095195	3645	Hansen AB	Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study.	AIDS	2012	38
23760347	3645	Benros ME	Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study.	JAMA psychiatry	2013	32
9649509	3661	Ronco LV	Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity.	Genes and development	1998	157
12829834	3661	Basler CF	The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.	Journal of virology	2003	173
14747536	3661	Collins SE	Innate cellular response to virus particle entry requires IRF3 but not virus replication.	Journal of virology	2004	72
15549108	3661	Balachandran S	A FADD-dependent innate immune mechanism in mammalian cells.	Nature	2004	75
17108032	3661	Liu P	Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells.	Journal of virology	2007	123
17540767	3661	Holm GH	Retinoic acid-inducible gene-I and interferon-beta promoter stimulator-1 augment proapoptotic responses following mammalian reovirus infection via interferon regulatory factor-3.	The Journal of biological chemistry	2007	59
17761676	3661	Devaraj SG	Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus.	The Journal of biological chemistry	2007	83
19706707	3661	Doehle BP	Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells.	Journal of virology	2009	52
20360684	3661	Chattopadhyay S	Viral apoptosis is induced by IRF-3-mediated activation of Bax.	The EMBO journal	2010	81
21931555	3661	Unterholzner L	Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7.	PLoS pathogens	2011	43
22922673	3661	Wegmann F	Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens.	Nature biotechnology	2012	34
25521078	3661	Olagnier D	Cellular oxidative stress response controls the antiviral and apoptotic programs in dengue virus-infected dendritic cells.	PLoS pathogens	2014	28
8356453	3700	Zhu T	Genotypic and phenotypic characterization of HIV-1 patients with primary infection.	Science	1993	436
9210678	3700	Boyd MR	Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.	Antimicrobial agents and chemotherapy	1997	118
11481487	3700	Reid W	An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction.	Proceedings of the National Academy of Sciences of the United States of America	2001	124
11825572	3700	Kwon DS	DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection.	Immunity	2002	166
14755730	3700	Haughey NJ	Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia.	Annals of neurology	2004	86
19287373	3700	Scheid JF	Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.	Nature	2009	368
20643940	3700	Doores KJ	Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.	Proceedings of the National Academy of Sciences of the United States of America	2010	119
21389135	3700	Gray ES	The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.	Journal of virology	2011	175
25355869	3700	Liu M	Polyreactivity and autoreactivity among HIV-1 antibodies.	Journal of virology	2015	39
26237403	3700	Santra S	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.	PLoS pathogens	2015	35
26481100	3700	Hou P	Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection.	Scientific reports	2015	25
26985324	3700	Melillo B	Small-Molecule CD4-Mimics: Structure-Based Optimization of HIV-1 Entry Inhibition.	ACS medicinal chemistry letters	2016	12
8698862	3845	Missale G	Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.	The Journal of clinical investigation	1996	122
10644379	3845	Kolykhalov AA	Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo.	Journal of virology	2000	169
14578911	3845	Lamarre D	An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.	Nature	2003	147
15611288	3845	Timm J	CD8 epitope escape and reversion in acute HCV infection.	The Journal of experimental medicine	2004	100
17942558	3845	Luo D	Crystal structure of the NS3 protease-helicase from dengue virus.	Journal of virology	2008	64
18195353	3845	Scheel TK	Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.	Proceedings of the National Academy of Sciences of the United States of America	2008	70
18796313	3845	Sampath A	Molecular targets for flavivirus drug discovery.	Antiviral research	2009	71
19270292	3845	Balsitis SJ	Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining.	The American journal of tropical medicine and hygiene	2009	83
19561589	3845	DuPage M	Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase.	Nature protocols	2009	159
20837518	3845	Duangchinda T	Immunodominant T-cell responses to dengue virus NS3 are associated with DHF.	Proceedings of the National Academy of Sciences of the United States of America	2010	49
22256805	3845	Lok AS	Preliminary study of two antiviral agents for hepatitis C genotype 1.	The New England journal of medicine	2012	146
22491452	3845	Burbelo PD	Serology-enabled discovery of genetically diverse hepaciviruses in a new host.	Journal of virology	2012	54
22674987	3845	Jiang J	Cell culture-adaptive mutations promote viral protein-protein interactions and morphogenesis of infectious hepatitis C virus.	Journal of virology	2012	33
23152524	3845	Bartels DJ	Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.	Journal of virology	2013	37
23178977	3845	Karino Y	Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.	Journal of hepatology	2013	35
23725851	3845	Seymour MT	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.	The Lancet. Oncology	2013	65
25445400	3845	Lenz O	Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.	Journal of hepatology	2015	31
25909356	3845	Zeuzem S	Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.	Annals of internal medicine	2015	64
26491167	3845	Shi M	Divergent Viruses Discovered in Arthropods and Vertebrates Revise the Evolutionary History of the Flaviviridae and Related Viruses.	Journal of virology	2015	21
18357343	4153	MacLennan CA	The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children.	The Journal of clinical investigation	2008	75
20930072	4153	Ram S	Infections of people with complement deficiencies and patients who have undergone splenectomy.	Clinical microbiology reviews	2010	56
25216635	4153	Kang JH	An extracorporeal blood-cleansing device for sepsis therapy.	Nature medicine	2014	30
8371352	4179	Naniche D	Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus.	Journal of virology	1993	279
8402913	4179	Dörig RE	The human CD46 molecule is a receptor for measles virus (Edmonston strain).	Cell	1993	315
9696838	4179	Mrkic B	Measles virus spread and pathogenesis in genetically modified mice.	Journal of virology	1998	104
10619434	4179	Santoro F	CD46 is a cellular receptor for human herpesvirus 6.	Cell	1999	108
10972291	4179	Tatsuo H	SLAM (CDw150) is a cellular receptor for measles virus.	Nature	2000	279
12915534	4179	Segerman A	Adenovirus type 11 uses CD46 as a cellular receptor.	Journal of virology	2003	107
14566335	4179	Gaggar A	CD46 is a cellular receptor for group B adenoviruses.	Nature medicine	2003	199
19837375	4179	Joubert PE	Autophagy induction by the pathogen receptor CD46.	Cell host and microbe	2009	69
9065404	4758	Taubenberger JK	Initial genetic characterization of the 1918 "Spanish" influenza virus.	Science	1997	124
9302301	4758	Hayden FG	Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.	The New England journal of medicine	1997	107
10430945	4758	Neumann G	Generation of influenza A viruses entirely from cloned cDNAs.	Proceedings of the National Academy of Sciences of the United States of America	1999	465
10517426	4758	Hayden FG	Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment.	JAMA	1999	110
10520648	4758	Cox NJ	Influenza.	Lancet	1999	131
10697061	4758	Treanor JJ	Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.	JAMA	2000	161
10866439	4758	Nicholson KG	Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.	Lancet	2000	124
10920197	4758	Lin YP	Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates.	Proceedings of the National Academy of Sciences of the United States of America	2000	164
12103431	4758	Ives JA	The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.	Antiviral research	2002	110
14643124	4758	Nicholson KG	Influenza.	Lancet	2003	175
14730275	4758	Peltola VT	Respiratory viruses predisposing to bacterial infections: role of neuraminidase.	The Pediatric infectious disease journal	2004	80
15337401	4758	Kiso M	Resistant influenza A viruses in children treated with oseltamivir: descriptive study.	Lancet	2004	194
15470432	4758	Kobasa D	Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus.	Nature	2004	139
15507653	4758	Matrosovich MN	Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium.	Journal of virology	2004	130
16153179	4758	Parrish CR	The origins of new pandemic viruses: the acquisition of new host ranges by canine parvovirus and influenza A viruses.	Annual review of microbiology	2005	79
16229762	4758	Gani R	Potential impact of antiviral drug use during influenza pandemic.	Emerging infectious diseases	2005	68
16282492	4758	Tumpey TM	Pathogenicity of influenza viruses with genes from the 1918 pandemic virus: functional roles of alveolar macrophages and neutrophils in limiting virus replication and mortality in mice.	Journal of virology	2005	168
16371632	4758	de Jong MD	Oseltamivir resistance during treatment of influenza A (H5N1) infection.	The New England journal of medicine	2005	238
16533883	4758	Salomon R	The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04.	The Journal of experimental medicine	2006	152
16840338	4758	Baccam P	Kinetics of influenza A virus infection in humans.	Journal of virology	2006	144
16945980	4758	Chen R	Avian influenza virus exhibits rapid evolutionary dynamics.	Molecular biology and evolution	2006	67
17088346	4758	Nelson AL	Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance.	Infection and immunity	2007	87
17109288	4758	Baz M	Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child.	Clinical infectious diseases 	2006	63
17112602	4758	Hurt AC	Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.	Antiviral research	2007	61
17298168	4758	Sandbulte MR	Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.	PLoS medicine	2007	96
17855542	4758	Yen HL	Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.	Journal of virology	2007	67
18374680	4758	Rothberg MB	Complications of viral influenza.	The American journal of medicine	2008	91
18480754	4758	Collins PJ	Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.	Nature	2008	115
18516303	4758	Dugan VG	The evolutionary genetics and emergence of avian influenza viruses in wild birds.	PLoS pathogens	2008	141
18523003	4758	Zheng BJ	Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus.	Proceedings of the National Academy of Sciences of the United States of America	2008	86
19211790	4758	Van Hoeven N	Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air.	Proceedings of the National Academy of Sciences of the United States of America	2009	94
19392624	4758	Trappetti C	Sialic acid: a preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host.	The Journal of infectious diseases	2009	63
19687228	4758	Uchiyama S	The surface-anchored NanA protein promotes pneumococcal brain endothelial cell invasion.	The Journal of experimental medicine	2009	47
19696719	4758	Centers for Disease Control and Prevention (CDC).	Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009.	MMWR. Morbidity and mortality weekly report	2009	73
19745803	4758	Centers for Disease Control and Prevention (CDC).	Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009.	MMWR. Morbidity and mortality weekly report	2009	76
19822627	4758	Kumar A	Critically ill patients with 2009 influenza A(H1N1) infection in Canada.	JAMA	2009	296
20071564	4758	Ge X	Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus.	Journal of virology	2010	45
20080770	4758	Kiso M	T-705 (favipiravir) activity against lethal H5N1 influenza A viruses.	Proceedings of the National Academy of Sciences of the United States of America	2010	50
20100088	4758	Baz M	Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses.	The Journal of infectious diseases	2010	51
20739532	4758	Seibert CW	Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models.	Journal of virology	2010	50
21288815	4758	Ghedin E	Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance.	The Journal of infectious diseases	2011	39
21342900	4758	Skarbinski J	Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States--September-October 2009.	Clinical infectious diseases 	2011	36
21345415	4758	Mosby LG	2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature.	American journal of obstetrics and gynecology	2011	43
21435708	4758	Ruuskanen O	Viral pneumonia.	Lancet	2011	133
21878571	4758	Palese P	Why do influenza virus subtypes die out? A hypothesis.	mBio	2011	45
22308500	4758	Pica N	Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses.	Proceedings of the National Academy of Sciences of the United States of America	2012	90
22311680	4758	Nguyen HT	Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.	Antiviral therapy	2012	43
22561367	4758	Hurt AC	Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia.	The Journal of infectious diseases	2012	35
23307936	4758	Couch RB	Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase.	The Journal of infectious diseases	2013	39
23577628	4758	Gao R	Human infection with a novel avian-origin influenza A (H7N9) virus.	The New England journal of medicine	2013	589
23726392	4758	Hu Y	Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance.	Lancet	2013	93
24261589	4758	Cohen M	Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase.	Virology journal	2013	32
24453375	4758	Krammer F	Divergent H7 immunogens offer protection from H7N9 virus challenge.	Journal of virology	2014	23
24699865	4758	Butler J	Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.	PLoS pathogens	2014	34
24815805	4758	Muthuri SG	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.	The Lancet. Respiratory medicine	2014	69
24891213	4758	Webster RG	Continuing challenges in influenza.	Annals of the New York Academy of Sciences	2014	41
24960271	4758	Wohlbold TJ	In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.	Viruses	2014	23
25108173	4758	Rossignol JF	Nitazoxanide: a first-in-class broad-spectrum antiviral agent.	Antiviral research	2014	30
25124927	4758	Marjuki H	Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.	The Journal of infectious diseases	2015	15
25721488	4758	Takashita E	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.	Antiviral research	2015	19
25759506	4758	Wohlbold TJ	Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.	mBio	2015	17
16304249	5580	Sakr Y	High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury.	Chest	2005	87
16424713	5580	Vincent JL	Sepsis in European intensive care units: results of the SOAP study.	Critical care medicine	2006	432
18769349	5580	Cantrell RA	A pilot study of food supplementation to improve adherence to antiretroviral therapy among food-insecure adults in Lusaka, Zambia.	Journal of acquired immune deficiency syndromes	2008	84
19798021	5580	Centers for Disease Control and Prevention (CDC).	Bacterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1) - United States, May-August 2009.	MMWR. Morbidity and mortality weekly report	2009	135
23676442	5580	Larson HJ	Measuring vaccine confidence: analysis of data obtained by a media surveillance system used to analyse public concerns about vaccines.	The Lancet. Infectious diseases	2013	34
10618385	5621	Zahn R	NMR solution structure of the human prion protein.	Proceedings of the National Academy of Sciences of the United States of America	2000	225
11476832	5621	Wadsworth JD	Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay.	Lancet	2001	158
14522861	5621	Gambetti P	Sporadic and familial CJD: classification and characterisation.	British medical bulletin	2003	118
14562104	5621	Deleault NR	RNA molecules stimulate prion protein conversion.	Nature	2003	134
15302196	5621	Peden AH	Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.	Lancet	2004	139
16135751	5621	Kong Q	Chronic wasting disease of elk: transmissibility to humans examined by transgenic mouse models.	The Journal of neuroscience 	2005	78
16391566	5621	Mead S	Prion disease genetics.	European journal of human genetics 	2006	63
17161728	5621	Wroe SJ	Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report.	Lancet	2006	86
17242357	5621	Lu X	Beta-sheet core of human prion protein amyloid fibrils as determined by hydrogen/deuterium exchange.	Proceedings of the National Academy of Sciences of the United States of America	2007	72
17585315	5621	Aguzzi A	Insights into prion strains and neurotoxicity.	Nature reviews. Molecular cell biology	2007	98
17923484	5621	Barron RM	High titers of transmissible spongiform encephalopathy infectivity associated with extremely low levels of PrPSc in vivo.	The Journal of biological chemistry	2007	69
18025469	5621	Cobb NJ	Molecular architecture of human prion protein amyloid: a parallel, in-register beta-structure.	Proceedings of the National Academy of Sciences of the United States of America	2007	111
18064447	5621	Vella LJ	The role of exosomes in the processing of proteins associated with neurodegenerative diseases.	European biophysics journal 	2008	58
18519020	5621	Béringue V	Prion agent diversity and species barrier.	Veterinary research	2008	51
18558863	5621	Aguzzi A	The prion's elusive reason for being.	Annual review of neuroscience	2008	132
19231987	5621	Caughey B	Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.	Annual review of biochemistry	2009	119
19239250	5621	Cobb NJ	Prion diseases and their biochemical mechanisms.	Biochemistry	2009	51
19424437	5621	Marijanovic Z	Identification of an intracellular site of prion conversion.	PLoS pathogens	2009	64
19436715	5621	Barria MA	De novo generation of infectious prions in vitro produces a new disease phenotype.	PLoS pathogens	2009	50
19789378	5621	Aguzzi A	Prions: protein aggregation and infectious diseases.	Physiological reviews	2009	118
19805070	5621	Wille H	Natural and synthetic prion structure from X-ray fiber diffraction.	Proceedings of the National Academy of Sciences of the United States of America	2009	68
20070383	5621	Peden A	Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia.	Haemophilia 	2010	41
20304915	5621	Kim JI	Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors.	The Journal of biological chemistry	2010	96
21347353	5621	Gonzalez-Montalban N	Highly efficient protein misfolding cyclic amplification.	PLoS pathogens	2011	40
21441913	5621	Smirnovas V	Structural organization of brain-derived mammalian prions examined by hydrogen-deuterium exchange.	Nature structural and molecular biology	2011	82
21558432	5621	Orrú CD	Prion disease blood test using immunoprecipitation and improved quaking-induced conversion.	mBio	2011	51
22282814	5621	Béringue V	Facilitated cross-species transmission of prions in extraneural tissue.	Science	2012	40
22710755	5621	Puoti G	Sporadic human prion diseases: molecular insights and diagnosis.	The Lancet. Neurology	2012	45
22711839	5621	Deleault NR	Cofactor molecules maintain infectious conformation and restrict strain properties in purified prions.	Proceedings of the National Academy of Sciences of the United States of America	2012	72
23294335	5621	Tycko R	Molecular structures of amyloid and prion fibrils: consensus versus controversy.	Accounts of chemical research	2013	46
24120764	5621	Miller MB	Cofactor molecules induce structural transformation during infectious prion formation.	Structure	2013	27
25028516	5621	Groveman BR	Parallel in-register intermolecular β-sheet architectures for prion-seeded prion protein (PrP) amyloids.	The Journal of biological chemistry	2014	36
25099576	5621	Orrú CD	A test for Creutzfeldt-Jakob disease using nasal brushings.	The New England journal of medicine	2014	39
25631286	5621	Wickner RB	Yeast prions: structure, biology, and prion-handling systems.	Microbiology and molecular biology reviews 	2015	17
26086786	5621	Orrú CD	Bank Vole Prion Protein As an Apparently Universal Substrate for RT-QuIC-Based Detection and Discrimination of Prion Strains.	PLoS pathogens	2015	24
7743510	6279	Blaser MJ	Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach.	Cancer research	1995	433
9135515	6279	Parsonnet J	Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection.	Gut	1997	200
10364597	6279	Yamaoka Y	Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: studies in four different countries.	Journal of clinical microbiology	1999	136
19798427	6279	Oldani A	Helicobacter pylori counteracts the apoptotic action of its VacA toxin by injecting the CagA protein into gastric epithelial cells.	PLoS pathogens	2009	50
9751057	7097	Yang RB	Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling.	Nature	1998	195
10384090	7097	Yoshimura A	Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2.	Journal of immunology	1999	258
10559223	7097	Lien E	Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products.	The Journal of biological chemistry	1999	227
11035751	7097	Lorenz E	A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection.	Infection and immunity	2000	101
12430718	7097	Bsibsi M	Broad expression of Toll-like receptors in the human central nervous system.	Journal of neuropathology and experimental neurology	2002	216
12946842	7097	Becker I	Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2.	Molecular and biochemical parasitology	2003	90
14981245	7097	Komai-Koma M	TLR2 is expressed on activated T cells as a costimulatory receptor.	Proceedings of the National Academy of Sciences of the United States of America	2004	119
15294983	7097	Gehring AJ	Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macrophage class II MHC antigen processing.	Journal of immunology	2004	75
17082626	7097	Boehme KW	Human cytomegalovirus envelope glycoproteins B and H are necessary for TLR2 activation in permissive cells.	Journal of immunology	2006	102
18201283	7097	Herbst-Kralovetz MM	Quantification and comparison of toll-like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia.	American journal of reproductive immunology	2008	52
19011041	7097	Chao W	Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart.	American journal of physiology. Heart and circulatory physiology	2009	72
19897561	7097	Taylor AE	Defective macrophage phagocytosis of bacteria in COPD.	The European respiratory journal	2010	56
22922410	7097	Yipp BG	Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo.	Nature medicine	2012	149
14729660	7098	Karikó K	mRNA is an endogenous ligand for Toll-like receptor 3.	The Journal of biological chemistry	2004	219
15153468	7098	Karikó K	Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3.	Journal of immunology	2004	85
15579900	7098	Guillot L	Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus.	The Journal of biological chemistry	2005	188
15652398	7098	Farina C	Preferential expression and function of Toll-like receptor 3 in human astrocytes.	Journal of neuroimmunology	2005	68
15731229	7098	Rudd BD	Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression.	Journal of virology	2005	80
15961631	7098	Choe J	Crystal structure of human toll-like receptor 3 (TLR3) ectodomain.	Science	2005	118
16424203	7098	Groskreutz DJ	Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells.	Journal of immunology	2006	79
17872438	7098	Zhang SY	TLR3 deficiency in patients with herpes simplex encephalitis.	Science	2007	283
18367536	7098	West J	Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection.	Journal of virology	2008	59
18508883	7098	Kong KF	Dysregulation of TLR3 impairs the innate immune response to West Nile virus in the elderly.	Journal of virology	2008	71
18562533	7098	Wilson JR	West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction.	Journal of virology	2008	63
19625408	7098	Wang N	Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells.	Journal of virology	2009	76
19720839	7098	Iwakiri D	Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3.	The Journal of experimental medicine	2009	68
20832341	7098	Pérez de Diego R	Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis.	Immunity	2010	81
21911422	7098	Guo Y	Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity.	The Journal of experimental medicine	2011	67
22030901	7098	Li K	Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates.	Hepatology	2012	57
23103873	7098	Lafaille FG	Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells.	Nature	2012	70
9237759	7099	Medzhitov R	A human homologue of the Drosophila Toll protein signals activation of adaptive immunity.	Nature	1997	968
11921384	7099	Hagberg H	Models of white matter injury: comparison of infectious, hypoxic-ischemic, and excitotoxic insults.	Mental retardation and developmental disabilities research reviews	2002	94
11996613	7099	Lorenz E	Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock.	Archives of internal medicine	2002	123
12045108	7099	Raetz CR	Lipopolysaccharide endotoxins.	Annual review of biochemistry	2002	920
12324469	7099	Latz E	Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction.	The Journal of biological chemistry	2002	126
12404174	7099	Agnese DM	Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections.	The Journal of infectious diseases	2002	104
15608698	7099	Miller SI	LPS, TLR4 and infectious disease diversity.	Nature reviews. Microbiology	2005	238
16953973	7099	Trent MS	Diversity of endotoxin and its impact on pathogenesis.	Journal of endotoxin research	2006	85
17324405	7099	Hold GL	A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors.	Gastroenterology	2007	82
17384648	7099	Clark SR	Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood.	Nature medicine	2007	334
17660297	7099	Chen XM	A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection.	The Journal of biological chemistry	2007	136
17709532	7099	Awomoyi AA	Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children.	Journal of immunology	2007	61
17925445	7099	Ferwerda B	TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans.	Proceedings of the National Academy of Sciences of the United States of America	2007	85
19661804	7099	Tidswell M	Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.	Critical care medicine	2010	43
20079370	7099	Ramirez JL	The Toll immune signaling pathway control conserved anti-dengue defenses across diverse Ae. aegypti strains and against multiple dengue virus serotypes.	Developmental and comparative immunology	2010	51
22777111	7099	Salomao R	Bacterial sensing, cell signaling, and modulation of the immune response during sepsis.	Shock	2012	49
23225871	7099	McCusker RH	Immune-neural connections: how the immune system's response to infectious agents influences behavior.	The Journal of experimental biology	2013	57
24416461	7099	Ribeiro JM	An insight into the transcriptome of the digestive tract of the bloodsucking bug, Rhodnius prolixus.	PLoS neglected tropical diseases	2014	22
24766885	7099	Tan Y	A cross-disciplinary perspective on the innate immune responses to bacterial lipopolysaccharide.	Molecular cell	2014	28
25260379	7099	Ekaney ML	Impact of plasma histones in human sepsis and their contribution to cellular injury and inflammation.	Critical care	2014	24
25451009	7099	Ve T	Structure and function of Toll/interleukin-1 receptor/resistance protein (TIR) domains.	Apoptosis 	2015	18
25992865	7099	Anahtar MN	Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract.	Immunity	2015	46
26133659	7099	Boutagy NE	Metabolic endotoxemia with obesity: Is it real and is it relevant?	Biochimie	2016	20
26944199	7099	Zeng MY	Gut Microbiota-Induced Immunoglobulin G Controls Systemic Infection by Symbiotic Bacteria and Pathogens.	Immunity	2016	23
2762307	7124	Duh EJ	Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat.	Proceedings of the National Academy of Sciences of the United States of America	1989	228
7935762	7124	McGuire W	Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria.	Nature	1994	149
8198398	7124	Tracey KJ	Tumor necrosis factor: a pleiotropic cytokine and therapeutic target.	Annual review of medicine	1994	148
8637514	7124	Fisher CJ Jr	Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.	The New England journal of medicine	1996	158
9725266	7124	Balcewicz-Sablinska MK	Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha.	Journal of immunology	1998	106
10228190	7124	Present DH	Infliximab for the treatment of fistulas in patients with Crohn's disease.	The New England journal of medicine	1999	233
10839541	7124	Borovikova LV	Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin.	Nature	2000	542
11156641	7124	Wigg AJ	The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis.	Gut	2001	123
11596589	7124	Keane J	Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.	The New England journal of medicine	2001	504
12682019	7124	Jordan A	HIV reproducibly establishes a latent infection after acute infection of T cells in vitro.	The EMBO journal	2003	271
12799470	7124	Borisy AA	Systematic discovery of multicomponent therapeutics.	Proceedings of the National Academy of Sciences of the United States of America	2003	140
14719195	7124	Furst DE	Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).	The Journal of rheumatology	2003	78
14988838	7124	Shintani Y	Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance.	Gastroenterology	2004	127
15127338	7124	Wallis RS	Granulomatous infectious diseases associated with tumor necrosis factor antagonists.	Clinical infectious diseases 	2004	122
15383597	7124	Levy O	Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848.	Journal of immunology	2004	99
15489357	7124	Edwards JL	The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women.	Clinical microbiology reviews	2004	83
15613320	7124	Yonezawa A	Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha.	Journal of virology	2005	70
16022777	7124	Uiprasertkul M	Influenza A H5N1 replication sites in humans.	Emerging infectious diseases	2005	81
16162882	7124	Genovese MC	Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.	The New England journal of medicine	2005	212
16705109	7124	Bongartz T	Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.	JAMA	2006	366
16868999	7124	Dixon WG	Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.	Arthritis and rheumatism	2006	87
17202130	7124	Popa C	The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk.	Journal of lipid research	2007	83
17290043	7124	Rennard SI	The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease.	American journal of respiratory and critical care medicine	2007	64
17393394	7124	Curtis JR	Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists.	Arthritis and rheumatism	2007	56
17470824	7124	Sandborn WJ	Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.	Annals of internal medicine	2007	104
17940980	7124	Warfield KL	Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.	The Journal of infectious diseases	2007	96
18029267	7124	Gupta V	Intraocular tuberculosis--an update.	Survey of ophthalmology	2007	79
18161752	7124	Bradley JR	TNF-mediated inflammatory disease.	The Journal of pathology	2008	251
18550004	7124	Peyrin-Biroulet L	Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.	Clinical gastroenterology and hepatology 	2008	76
18709470	7124	Yang H	Mesothelioma epidemiology, carcinogenesis, and pathogenesis.	Current treatment options in oncology	2008	52
18848937	7124	Boetticher NC	A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis.	Gastroenterology	2008	62
19117595	7124	Furst DE	The risk of infections with biologic therapies for rheumatoid arthritis.	Seminars in arthritis and rheumatism	2010	43
19136369	7124	Wenzel SE	A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.	American journal of respiratory and critical care medicine	2009	68
19224750	7124	Strangfeld A	Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.	JAMA	2009	79
19854715	7124	Dixon WG	Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).	Annals of the rheumatic diseases	2010	71
20675706	7124	Galloway JB	Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.	Rheumatology	2011	73
22056398	7124	Grijalva CG	Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.	JAMA	2011	56
22684480	7124	Swan C	Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα.	Gut	2013	35
22760290	7124	Zhang J	Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.	JAMA	2012	37
23097584	7124	Marais S	Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome.	Clinical infectious diseases 	2013	34
23192911	7124	Listing J	The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.	Rheumatology	2013	32
23649185	7124	Ford AC	Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.	The American journal of gastroenterology	2013	37
23735746	7124	Sandborn WJ	Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.	Gastroenterology	2014	87
26008591	7124	Brenner D	Regulation of tumour necrosis factor signalling: live or let die.	Nature reviews. Immunology	2015	66
28264816	7124	Smolen JS	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.	Annals of the rheumatic diseases	2017	12
16354854	9126	Kollef MH	Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia.	Chest	2005	139
17682100	9126	Micek ST	Health care-associated pneumonia and community-acquired pneumonia: a single-center experience.	Antimicrobial agents and chemotherapy	2007	60
23855620	9126	Shindo Y	Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia.	American journal of respiratory and critical care medicine	2013	30
11226297	10332	Pöhlmann S	DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans.	Proceedings of the National Academy of Sciences of the United States of America	2001	90
11384997	10332	Mitchell DA	A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands.	The Journal of biological chemistry	2001	114
11739956	10332	Feinberg H	Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR.	Science	2001	166
12504546	10332	Simmons G	DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells.	Virology	2003	117
12634366	10332	Pöhlmann S	Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR.	Journal of virology	2003	104
12682107	10332	Tassaneetrithep B	DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells.	The Journal of experimental medicine	2003	217
14990712	10332	Takada A	Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry.	Journal of virology	2004	81
15195147	10332	Guo Y	Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR.	Nature structural and molecular biology	2004	115
15496474	10332	Jeffers SA	CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus.	Proceedings of the National Academy of Sciences of the United States of America	2004	86
16415006	10332	Davis CW	West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection.	Journal of virology	2006	120
18091991	10333	Ma X	Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease.	PloS one	2007	58
18159247	10333	Kuhlicke J	Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia.	PloS one	2007	62
19543380	10333	Delaloye J	Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.	PLoS pathogens	2009	110
19609346	10333	Barreiro LB	Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense.	PLoS genetics	2009	105
15952891	10392	Inohara	NOD-LRR proteins: role in host-microbial interactions and inflammatory disease.	Annual review of biochemistry	2005	242
16260731	10392	Netea MG	IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism.	Proceedings of the National Academy of Sciences of the United States of America	2005	85
16493424	10392	Strober W	Signalling pathways and molecular interactions of NOD1 and NOD2.	Nature reviews. Immunology	2006	201
18621008	10392	Xu XL	Bacterial peptidoglycan triggers Candida albicans hyphal growth by directly activating the adenylyl cyclase Cyr1p.	Cell host and microbe	2008	56
20148897	10392	Losick VP	LnaB: a Legionella pneumophila activator of NF-kappaB.	Cellular microbiology	2010	40
20389019	10392	Watanabe T	NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type I IFN and activation of the ISGF3 signaling pathway.	The Journal of clinical investigation	2010	67
22825450	10392	Azad AK	Innate immune gene polymorphisms in tuberculosis.	Infection and immunity	2012	69
25732381	10392	Suarez G	Modification of Helicobacter pylori Peptidoglycan Enhances NOD1 Activation and Promotes Cancer of the Stomach.	Cancer research	2015	16
27007849	10392	Keestra-Gounder AM	NOD1 and NOD2 signalling links ER stress with inflammation.	Nature	2016	30
17262812	10410	Wu F	Genome-wide gene expression differences in Crohn's disease and ulcerative colitis from endoscopic pinch biopsies: insights into distinctive pathogenesis.	Inflammatory bowel diseases	2007	74
22446628	10410	Everitt AR	IFITM3 restricts the morbidity and mortality associated with influenza.	Nature	2012	185
23055554	10410	Jia R	The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization.	Journal of virology	2012	46
23361009	10410	Zhang YH	Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals.	Nature communications	2013	57
23649619	10410	Anafu AA	Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry.	The Journal of biological chemistry	2013	28
23720721	10410	Mudhasani R	IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus.	Journal of virology	2013	42
23973767	10410	Kandathil AJ	Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver.	Gastroenterology	2013	29
24367104	10410	Wang Z	Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection.	Proceedings of the National Academy of Sciences of the United States of America	2014	59
25599080	10410	Bailey CC	IFITM-Family Proteins: The Cell's First Line of Antiviral Defense.	Annual review of virology	2014	31
10698995	10625	Young PR	An antigen capture enzyme-linked immunosorbent assay reveals high levels of the dengue virus protein NS1 in the sera of infected patients.	Journal of clinical microbiology	2000	104
11825945	10625	Alcon S	Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections.	Journal of clinical microbiology	2002	124
12149435	10625	Geiss GK	Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza.	Proceedings of the National Academy of Sciences of the United States of America	2002	138
12195436	10625	Seo SH	Lethal H5N1 influenza viruses escape host anti-viral cytokine responses.	Nature medicine	2002	204
12355369	10625	Libraty DH	High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever.	The Journal of infectious diseases	2002	158
14745017	10625	Li WX	Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing.	Proceedings of the National Academy of Sciences of the United States of America	2004	135
15047850	10625	Spann KM	Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages corrected.	Journal of virology	2004	154
15827150	10625	Spann KM	Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines.	Journal of virology	2005	95
15994826	10625	Lo MS	Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness.	Journal of virology	2005	94
16544248	10625	Avirutnan P	Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement.	The Journal of infectious diseases	2006	114
16775317	10625	Fernandez-Sesma A	Influenza virus evades innate and adaptive immunity via the NS1 protein.	Journal of virology	2006	125
17251292	10625	Elliott J	Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase.	Journal of virology	2007	68
18052531	10625	Avirutnan P	Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E.	PLoS pathogens	2007	68
18448542	10625	Lai CY	Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II.	Journal of virology	2008	85
18714359	10625	Dussart P	Evaluation of two new commercial tests for the diagnosis of acute dengue virus infection using NS1 antigen detection in human serum.	PLoS neglected tropical diseases	2008	54
18796704	10625	Hale BG	The multifunctional NS1 protein of influenza A viruses.	The Journal of general virology	2008	353
19218453	10625	Baskin CR	Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus.	Proceedings of the National Academy of Sciences of the United States of America	2009	151
20706626	10625	Tricou V	A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults.	PLoS neglected tropical diseases	2010	48
21518917	10625	Gutsche I	Secreted dengue virus nonstructural protein NS1 is an atypical barrel-shaped high-density lipoprotein.	Proceedings of the National Academy of Sciences of the United States of America	2011	39
21909448	10625	Tricou V	Kinetics of viremia and NS1 antigenemia are shaped by immune status and virus serotype in adults with dengue.	PLoS neglected tropical diseases	2011	46
21963675	10625	Collins PL	Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.	Virus research	2011	113
22202676	10625	Khaperskyy DA	Influenza A virus inhibits cytoplasmic stress granule formation.	FASEB journal 	2012	37
22441389	10625	Blacksell SD	Comparison of seven commercial antigen and antibody enzyme-linked immunosorbent assays for detection of acute dengue infection.	Clinical and vaccine immunology 	2012	31
22807519	10625	Nguyen NM	A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients.	The Journal of infectious diseases	2013	32
23255803	10625	Rivino L	Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.	Journal of virology	2013	31
24767772	10625	Aye KS	Pathologic highlights of dengue hemorrhagic fever in 13 autopsy cases from Myanmar.	Human pathology	2014	25
26355030	10625	Beatty PR	Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination.	Science translational medicine	2015	43
26355031	10625	Modhiran N	Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity.	Science translational medicine	2015	47
26859285	10625	Gyurech D	False positive dengue NS1 antigen test in a traveller with an acute Zika virus infection imported into Switzerland.	Swiss medical weekly	2016	17
27417494	10625	Stettler K	Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection.	Science	2016	71
1373735	10959	Grunfeld C	Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.	The Journal of clinical endocrinology and metabolism	1992	150
1967191	10959	Fahey JL	The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.	The New England journal of medicine	1990	152
2107573	10959	Sarver N	Ribozymes as potential anti-HIV-1 therapeutic agents.	Science	1990	147
2413459	10959	Mitsuya H	3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.	Proceedings of the National Academy of Sciences of the United States of America	1985	236
3290901	10959	Kohl NE	Active human immunodeficiency virus protease is required for viral infectivity.	Proceedings of the National Academy of Sciences of the United States of America	1988	275
8096374	10959	Koot M	Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.	Annals of internal medicine	1993	226
11157057	10959	Kelleher AD	Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses.	The Journal of experimental medicine	2001	198
12960819	10959	Fiebig EW	Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.	AIDS	2003	363
16501126	10959	Zuñiga R	Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control.	Journal of virology	2006	123
16537629	10959	Martinez-Picado J	Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1.	Journal of virology	2006	235
16954502	10959	Watanabe S	Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses.	Blood	2007	74
19229336	10959	Fenyö EM	International network for comparison of HIV neutralization assays: the NeutNet report.	PloS one	2009	60
19958227	10959	Nowacek AS	NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.	Nanomedicine	2009	53
20702636	10959	Wright JK	Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters.	Journal of virology	2010	43
21085591	10959	Currier JR	Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.	PloS one	2010	43
21992606	10959	Saleh S	Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells.	Retrovirology	2011	41
26676775	10959	Pallikkuth S	Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy.	Journal of virology	2015	22
16329186	22914	González S	Immunobiology of human NKG2D and its ligands.	Current topics in microbiology and immunology	2006	64
17202358	22914	Venkataraman GM	Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D.	Journal of immunology	2007	60
17312110	22914	Draghi M	NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection.	Journal of immunology	2007	65
19201769	22914	Fisicaro P	Early kinetics of innate and adaptive immune responses during hepatitis B virus infection.	Gut	2009	55
19470388	22914	Oliviero B	Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections.	Gastroenterology	2009	115
19542445	22914	Hedlund M	Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function.	Journal of immunology	2009	53
20080094	22914	Amadei B	Activation of natural killer cells during acute infection with hepatitis C virus.	Gastroenterology	2010	51
23601842	22914	Crome SQ	Natural killer cells regulate diverse T cell responses.	Trends in immunology	2013	30
23846901	22914	Chaigne-Delalande B	Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D.	Science	2013	37
15737993	23586	Li K	Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes.	The Journal of biological chemistry	2005	114
16116171	23586	Yoneyama M	Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity.	Journal of immunology	2005	410
16585524	23586	Loo YM	Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.	Proceedings of the National Academy of Sciences of the United States of America	2006	168
17053203	23586	Guo Z	NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I.	American journal of respiratory cell and molecular biology	2007	107
17140406	23586	Opitz B	IFNbeta induction by influenza A virus is mediated by RIG-I which is regulated by the viral NS1 protein.	Cellular microbiology	2007	110
17204473	23586	Onoguchi K	Viral infections activate types I and III interferon genes through a common mechanism.	The Journal of biological chemistry	2007	89
17356690	23586	Plumet S	Cytosolic 5'-triphosphate ended viral leader transcript of measles virus as activator of the RIG I-mediated interferon response.	PloS one	2007	66
17392790	23586	Gack MU	TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity.	Nature	2007	427
19017631	23586	Oshiumi H	Riplet/RNF135, a RING finger protein, ubiquitinates RIG-I to promote interferon-beta induction during the early phase of viral infection.	The Journal of biological chemistry	2009	80
19902255	23586	Ovsyannikova IG	Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes.	Human genetics	2010	45
20395558	23586	Schneider D	Increased cytokine response of rhinovirus-infected airway epithelial cells in chronic obstructive pulmonary disease.	American journal of respiratory and critical care medicine	2010	48
21102435	23586	Hayakawa S	ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses.	Nature immunology	2011	46
21147034	23586	Pang IK	Inflammasomes as mediators of immunity against influenza virus.	Trends in immunology	2011	42
21254160	23586	Thomas E	Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models.	Hepatology	2011	46
22312431	23586	Sun L	Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling.	PloS one	2012	38
23027947	23586	Paradkar PN	Secreted Vago restricts West Nile virus infection in Culex mosquito cells by activating the Jak-STAT pathway.	Proceedings of the National Academy of Sciences of the United States of America	2012	53
23498958	23586	Weber M	Incoming RNA virus nucleocapsids containing a 5'-triphosphorylated genome activate RIG-I and antiviral signaling.	Cell host and microbe	2013	43
23633948	23586	Goulet ML	Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity.	PLoS pathogens	2013	31
23950712	23586	Oshiumi H	A distinct role of Riplet-mediated K63-Linked polyubiquitination of the RIG-I repressor domain in human antiviral innate immune responses.	PLoS pathogens	2013	39
24075860	23586	Seo GJ	Reciprocal inhibition between intracellular antiviral signaling and the RNAi machinery in mammalian cells.	Cell host and microbe	2013	49
24316047	23586	Green AM	Innate immunity to dengue virus infection and subversion of antiviral responses.	Journal of molecular biology	2014	42
24478443	23586	Olagnier D	Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response.	Journal of virology	2014	27
24743923	23586	Runge S	In vivo ligands of MDA5 and RIG-I in measles virus-infected cells.	PLoS pathogens	2014	25
24931123	23586	Zhu J	Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor.	Immunity	2014	32
25704008	23586	Weber M	Influenza virus adaptation PB2-627K modulates nucleocapsid inhibition by the pathogen sensor RIG-I.	Cell host and microbe	2015	21
25968648	23586	Dalrymple NA	Dengue Virus NS Proteins Inhibit RIG-I/MAVS Signaling by Blocking TBK1/IRF3 Phosphorylation: Dengue Virus Serotype 1 NS4A Is a Unique Interferon-Regulating Virulence Determinant.	mBio	2015	20
26085147	23586	Hamel R	Biology of Zika Virus Infection in Human Skin Cells.	Journal of virology	2015	154
17096847	25870	Huijsdens XW	Community-acquired MRSA and pig-farming.	Annals of clinical microbiology and antimicrobials	2006	80
19608582	25870	Tenover FC	Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology.	The Journal of antimicrobial chemotherapy	2009	96
25631811	25870	Salipante SJ	Application of whole-genome sequencing for bacterial strain typing in molecular epidemiology.	Journal of clinical microbiology	2015	23
21613998	25939	Laguette N	SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx.	Nature	2011	457
22056990	25939	Goldstone DC	HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase.	Nature	2011	248
22174685	25939	Berger A	SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutières syndrome are highly susceptible to HIV-1 infection.	PLoS pathogens	2011	105
22284954	25939	Lim ES	The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx.	Cell host and microbe	2012	99
22327569	25939	Lahouassa H	SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates.	Nature immunology	2012	250
22362772	25939	Ahn J	HIV/simian immunodeficiency virus (SIV) accessory virulence factor Vpx loads the host cell restriction factor SAMHD1 onto the E3 ubiquitin ligase complex CRL4DCAF1.	The Journal of biological chemistry	2012	65
22589553	25939	Kim B	Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages.	The Journal of biological chemistry	2012	84
22972397	25939	Baldauf HM	SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells.	Nature medicine	2012	192
23035819	25939	Koppensteiner H	Macrophages and their relevance in Human Immunodeficiency Virus Type I infection.	Retrovirology	2012	63
23092122	25939	Descours B	SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells.	Retrovirology	2012	120
23158101	25939	White TE	Contribution of SAM and HD domains to retroviral restriction mediated by human SAMHD1.	Virology	2013	49
23426366	25939	Yan J	Tetramerization of SAMHD1 is required for biological activity and inhibition of HIV infection.	The Journal of biological chemistry	2013	53
23858451	25939	Franzolin E	The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells.	Proceedings of the National Academy of Sciences of the United States of America	2013	53
23872947	25939	Rehwinkel J	SAMHD1-dependent retroviral control and escape in mice.	The EMBO journal	2013	39
24141705	25939	Ji X	Mechanism of allosteric activation of SAMHD1 by dGTP.	Nature structural and molecular biology	2013	42
24336198	25939	Schwefel D	Structural basis of lentiviral subversion of a cellular protein degradation pathway.	Nature	2014	27
25267621	25939	Ji X	Structural basis of cellular dNTP regulation by SAMHD1.	Proceedings of the National Academy of Sciences of the United States of America	2014	21
16216651	26284	Alanis AJ	Resistance to antibiotics: are we in the post-antibiotic era?	Archives of medical research	2005	107
16394852	26284	Crum NF	Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras.	Journal of acquired immune deficiency syndromes	2006	157
18614927	26284	D'Souza G	Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study.	Journal of acquired immune deficiency syndromes	2008	70
20065332	26284	Mancini N	The era of molecular and other non-culture-based methods in diagnosis of sepsis.	Clinical microbiology reviews	2010	73
20502317	26284	Buchacz K	AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study.	AIDS	2010	60
20595106	26284	Jain AK	Tuberculosis of the spine: a fresh look at an old disease.	The Journal of bone and joint surgery. British volume	2010	63
21733755	26284	Hunter RL	Pathology of post primary tuberculosis of the lung: an illustrated critical review.	Tuberculosis	2011	37
21881561	26284	D'Costa VM	Antibiotic resistance is ancient.	Nature	2011	204
22653528	26284	Holt JL	Neuroimaging studies of the aging HIV-1-infected brain.	Journal of neurovirology	2012	38
23242849	26284	Ralph AP	Group a streptococcal diseases and their global burden.	Current topics in microbiology and immunology	2013	45
25245987	26284	Chatelain E	Chagas disease drug discovery: toward a new era.	Journal of biomolecular screening	2015	26
9237695	26503	Kalayanarooj S	Early clinical and laboratory indicators of acute dengue illness.	The Journal of infectious diseases	1997	108
22846613	26503	Bala S	Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection.	Journal of translational medicine	2012	42
22993296	26503	Pollock NR	A paper-based multiplexed transaminase test for low-cost, point-of-care liver function testing.	Science translational medicine	2012	38
23183526	26503	Suzuki Y	Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.	Journal of hepatology	2013	47
24436062	26503	Konerman MA	Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs.	Hepatology	2014	21
24604476	26503	Kumada H	Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.	Hepatology	2014	80
25099546	26503	Chung M	Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis.	The American journal of clinical nutrition	2014	23
16876901	29126	Mühlbauer M	PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis.	Journal of hepatology	2006	91
17195077	29126	Blank C	Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion.	Cancer immunology, immunotherapy 	2007	85
17287266	29126	Boni C	Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection.	Journal of virology	2007	198
19229109	29126	Franceschini D	PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV.	The Journal of clinical investigation	2009	87
22133721	29126	Amarnath S	The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.	Science translational medicine	2011	74
22271878	29126	Green MR	Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.	Clinical cancer research 	2012	66
23288508	29126	Lyford-Pike S	Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma.	Cancer research	2013	114
24387680	29126	Chang K	Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.	Critical care	2014	47
24391505	29126	Liu J	Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.	PLoS pathogens	2014	26
24626392	29126	Bowers NL	Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway.	PLoS pathogens	2014	37
25609381	29126	Khan AR	PD-L1hi B cells are critical regulators of humoral immunity.	Nature communications	2015	22
25751499	29126	Lussier DM	Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.	Journal of immunotherapy	2015	22
26598942	29126	Smyth MJ	Combination cancer immunotherapies tailored to the tumour microenvironment.	Nature reviews. Clinical oncology	2016	43
26977880	29126	Tang H	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.	Cancer cell	2016	19
12515819	30835	Tailleux L	DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells.	The Journal of experimental medicine	2003	138
12783086	30835	Navarro-Sanchez E	Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses.	EMBO reports	2003	126
15855154	30835	Lozach PY	Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals.	The Journal of biological chemistry	2005	73
18337571	30835	Rappocciolo G	Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN.	Journal of virology	2008	61
19386588	30835	Martinez-Nunez RT	MicroRNA-155 modulates the pathogen binding ability of dendritic cells (DCs) by down-regulation of DC-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN).	The Journal of biological chemistry	2009	60
15771572	51284	Liu YJ	IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors.	Annual review of immunology	2005	407
15827165	51284	Schlender J	Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus.	Journal of virology	2005	92
16224540	51284	Beignon AS	Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions.	The Journal of clinical investigation	2005	249
16365416	51284	Chaperot L	Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells.	Journal of immunology	2006	72
17190786	51284	Kawai T	Antiviral signaling through pattern recognition receptors.	Journal of biochemistry	2007	145
20100933	51284	Panda A	Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response.	Journal of immunology	2010	115
24966195	51284	Addo MM	Sex-based differences in HIV type 1 pathogenesis.	The Journal of infectious diseases	2014	23
25411473	51284	Wu TY	Rational design of small molecules as vaccine adjuvants.	Science translational medicine	2014	23
26553869	51284	Sampey GC	Exosomes from HIV-1-infected Cells Stimulate Production of Pro-inflammatory Cytokines through Trans-activating Response (TAR) RNA.	The Journal of biological chemistry	2016	20
9701160	51497	Shankar AH	Zinc and immune function: the biological basis of altered resistance to infection.	The American journal of clinical nutrition	1998	147
11375434	51497	Stephensen CB	Vitamin A, infection, and immune function.	Annual review of nutrition	2001	112
11905816	51497	Wills-Karp M	The germless theory of allergic disease: revisiting the hygiene hypothesis.	Nature reviews. Immunology	2001	153
14726604	51497	Guzik TJ	Nitric oxide and superoxide in inflammation and immune regulation.	Journal of physiology and pharmacology 	2003	126
15032590	51497	North RJ	Immunity to tuberculosis.	Annual review of immunology	2004	235
16166100	51497	Howarth PH	Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma.	Thorax	2005	93
17726308	51497	Wintergerst ES	Contribution of selected vitamins and trace elements to immune function.	Annals of nutrition and metabolism	2007	68
18342898	51497	Schneider BS	The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response.	Transactions of the Royal Society of Tropical Medicine and Hygiene	2008	71
18688037	51497	Fairweather D	Sex differences in autoimmune disease from a pathological perspective.	The American journal of pathology	2008	78
18952487	51497	Wang KX	Osteopontin: role in immune regulation and stress responses.	Cytokine and growth factor reviews	2008	159
19079189	51497	Cecchinato V	Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques.	Mucosal immunology	2008	92
19406170	51497	Hewitson JP	Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity.	Molecular and biochemical parasitology	2009	160
19912252	51497	Crome SQ	Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease.	Clinical and experimental immunology	2010	62
20192806	51497	Zhu J	Differentiation of effector CD4 T cell populations (*).	Annual review of immunology	2010	668
21198665	51497	Liu MA	DNA vaccines: an historical perspective and view to the future.	Immunological reviews	2011	97
21233414	51497	Wink DA	Nitric oxide and redox mechanisms in the immune response.	Journal of leukocyte biology	2011	104
21246542	51497	de Lalla C	High-frequency and adaptive-like dynamics of human CD1 self-reactive T cells.	European journal of immunology	2011	40
21506647	51497	Bode C	CpG DNA as a vaccine adjuvant.	Expert review of vaccines	2011	99
22719180	51497	Sykes L	The Th1:th2 dichotomy of pregnancy and preterm labour.	Mediators of inflammation	2012	32
23791644	51497	Hawkins RD	Global chromatin state analysis reveals lineage-specific enhancers during the initiation of human T helper 1 and T helper 2 cell polarization.	Immunity	2013	30
24286760	51497	Bergink V	Autoimmunity, inflammation, and psychosis: a search for peripheral markers.	Biological psychiatry	2014	32
24975812	51497	Scheiermann J	Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.	Vaccine	2014	25
25454872	51497	van Dissel JT	A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.	Vaccine	2014	21
26095509	51497	Luabeya AK	First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.	Vaccine	2015	17
26702627	51497	Tappe D	Cytokine kinetics of Zika virus-infected patients from acute to reconvalescent phase.	Medical microbiology and immunology	2016	14
27640624	51497	Liew FY	Interleukin-33 in health and disease.	Nature reviews. Immunology	2016	19
11130078	54106	Hemmi H	A Toll-like receptor recognizes bacterial DNA.	Nature	2000	1194
16763660	54106	Krieg AM	Therapeutic potential of Toll-like receptor 9 activation.	Nature reviews. Drug discovery	2006	255
17261807	54106	Parroche P	Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9.	Proceedings of the National Academy of Sciences of the United States of America	2007	160
19211030	54106	Vollmer J	Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.	Advanced drug delivery reviews	2009	101
20442853	54106	Nguyen M	Acquisition of adult-like TLR4 and TLR9 responses during the first year of life.	PloS one	2010	45
24308579	54106	Shirota H	Recent progress concerning CpG DNA and its use as a vaccine adjuvant.	Expert review of vaccines	2014	21
26168081	54106	Meller S	T(H)17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26.	Nature immunology	2015	19
15087226	54474	Crotty S	Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system.	Journal of immunological methods	2004	159
16502413	54474	Thomas DA	Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.	Cancer	2006	80
20980506	54474	Ma SD	A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas.	Journal of virology	2011	60
21856867	54474	Wierda WG	Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.	Blood	2011	37
22438256	54474	Sehn LH	A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies.	Blood	2012	41
23319647	54474	Marzi A	Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.	Proceedings of the National Academy of Sciences of the United States of America	2013	45
24401022	54474	Goede V	Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.	The New England journal of medicine	2014	173
25412906	54474	Di Bisceglie AM	Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?	Hepatology	2015	21
25636338	54474	Castillo JJ	The biology and treatment of plasmablastic lymphoma.	Blood	2015	22
15492621	55016	Jager RD	Risks of intravitreous injection: a comprehensive review.	Retina	2004	71
17414725	55016	Esteban A	Sepsis incidence and outcome: contrasting the intensive care unit with the hospital ward.	Critical care medicine	2007	63
19274071	55016	Sissoko D	Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period.	PLoS neglected tropical diseases	2009	60
19498336	55016	Centers for Disease Control and Prevention (CDC).	Update: novel influenza A (H1N1) virus infection - Mexico, March-May, 2009.	MMWR. Morbidity and mortality weekly report	2009	49
21923436	55016	Kullar R	High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.	Pharmacotherapy	2011	37
22914561	55016	Feikin DR	Viral and bacterial causes of severe acute respiratory illness among children aged less than 5 years in a high malaria prevalence area of western Kenya, 2007-2010.	The Pediatric infectious disease journal	2013	31
22937071	55016	Feikin DR	Etiology and Incidence of viral and bacterial acute respiratory illness among older children and adults in rural western Kenya, 2007-2010.	PloS one	2012	43
26993883	55016	Cauchemez S	Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study.	Lancet	2016	125
14727222	57506	Charles PG	Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.	Clinical infectious diseases 	2004	99
19199552	57506	Maor Y	Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia.	The Journal of infectious diseases	2009	46
19369444	57506	Musta AC	Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.	Journal of clinical microbiology	2009	52
20065327	57506	Howden BP	Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.	Clinical microbiology reviews	2010	181
20451243	57506	Dixit E	Peroxisomes are signaling platforms for antiviral innate immunity.	Cell	2010	205
20962078	57506	White LK	Chikungunya virus induces IPS-1-dependent innate immune activation and protein kinase R-independent translational shutoff.	Journal of virology	2011	40
22427742	57506	Patel MR	Convergent evolution of escape from hepaciviral antagonism in primates.	PLoS biology	2012	33
24390337	57506	Feng Q	Enterovirus 2Apro targets MDA5 and MAVS in infected cells.	Journal of virology	2014	29
25644461	57506	Chan YK	RIG-I-like receptor regulation in virus infection and immunity.	Current opinion in virology	2015	22
16267772	57823	Pai R	Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States.	The Journal of infectious diseases	2005	88
16598044	57823	Kyaw MH	Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.	The New England journal of medicine	2006	152
17529860	57823	Pelton SI	Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.	The Pediatric infectious disease journal	2007	90
17940232	57823	Pichichero ME	Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children.	JAMA	2007	75
19564254	57823	Huang SS	Continued impact of pneumococcal conjugate vaccine on carriage in young children.	Pediatrics	2009	98
22374921	57823	Bewick T	Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia.	Thorax	2012	31
23804191	57823	Dagan R	Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.	Clinical infectious diseases 	2013	32
24567842	57823	Lee GM	Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts.	Journal of the Pediatric Infectious Diseases Society	2014	26
26132078	57823	van der Linden M	Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany.	PloS one	2015	19
12167863	60489	Sheehy AM	Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.	Nature	2002	920
12808466	60489	Mangeat B	Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.	Nature	2003	587
12809610	60489	Harris RS	DNA deamination mediates innate immunity to retroviral infection.	Cell	2003	551
12859895	60489	Mariani R	Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.	Cell	2003	403
14528300	60489	Sheehy AM	The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.	Nature medicine	2003	424
14557625	60489	Kao S	The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.	Journal of virology	2003	151
14978281	60489	Schröfelbauer B	A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).	Proceedings of the National Academy of Sciences of the United States of America	2004	145
14999100	60489	Bogerd HP	A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor.	Proceedings of the National Academy of Sciences of the United States of America	2004	146
15054139	60489	Xu H	A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.	Proceedings of the National Academy of Sciences of the United States of America	2004	123
15210704	60489	Svarovskaia ES	Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.	The Journal of biological chemistry	2004	132
15269786	60489	Sawyer SL	Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.	PLoS biology	2004	197
15829920	60489	Chiu YL	Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.	Nature	2005	221
16140735	60489	Ylinen LM	Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles.	Journal of virology	2005	81
16971427	60489	Guo F	Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.	Journal of virology	2006	108
17259974	60489	Okeoma CM	APOBEC3 inhibits mouse mammary tumour virus replication in vivo.	Nature	2007	97
17522211	60489	Opi S	Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.	Journal of virology	2007	57
17855362	60489	Li XY	APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.	The Journal of biological chemistry	2007	86
19266078	60489	Huthoff H	RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1.	PLoS pathogens	2009	85
20463080	60489	Sadler HA	APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.	Journal of virology	2010	69
20660203	60489	Kim EY	Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure.	Journal of virology	2010	43
23152537	60489	Gillick K	Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination.	Journal of virology	2013	41
10756000	81502	Ribes JA	Zygomycetes in human disease.	Clinical microbiology reviews	2000	209
16482227	81502	Dunning Hotopp JC	Comparative genomics of emerging human ehrlichiosis agents.	PLoS genetics	2006	188
17715376	81502	Lockhart SR	Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004.	Journal of clinical microbiology	2007	85
14985764	85363	Stremlau M	The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.	Nature	2004	752
15249685	85363	Hatziioannou T	Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.	Proceedings of the National Academy of Sciences of the United States of America	2004	186
15249687	85363	Keckesova Z	The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities.	Proceedings of the National Academy of Sciences of the United States of America	2004	179
15280539	85363	Perron MJ	TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells.	Proceedings of the National Academy of Sciences of the United States of America	2004	152
15649369	85363	Yap MW	A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction.	Current biology 	2005	193
15709033	85363	Stremlau M	Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.	Journal of virology	2005	187
15767395	85363	Song B	Retrovirus restriction by TRIM5alpha variants from Old World and New World primates.	Journal of virology	2005	104
15994791	85363	Perez-Caballero D	Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity.	Journal of virology	2005	134
16540544	85363	Stremlau M	Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor.	Proceedings of the National Academy of Sciences of the United States of America	2006	341
16808955	85363	Javanbakht H	Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding.	Virology	2006	65
16809279	85363	Li Y	Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection.	Journal of virology	2006	62
16973579	85363	Anderson JL	Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.	Journal of virology	2006	91
17135314	85363	Perron MJ	The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid.	Journal of virology	2007	83
17588933	85363	Kaiser SM	Restriction of an extinct retrovirus by the human TRIM5alpha antiviral protein.	Science	2007	55
18497858	85363	Rold CJ	Proteasomal degradation of TRIM5alpha during retrovirus restriction.	PLoS pathogens	2008	60
18799573	85363	Langelier CR	Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication.	Journal of virology	2008	78
22114335	85363	Roa A	RING domain mutations uncouple TRIM5α restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating.	Journal of virology	2012	37
23505372	85363	Kutluay SB	Fates of retroviral core components during unrestricted and TRIM5-restricted infection.	PLoS pathogens	2013	32
19161423	112744	Dubin PJ	Th17 cytokines and mucosal immunity.	Immunological reviews	2008	60
19410689	112744	Louten J	Development and function of TH17 cells in health and disease.	The Journal of allergy and clinical immunology	2009	63
20123958	112744	Puel A	Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I.	The Journal of experimental medicine	2010	152
20123959	112744	Kisand K	Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines.	The Journal of experimental medicine	2010	148
20674321	112744	Puel A	Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines?	Current opinion in immunology	2010	48
21350122	112744	Puel A	Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity.	Science	2011	216
22838497	112744	Huppler AR	Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy.	Arthritis research and therapy	2012	36
22949323	112744	Cypowyj S	Immunity to infection in IL-17-deficient mice and humans.	European journal of immunology	2012	34
23026768	112744	Puel A	Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis.	Current opinion in allergy and clinical immunology	2012	52
23563688	112744	Bermejo DA	Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORγt and Ahr that leads to IL-17 production by activated B cells.	Nature immunology	2013	46
25174402	112744	De Simone V	Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth.	Oncogene	2015	37
26160376	112744	Okada S	IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations.	Science	2015	42
16470011	114548	Dinarello CA	Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process.	The American journal of clinical nutrition	2006	77
17442855	114548	Lamkanfi M	Caspase-1 inflammasomes in infection and inflammation.	Journal of leukocyte biology	2007	60
18005730	114548	Willingham SB	Microbial pathogen-induced necrotic cell death mediated by the inflammasome components CIAS1/cryopyrin/NLRP3 and ASC.	Cell host and microbe	2007	105
19454352	114548	Hise AG	An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans.	Cell host and microbe	2009	163
19798428	114548	Cillóniz C	Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes.	PLoS pathogens	2009	93
19826485	114548	Craven RR	Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells.	PloS one	2009	115
20008285	114548	Meixenberger K	Listeria monocytogenes-infected human peripheral blood mononuclear cells produce IL-1beta, depending on listeriolysin O and NLRP3.	Journal of immunology	2010	65
20368800	114548	Saïd-Sadier N	Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase.	PloS one	2010	90
20383149	114548	Ichinohe T	Influenza virus activates inflammasomes via its intracellular M2 ion channel.	Nature immunology	2010	166
20980503	114548	Barlan AU	Adenovirus membrane penetration activates the NLRP3 inflammasome.	Journal of virology	2011	51
21349431	114548	Guarda G	Type I interferon inhibits interleukin-1 production and inflammasome activation.	Immunity	2011	203
21740493	114548	Wong KW	Critical role for NLRP3 in necrotic death triggered by Mycobacterium tuberculosis.	Cellular microbiology	2011	46
21994322	114548	Burdette D	Hepatitis C virus activates interleukin-1β via caspase-1-inflammasome complex.	The Journal of general virology	2012	34
22461501	114548	Shenoy AR	GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals.	Science	2012	88
22948162	114548	Juliana C	Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation.	The Journal of biological chemistry	2012	98
23086037	114548	Lee HM	Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes.	Diabetes	2013	78
23427152	114548	Johnson KE	Herpes simplex virus 1 infection induces activation and subsequent inhibition of the IFI16 and NLRP3 inflammasomes.	Journal of virology	2013	64
23633957	114548	Negash AA	IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease.	PLoS pathogens	2013	88
23737748	114548	McAuley JL	Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and disease.	PLoS pathogens	2013	45
23937860	114548	Hillegass JM	Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells.	Particle and fibre toxicology	2013	27
24009231	114548	Hottz ED	Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation.	Blood	2013	34
24137163	114548	Zhong Y	Functions of NOD-Like Receptors in Human Diseases.	Frontiers in immunology	2013	32
24398679	114548	Bakele M	Localization and functionality of the inflammasome in neutrophils.	The Journal of biological chemistry	2014	20
24453977	114548	Ataide MA	Malaria-induced NLRP12/NLRP3-dependent caspase-1 activation mediates inflammation and hypersensitivity to bacterial superinfection.	PLoS pathogens	2014	30
24939850	114548	Guo H	HIV-1 infection induces interleukin-1β production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes.	The Journal of biological chemistry	2014	22
25217959	114548	Canna SW	An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome.	Nature genetics	2014	53
25330206	114548	Abais JM	Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector?	Antioxidants and redox signaling	2015	24
25686105	114548	Coll RC	A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.	Nature medicine	2015	119
25993444	114548	Schaale K	Strain- and host species-specific inflammasome activation, IL-1β release, and cell death in macrophages infected with uropathogenic Escherichia coli.	Mucosal immunology	2016	11
26341399	114548	Bronner DN	Endoplasmic Reticulum Stress Activates the Inflammasome via NLRP3- and Caspase-2-Driven Mitochondrial Damage.	Immunity	2015	27
26549800	114548	Jo EK	Molecular mechanisms regulating NLRP3 inflammasome activation.	Cellular and molecular immunology	2016	26
26877061	114548	Karmakar M	Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP.	Nature communications	2016	23
26972847	114548	Iannitti RG	IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis.	Nature communications	2016	11
27313051	114548	Arbore G	T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4⁺ T cells.	Science	2016	26
23258413	115004	Sun L	Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway.	Science	2013	458
24077100	115004	Ablasser A	Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP.	Nature	2013	76
25401470	115004	Jeremiah N	Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations.	The Journal of clinical investigation	2014	42
25517615	115004	Woo SR	STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.	Immunity	2014	101
25642965	115004	West AP	Mitochondrial DNA stress primes the antiviral innate immune response.	Nature	2015	82
25831530	115004	Orzalli MH	cGAS-mediated stabilization of IFI16 promotes innate signaling during herpes simplex virus infection.	Proceedings of the National Academy of Sciences of the United States of America	2015	35
27058035	115004	Paijo J	cGAS Senses Human Cytomegalovirus and Induces Type I Interferon Responses in Human Monocyte-Derived Cells.	PLoS pathogens	2016	15
10608744	123228	Vaughn DW	Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.	The Journal of infectious diseases	2000	404
16207951	123228	Johnson BW	Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay.	Journal of clinical microbiology	2005	82
21219179	148022	Casanova JL	Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics.	Annual review of immunology	2011	95
21252049	148022	Gao B	Innate immunity in alcoholic liver disease.	American journal of physiology. Gastrointestinal and liver physiology	2011	59
21298114	148022	Coler RN	Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.	PloS one	2011	94
21931545	148022	Qu L	Disruption of TLR3 signaling due to cleavage of TRIF by the hepatitis A virus protease-polymerase processing intermediate, 3CD.	PLoS pathogens	2011	36
22105173	148022	Sancho-Shimizu V	Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency.	The Journal of clinical investigation	2011	68
22347990	148022	Sancho-Shimizu V	Inborn errors of anti-viral interferon immunity in humans.	Current opinion in virology	2011	40
22474023	148022	Figueroa L	The Asp299Gly polymorphism alters TLR4 signaling by interfering with recruitment of MyD88 and TRIF.	Journal of immunology	2012	40
22610250	148022	Netea MG	Genetic variation in Toll-like receptors and disease susceptibility.	Nature immunology	2012	82
19684573	282617	Ge D	Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.	Nature	2009	904
19939920	282617	Osterlund P	Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons.	Journal of virology	2010	53
20060832	282617	Rauch A	Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.	Gastroenterology	2010	306
20176026	282617	McCarthy JJ	Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin.	Gastroenterology	2010	82
20389235	282617	Rallón NI	Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.	AIDS	2010	53
20399780	282617	Thompson AJ	Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.	Gastroenterology	2010	186
20578254	282617	Montes-Cano MA	Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes.	Hepatology	2010	53
20637200	282617	Tillmann HL	A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice.	Gastroenterology	2010	83
20708617	282617	Fukuhara T	Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.	Gastroenterology	2010	54
20803561	282617	Grebely J	Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.	Hepatology	2010	48
20950615	282617	Balagopal A	IL28B and the control of hepatitis C virus infection.	Gastroenterology	2010	77
21111740	282617	Dill MT	Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.	Gastroenterology	2011	90
21254179	282617	Charlton MR	Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection.	Hepatology	2011	47
21402922	282617	Dring MM	Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection.	Proceedings of the National Academy of Sciences of the United States of America	2011	41
21413051	282617	Ruiz-Extremera A	Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children.	Hepatology	2011	38
21468124	282617	Hofmann WP	A new standard of care for the treatment of chronic HCV infection.	Nature reviews. Gastroenterology and hepatology	2011	53
21480318	282617	Bitetto D	Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C.	Hepatology	2011	39
21931540	282617	Suppiah V	IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.	PLoS medicine	2011	41
21951981	282617	Asselah T	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C.	Journal of hepatology	2012	34
22180014	282617	Bochud PY	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.	Hepatology	2012	38
22192885	282617	Beinhardt S	Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection.	Gastroenterology	2012	30
22234804	282617	Liu L	Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution.	Hepatology	2012	30
22248663	282617	Thomas E	HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.	Gastroenterology	2012	97
22331604	282617	Naggie S	Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.	Hepatology	2012	35
22626609	282617	Poordad F	Factors that predict response of patients with hepatitis C virus infection to boceprevir.	Gastroenterology	2012	51
23089201	282617	Zhang S	Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection.	Gastroenterology	2013	38
23298311	282617	Jiménez-Sousa MA	Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.	BMC medicine	2013	26
23420232	282617	Duggal P	Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts.	Annals of internal medicine	2013	54
23703931	282617	Noureddin M	Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.	Hepatology	2013	31
23712427	282617	Bibert S	IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction.	The Journal of experimental medicine	2013	63
23836238	282617	Horner SM	Regulation of hepatic innate immunity by hepatitis C virus.	Nature medicine	2013	82
23944300	282617	Zeuzem S	Faldaprevir and deleobuvir for HCV genotype 1 infection.	The New England journal of medicine	2013	55
24184132	282617	Everson GT	Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.	Gastroenterology	2014	41
24911972	282617	Poveda E	Update on hepatitis C virus resistance to direct-acting antiviral agents.	Antiviral research	2014	40
25048716	282617	Rehermann B	Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.	Hepatology	2015	26
25596313	282617	Moreno C	Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4.	Journal of hepatology	2015	16
25942723	282617	Poordad F	Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.	JAMA	2015	17
26476290	282617	Feld JJ	Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.	Journal of hepatology	2016	12
26547499	282617	Wilder JM	Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.	Hepatology	2016	10
26803446	282617	Abergel A	Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.	The Lancet. Infectious diseases	2016	10
23291588	101180976	Prokunina-Olsson L	A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.	Nature genetics	2013	201
24169568	101180976	Hamming OJ	Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses.	The EMBO journal	2013	42
24367041	101180976	Meissner EG	IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.	The Journal of infectious diseases	2014	24
26406534	101180976	Peiffer KH	Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3.	Hepatology	2016	11
